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ZUSAMMENFASSUNG
Tumore in den verschiedenen Organen stellen oft einen Phänotyp dar, der als
Mikrosatelliteninstabilität (MSI) bekannt ist und durch eine signifikante Erhöhung
der Instabilität von aufeinanderfolgenden Tandem-Wiederholungen, so genannten
Mikrosatelliten, charakterisiert wird. Dieser Phänotyp ist auf einen Defekt in der
Reparatur von Einzelstrandschlaufen in den repetitiven Sequenzen während der
DNA-Replikation zurückzuführen. Dazu kommt ein Defekt in der Reparatur von
fehlgepaarten Basen. Beides wird durch einen Defekt im sogenannten
postreplikativen Mismatch-Reparatur-System (MMR) verursacht. Ein Defekt des
MMR-Systems ist die molekulare Ursache für eine familiäre Form des
Dickdarmkrebses (hereditary non-polyposis colorectal cancer, HNPCC-Syndrom),
welche für ~5% aller Darmkrebserkrankungen verantwortlich ist.  MSI wurde auch
bei ~10% von sporadischen Darmkrebserkrankungen entdeckt (d.h. ohne familiäre
Aggregation), sowie bei anderen Tumoren (Kopf- und Hals-, Lungen-, Prostata-,
Brust-, Harnblasen-, Hautkrebs usw.). Der MMR-Defekt bei diesen letzteren
Tumortypen tritt während späterer Entwicklungsstadien auf und dürfte somit nicht
der Primärgrund für die zelluläre Transformation sein. Der MMR-Defekt verursacht
einen Mutatorphänotyp und vermittelt Resistenz gegenüber verschiedener
Chemotherapeutika. Diese Charakteristika beeinflussen nicht nur die Prognose
Figure 1. Schematische Abbildung des Verlaufes meiner Dissertation. Eine neue isogene Zell-
Linie mit defektem oder funktionierendem MMR-System wurde entwickelt, um verschiedene
biologische Rollen der MMR zu studieren.
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sondern auch das Ergebnis der Tumortherapie. Damit neue therapeutische Strategien
entwickelt werden können, ist es sehr wichtig, die molekularen Mechanismen der
MMR und die biologischen Prozesse, an welchen dieses Reparatursystem beteiligt
ist, zu verstehen.
Eine der Limitationen von Studien der biologischen Rollen der MMR war der
Mangel an isogenen Zell-Linien mit entweder defektem oder funktionierendem
MMR-System. Daher begann ich, ein neues Experimentalsystem zu entwickeln, in
welchem man die Expression eines MMR-Gens regulieren kann. Ich korrigierte den
MMR-Defekt der menschlichen embryonalen Nierenzell-Linie 293T durch die
exogene Expression von hMLH1 mit Hilfe des TetOff-Systems, und konstruierte
damit eine neue Zell-Linie, genannt 293T La (Fig. 1). In diesen Zellen kann die
Expression von hMLH1 mit Doxycyclin (DOX) genau reguliert werden und
deswegen können diese Zellen auch dazu verwendet werden, den Phänotyp der
Zellen mit unvollständiger Expression von hMLH1 zu untersuchen. Wir zeigten, dass
die Expression von hMLH1 den MMR-Defekt sowohl in vitro als auch in vivo
korrigiert.
In der Literatur wurde umfassend dokumentiert, dass der MMR-Defekt eine
erhöhte Toleranz gegenüber alkylierenden Agenzien verursacht. Wir zeigten, dass
die Expression von hMLH1 die Sensitivität gegenüber MNNG in 293T La-Zellen
wiederherstellte. Zudem führte sie zur Aktivierung einer durch DNA-Schäden
ausgelösten Signal-Kaskade und zum G2/M Zellzyklus-Arrest. Außerdem haben wir
gezeigt, dass der Arrest nach der Behandlung mit niedriger MNNG-Konzentration
von einem voll funktionierenden MMR-System abhängig ist und Replikation
verlangt, wohingegen er nach Behandlung mit hoher MNNG-Konzentration MMR-
und replikationsunabhängig ist (d.h. er tritt auch in stillstehenden Zellen auf).
Wie bereits weiter oben erwähnt, ist es möglich, die Expression von hMLH1
genau zu regulieren. Wir nutzten diese Tatsache, um zu testen, wie die Variation der
Menge von hMLH1 den MMR-Status und die Sensitivität gegenüber alkylierenden
Agenzien beeinflusst. Die Zellen, die nur 10% der normalen Menge des hMLH1
exprimierten, wiesen immer noch ein funktionierendes MMR-System auf, was
sowohl in vitro als auch in vivo gezeigt werden konnte. Sie waren aber zugleich
resistent gegenüber der Behandlung mit MNNG. Ein funktionierendes MMR-System
und die Sensitivität gegenüber MNNG benötigen deswegen verschiedene Mengen an
hMLH1. Diese Resultate zeigten, dass Zellen, die weniger als die normale Menge
von hMLH1 exprimieren, keinen normalen Phänotyp aufweisen, obwohl sie ein
funktionierendes MMR-System besitzen. Der festgestellte Defekt in der Aktivierung
eines Signal-Checkpoints infolge von DNA-Schäden könnte erklären, wie der MMR-
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Defekt zur zellulären Transformation und zum Tumorwachstum führen kann: Wenn
die normalen Darmepithelzellen beschädigt werden, sollte dies zum programmierten
Zelltod führen. Zellen hingegen, die niedrige Mengen an hMLH1 exprimieren,
können den Checkpoint nicht aktivieren und somit auch keinen Zelltod einleiten. Die
Zellen könnten stattdessen Mutationen anhäufen, die es ihnen erlauben würden, sich
weiter zu vermehren und somit zur Transformation beizutragen.
Es wurde vor Kurzem gezeigt, dass ein funktionierendes MMR-System für die
Aktivierung des S-Phase-Checkpoints nach der Behandlung mit ionisierender
Strahlung erforderlich ist. Diese Beobachtung widersprach verschiedenen
vorhergegangenen Studien. Es ist möglich, dass die Zell-Linien, die in diesen
Studien verwendet wurden, nachträglich verschiedene Mutationen im genetischen
Hintergrund anhäuften, wie zum Beispiel in Genen, welche zum p53-Weg gehören.
Das würde unvermeidlich zu nicht wiederholbaren Ergebnissen führen. Wir
benutzten deswegen das isogene 293T La-System, und wir zeigten, dass der S-
Phase-Checkpoint sowohl in Zellen mit defekter als auch solchen mit
funktionierender MMR voll aktiviert wurde. Das MMR-System spielt also keine
Rolle in der Aktivierung der Checkpoints nach der Behandlung mit ionisierender
Strahlung.
Im zweiten Teil dieser Arbeit begann ich, eine neue Methode zur Therapie von
Tumoren mit MMR-Defekt zu entwickeln, welche den MSI-Phänotyp dieser Zellen
ausnutzt. Das Prinzip unserer Methode ist es, ein Konstrukt in die Zellen
einzuführen, das ein sich wiederholendes Toxin-Gen in der kodierenden Sequenz
enthält. Da die Wiederholungssequenz das Leseraster des Toxin-Gens verschiebt,
führt sie zu einem fehlerhaften Peptid und zu verfrühtem Translationsabbruch. In
Zellen mit einem MMR-Defekt wäre das Konstrukt jedoch instabil und anfällig auf
frameshift-Mutationen. Falls nun eine frameshift-Mutation das korrekte Leseraster
des Toxingens wiederherstellte, würde das Konstrukt ein funktionsfähiges Toxin
kodieren, und die Zelle würde getötet. Die Anfangsexperimente sollten die
Machbarkeit dieser Methode beweisen und zur Identifikation solcher
Wiederholungssequenzen führen, welche grosse Unterschiede bezüglich Stabilität in
Zellen mit oder ohne funktionsfähiger MMR aufweisen. Zu diesem Zweck habe ich
eine Wiederholungssequenz  in das Leseraster einer Genfusion eingeführt, die bei
frameshift-Mutationen innerhalb dieser Sequenz die Expression der Thymidin-
Kinase (TK) inaktiviert, was die Zellen Ganciclovir-beständig macht. Ich habe dieses
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Konstrukt in die 293T La-Zellen eingeführt und konnte zeigen, dass die (C)12-
Wiederholung in Zellen mit funktionierendem MMR-System 20-mal stabiler ist als
in Zellen mit defekter MMR. Unser System kann die Stabilität verschiedener
Wiederholungssequenzen unter strikt isogenen Bedingungen abschätzen, ist damit
besser als alle bisherigen Methoden und kann zudem dafür verwendet werden, viele
verschiedene Wiederholungssequenzen zu testen, um die für das Gentherapieprojekt
am besten geeignete Sequenz zu identifizieren.
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1. SUMMARY
Tumors in different organs frequently display a phenotype known as
microsatellite intability (MSI), which is characterized by a significant increase in the
instability of repeated DNA sequence elements. This phenotype results from a failure
to correct strand misalignments arising in these repeats during DNA replication. This
anomaly, together with a defect in the correction of base/base mismatches, is caused
by the loss of the postreplicative mismatch repair (MMR). MMR deficiency has been
shown to be the underlying molecular cause of hereditary non-polyposis colon
cancer (HNPCC), which accounts for ~5% of colon cancers. MSI is also found in
~10% of sporadic colon cancers (i.e. without familiar aggregation), as well as other
tumors (cancers of head and neck, lung, prostate, breast, bladder, skin etc). Although
the MMR defect in these latter cancers probably arises during later stages of tumor
development and is thus unlikely to be the primary cause of cellular transformation,
inactivation of MMR results in a mutator phenotype and resistance to certain types of
chemotherapeutics. As these characteristics influence not only the prognosis, but also
the outcome of tumor therapy, the understanding of the molecular mechanism of
MMR, and of biological processes it is involved in, is of paramount importance for
the development of novel therapeutic strategies.
Figure 1. Scheme of the course of the PhD thesis. An isogenic MMR-proficient and MMR-deficient
cellular system was developed in order to study various biological roles of MMR.
Isogenic MMR+
and MMR- cellular
system
    293T La
Checkpoint activation upon
treatment with alkylating agents
and its dependence on MMR
Response of MMR+
and MMR- cells to
ionizing radiation
Phenotype of cells
expressing reduced
levels of hMLH1
A novel therapeutic approach
exploiting MSI phenotype
of MMR- tumor cells
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One of the limitations of the study of the biological roles of MMR was the lack
of isogenic MMR-proficient and -deficient human cells. I therefore set out to
generate a new experimental isogenic system, in which the expression of a MMR
gene could be modulated. I corrected the MMR defect of the human embryonic
kidney 293T cells by exogenous expression of the MMR gene hMLH1 with the help
of the inducible TetOffTM system, creating a new cell line, 293T La (Fig. 1). In these
cells, the expression of hMLH1 can be finely regulated by doxycycline (DOX) and
they are therefore suitable to study also the phenotypic effects of partial
downregulation of hMLH1. We showed that the expression of hMLH1 corrected the
MMR defect both in-vivo and in-vitro.
It has been well documented that a MMR defect brings about resistance to
alkylating agents. We showed that the expression of hMLH1 in 293T La cells
restores sensitivity to MNNG and leads to the activation of DNA damage signaling
pathways and G2/M cell cycle arrest. Moreover, it was shown that upon treatment
with low MNNG concentrations, the checkpoint activation is fully dependent on
functional MMR and requires replication, whereas treatment with high MNNG
concentrations activates checkpoint in an MMR-independent manner, which does not
require replication (i.e. occurs also in arrested cells).
As stated above, in the 293T La  cells, it is possible to modulate hMLH1
expression. We used this opportunity to test how the variation in the amount of
hMLH1 affected MMR efficiency and response to alkylating agents. Cells
expressing 10% of the maximal amount of hMLH1 were still proficient in both in-
vitro and in-vivo MMR assays, but failed to arrest upon MNNG treatment. MMR
proficiency and response to MNNG required different levels of hMLH1 expression.
This finding suggested that cells expressing lower than wild-type levels of MMR
proteins, which occurs for example when the hMLH1 promoter is only partially
methylated, are not phenotypically normal, despite being MMR-proficient. The
observed defect in activation of DNA damage checkpoints helps explain how the loss
of MMR might accelerate cellular transformation and tumor progression: when
normal colonic epithelial cells become damaged, they should undergo apoptosis. In
contrast, cells with a defect in DNA damage signaling, such as those expressing
suboptimal levels of hMLH1, would not activate cell cycle checkpoints and
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apoptosis. Instead, they might acquire mutations that allow them to continue to
proliferate and contribute to transformation.
It has been recently reported that MMR is required for S-phase checkpoint
activation upon ionizing radiation. This observation was in disagreement with
several previous studies. It might be possible that the cell lines used in these studies
acquired additional mutations in the genetic background in various laboratories, such
as in genes belonging to the p53 signaling pathway, which would inevitably lead to
irreproducible results. We therefore used the isogenic 293T La system and we
showed that the S-phase checkpoint is activated in both MMR-proficient and
–deficient cells, and, therefore, that MMR does not play a role in S-phase checkpoint
activation upon treatment with ionizing radiation.
Next, I set out to design a novel approach to therapy of tumors with a MMR
defect, which would take advantage of the MSI phenotype of MMR-deficient tumor
cells. The principle underlying our method is to introduce into the cells a gene
coding for a toxin that would contain a labile microsatellite sequence within its open
reading frame (ORF). Because the microsatellite would frameshift the ORF, the ORF
would not encode a functional polypeptide. However, upon the introduction of this
vector into MMR-deficient cells, the microsatellite will become prone to frameshift
mutagenesis during DNA replication. In cases where the frameshifting process
returns the toxin gene into its proper reading frame, the gene will express a
functional toxin and the cell will be killed. In contrast, the microsatellite should
remain stable in MMR-proficient cells. The initial experiments designed to obtain the
proof of principle of this approach must identify repeats with the highest difference
in stability between MMR-proficient and -deficient cells. To this end, I inserted a
microsatellite into the coding region of a fusion gene containing thymidine kinase
(TK), such that the frameshifts within this motif would abolish the expression of TK,
making the cells resistant to ganciclovir. I stably transfected this construct into 293T
La cells. I showed that a (C)12 repeat was 20 times more stable in MMR-proficient
cells than in cells with a MMR defect. The established assay enables us to evaluate
the mutation frequency of microsatellites in a strictly isogenic MMR-proficient and -
deficient genetic background, which is superior to all other assays developed to date.
Moreover, this system can be easily applied to screen a high number of
microsatellites in order to find those best suitable for gene therapy.
Introduction
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2. INTRODUCTION
Deoxyribonucleic acid (DNA) carries the genetic information of the cell. Living
organisms developed strategies that enable them to pass this information from one
cell to another while minimizing the number of mutations. The accuracy of
eukaryotic replication is maintained on three different levels. At first, polymerases
involved in DNA replication are highly accurate, incorporating the incorrect
nucleotide at frequencies of only ~1x10-5. Second, the 3’Æ 5’ editing exonuclease
activity, which is associated with replicative DNA polymerases, increases the
accuracy approximately 100-fold. Third, following DNA replication, the
postreplicative DNA mismatch repair (MMR) can recognize erroneously
incorporated nucleotides and replace them with correct ones, bringing the overall
mutation frequency during replication of genomic DNA to only ~1x10-10 (Kunkel
1992).
DNA is also being constantly damaged by a variety of chemicals, including
reactive oxygen species (ROS), alkylating and crosslinking agents, and others. These
arise in part as a byproduct of metabolism or are introduced from the ‘environment’:
diet, chemicals and lifestyle. Moreover, radiation (e.g. sunlight) and spontaneous
hydrolysis (deamination or base loss) also cause DNA damage. Cells have developed
various repair pathways that enable them to remove this damage from DNA. This
can be done either directly by damage reversal pathways, as in the case of conversion
of O-6-methylguanine to guanine by O-6-methylguanine-DNA methyltransferase, or
by one of the two excision mechanisms, base excision (BER) and nucleotide excision
repair (NER). In case the damage cannot be removed, cells still posses various
‘damage tolerance’ pathways that enable them to duplicate their genomes despite the
presence of the lesions. Homologous recombination (HR) is an error-free pathway,
because it uses the genetic information present in the homologous sequences or in
the undamaged sister chromatid, whereas translesion synthesis (TLS) is a process
during which the replication machinery reads through lesions contained in the DNA
template, thus inducing mutations at a high frequency, while maintaining the
integrity of DNA. Ionizing radiation and certain chemicals cause single and double
strand breaks. Non-homologous end joining (NHEJ) and homologous recombination
(HR) are the two major pathways responsible for repairing of this kind of damage.
Introduction
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The fact that defects in the above mentioned DNA repair processes often lead to
embryonic lethality, serious diseases, developmental defects and cancer underline the
importance of maintaining genomic stability. In the following text, I will focus on
postreplicative MMR: I will briefly review our current knowledge of the mechanism
of MMR, the involvement of MMR in resistance to certain types of DNA damaging
agents and the link between MMR defects and cancer.
2.1. Mechanism of eukaryotic mismatch repair
The primary function of MMR is to remove base/base mismatches and loops of
extrahelical nucleotides that arise due to either erroneous nucleotide incorporation or
polymerase slippage during DNA replication, respectively (Jiricny 1998). Unlike in
E. coli, where the MMR reaction has been reconstituted in-vitro with purified
proteins (Lahue et al. 1989) and the structure of MutS-DNA complex determined
(Lamers et al. 2000, Fig. 2), the exact composition of eukaryotic MMR system
remains unclear.
Figure 2. Overview of the MutS–DNA complex in E. coli. a, stereo view from the front. b, Side view,
rotated 80° from structure in a. DNA and ADP are coloured red, the mismatch-binding monomer light
green, and the second monomer blue (Lamers et al. 2000).
For mismatch recognition in human cells, the hMSH2 protein forms a
heterodimer with either hMSH6 or hMSH3. The hMSH2/hMSH6 complex, also
called hMutSa, is responsible for the recognition of base/base mismatches and
shorter extrahelical loops, whereas the hMSH2/hMSH3 complex, called hMutSb, is
Introduction
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specific for larger extrahelical loops (Palombo et al. 1996). Since the expression of
hMSH3 is lower as compared to hMSH6, hMutSa is the major mismatch recognition
complex (Fig. 3). Upon recognition, the heterodimer forms a ring around DNA. On
ATP binding, this ring undergoes a conformational change; it is released from the
mispair and slides along the DNA (Gradia et al. 1997). The exact biological role of
this step has not been understood yet.
Figure 3. Schematic representation of mismatch (a) and IDL (b) recognition in human cells (Marra
and Schaer 1999).
A very important step in the MMR reaction is strand discrimination, a process
that helps distinguish the template strand containing the correct sequence, from the
newly synthesized strand containing the base erroneously mispaired with that on the
template strand. Strand discrimination applies also to the resolution of loops of
extrahelical bases present in one DNA strand (insertion/deletion loops). Unlike in E.
coli, where the strand discrimination signals are hemimethylated GATC sequences
recognized by the endonuclease MutH (Laengle-Rouault et al. 1986), this process is
poorly understood in eukaryotes. However, recent evidence suggested that
hMSH2/hMSH6 complex interacts with proliferating cell nuclear antigen (PCNA,
Kleczkowska et al. 2001) and this interaction significantly increases the affinity
Introduction
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towards mismatches versus normal Watson-Crick base pairs (Lau and Kolodner
2003, Flores-Rozas et al. 2000). Recent data point towards a hypothesis (Fig. 4),
where the hMutSa heterodimer travels along DNA with the replication complex
through interaction with PCNA. Once this complex encounters a mismatch, hMutSa
is transferred from PCNA to the mismatch. In this model, direct coupling of
hMSH6/hMSH2 with DNA replication might explain the strand discrimination. It
was also shown that strand discontinuities such as nicks can direct the mismatch-
dependent exonucleolysis to the nicked strand (Holmes et al. 1990, Thomas et al.
1991). It is possible that Okazaki fragments in the lagging strand and the 3’ DNA
end in the leading strand can direct the repair reaction to the nascent strand.  In
addition, upon mismatch recognition, the replication complex might be destabilized
through direct interactions, which would then allow the assembly of the MMR
repairosome (Lau and Kolodner 2003). However, further experiments are required to
substantiate this hypothesis.
Figure 4. A schematic representation of eukaryotic MMR (kindly provided by G. Marra)
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The events downstream of mismatch recognition are also elusive. A heterodimer
consisting of hMLH1 and hPMS2 (hMutLa) is traditionally described to coordinate
mismatch recognition with the downstream events of MMR reaction; it is believed to
act as a ‘molecular matchmaker’ that controls protein/protein interactions (Li and
Modrich 1995, Raschle et al. 2002). hMLH1 can also form complexes with hPMS1
or hMLH3 (Raschle et al. 1999, Lipkin et al. 2000, Kondo et al. 2001). Whereas
hMLH1 is essential for MMR, and the hMutLa heterodimer is the predominant
complex, the roles of hPMS1 and hMLH3 in MMR are not clear. For the final
excision, resynthesis and ligation steps, the following proteins might be involved:
exonuclease 1 (EXO1), possibly helicase/s, single-stranded DNA-binding protein
(RPA), PCNA, polymerases d and e, and DNA ligase I (Harfe and Jinks-Robertson
2000).
2.2. Processing of DNA damage by MMR
The primary role of the MMR pathway is to recognize and repair base/base
mispairs and strand misalignments arising during DNA replication; however, MMR
proteins can also process DNA damage (Marra and Schar 1999). The recognition of
O6-methylguanine (O6-meG) residues caused by N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG), and cis-diammine-dichloroplatinum (cisplatin) induced DNA damage by
the MMR proteins has been reported for the first time in E. coli about 20 years ago
(Karran and Marinus 1982, Fram et al. 1985). Later, tolerance to alkylating agents
and cisplatin has been observed also in human MMR-deficient cells (Branch et al.
1993, Aebi et al. 1997, Karran 2001, Bellacosa 2001). For example, the crosslinking
agent cisplatin kills MMR-proficient cells 2-3-fold more efficiently than MMR-
deficient ones and in case of methylating agents such as MNNG the difference is
about 100-fold. Since cisplatin and some methylating agents (temozolomide) are
used in cancer chemotherapy, it is of great interest to understand how MMR-
dependent molecular mechanisms participate in the modulation of cellular sensitivity
to these drugs.
MMR can recognize DNA lesions arising by one of the two following
mechanisms. 1) DNA damaging agents, either endogenous or exogenous, can induce
damage of deoxyribonucleotides (dNTPs) in the nucleotide pool. As many modified
Introduction
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nucleotides often form non Watson Crick base pairs, immediately after such a
modified nucleotide gets incorporated into DNA and forms a mispair, it becomes a
substrate for MMR. In this case, MMR removes the modified base from DNA. For
example, MMR has been reported to remove 8-oxoguanine (8-oxoG) incorporated from
the oxidized dNTP pool, and MMR-deficient cell lines were shown to contain higher,
both steady state and H2O2 induced, 8-oxoG levels (Colussi et al. 2002). However, the
processing of this kind of damage by the MMR pathway appears to be of minor
importance. 2) When some mutagens damage DNA directly, the induced lesions or
the mismatch caused following DNA replication through these lesions are identified
as MMR substrates, but this time the modified nucleotides are in the template strand
and thus cannot be removed by the MMR system.
Involvement of MMR in promoting the cytotoxicity of alkylating agents
Simple alkylating agents such as MNNG induce the formation of mostly N7-
methylguanine, N3-methyladenine and N3-methylguanine DNA adducts, all of which
are removed by base excision repair (BER, Beranek 1990, Mitra and Kaina 1993).
Mutants deficient in BER are hypersensitive to MNNG, suggesting potential
cytotoxicity of these lesions. On the other hand, cells deficient in MMR are without
exception highly resistant to MNNG. Therefore, unlike BER, which is responsible
for the removal of a subset of MNNG induced lesions and helps the cells to survive,
the MMR pathway acts in the opposite direction, i.e. promotes cell death. This
cytotoxicity of MNNG has been linked to the processing of O6-methylguanine (O6-
MeG), a minor lesion accounting for only 0.3-8 % of total DNA alkylations, by the
MMR pathway (Hickman and Samson 1999). O6-meG often mispairs with thymine (T)
following DNA replication. Upon treatment with MNNG, MMR does not recognize
the lesions until S-phase, when the O6-meG/T mispairs are formed. MMR-proficient
cells have been described to undergo MNNG-induced cell cycle arrest and apoptosis,
whereas in MMR-deficient cells, the DNA damage accumulates but does not trigger
cell death. For this reason, the accumulation of O6-meG in MMR-deficient cells has
been named methylation ‘tolerance’, a term more appropriate than resistance.
To this point, two major models explaining the role of MMR in processing of
this kind of DNA damage have been suggested. In the first one, originally suggested
Introduction
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for bacteria, cell death is a consequence of misguided effort by MMR to correct the
lesion: as the modified nucleotide is located after replication in the template strand,
MMR removes the undamaged nucleotide from the nascent strand. MMR was
suggested to initiate a ‘futile cycle’ of repair and synthesis, when the MMR directed
repair resynthesizes the nascent strand while the damaged nucleotide persists. Such a
process was suggested to ultimately lead to cell cycle arrest and induce apoptosis
(Karran and Bignami 1994). The second model, hereafter referred to as ‘direct
signaling model’, suggests that MMR proteins function as DNA damage sensors,
being an integral part of the process of programmed cell death (Hawn et al. 1995). It
presupposes a completely new function for MMR, i.e. direct transmitting of the
signal to the apoptotic machinery. The latter model, further modified by Fishel
(1999), proposes that constant loading of hMutSa sliding clamps at the O6-meG/T
mispairs is responsible for the transmission of the DNA damage signal to the
apoptotic machinery. The model is further based on the observation that
overexpression of either hMLH1 or hMSH2 leads to apoptosis (Zhang et al. 1999).
However, several observations are in disagreement with this latter model. At
first, the accumulation of hMSH2/hMSH6 heterodimers at the mispair site has not
been shown experimentally and the induction of apoptosis by hMLH1 or hMSH2
overexpression seems to be limited to only some cell types. In this thesis, I will
introduce the 293T La cell line, which expresses very large amounts of hMLH1 that
do not seem to be toxic.
Figure 5. A model of induction of apoptosis by
O6-MeG in MMR+ cells (adapted from Ochs and
Kaina 2000).
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Recent evidence points towards a model (Fig. 5), where MMR-activated futile
cycle of repair and synthesis generates lesions in the genomic DNA, which are
converted to secondary lesions such as double strand breaks (DSB) in the second cell
cycle, that ultimately cause cell cycle arrest and death (Ochs and Kaina 2000). This
is supported by the observation that MMR-proficient cells arrest only in the second
cell cycle post treatment as observed already more than 20 years ago by Plant and
Roberts (1971) and recent data by Ochs and Kaina (2000), who observed generation
of DSB 48 hours post treatment followed by activation of apoptosis 24 hours later.
Results presented later in this thesis provide additional evidence in support of this
model and characterize the cell death pathways induced by methylating agents.
Involvement of MMR in promoting the cytotoxicity of cisplatin
The mechanism of resistance of MMR-deficient cells to cisplatin-induced DNA
adducts is more complex. Cisplatin reacts preferentially with N7 atoms of purine
residues in DNA, forming mostly 1,2-d(GpG) and 1,2-d(ApG) and other types of
intrastrand crosslinks, monoadducts and interstrand crosslinks (Marra and Schaer
1999). However, cisplatin induced DNA damage differs dramatically from
methylation damage. Whereas O6-meG residues do not block DNA synthesis and go
basically undetected in MMR- cells, cisplatin-induced crosslinks efficiently block
replicative DNA polymerases. Stalled replication forks can then be resolved by
recombination (in mammalian cells preferentially by homologous recombination) or,
alternatively, the lesions can be bypassed by translesion polymerases, at the price of
generating mispairs. Even before replication, intrastrand crosslinks are recognized
and efficiently repaired by the nucleotide excision repair (NER). Resistance to
cisplatin can be caused, apart from MMR status, by several mechanisms including
factors controlling cell death, modifications in drug uptake and efflux, and p53 status
(Johnson et al. 1997, Anthoney et al. 1996, Righetti et al. 1999). A recent study of
resistance profiles among the NCI panel of 60 cell lines that are used to evaluate
anticancer drugs did not find correlation between MMR status and cisplatin
resistance (Taverna et al. 2000). Therefore, other factors than MMR status are the
principal contributors to resistance. However, when the resistance to cisplatin
treatment was observed in a syngenic system using the MMR-deficient cell line
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HCT116 and the MMR-proficient cell line HCT116+Chr3 where the MMR defect
had been corrected by chromosome 3 transfer, the level of resistance of the MMR-
deficient cells was reproducibly ~2 fold higher (Fink et al. 1996). Using the 293T La
system, which is described in this thesis, we could confirm these results in a strictly
isogenic system. Moreover, recent clinical data suggested that treatment of tumors
with cisplatin selects for cells that do not express MMR proteins (see below).
Therefore, the link between MMR-deficiency and cisplatin resistance has been
clearly shown both in vitro and in vivo  (Aebi et al. 1996, Fink et al. 1997), but
MMR-deficiency does not play such a prominent role as in case of processing DNA
damage caused by alkylating agents.
Several models have been proposed to explain the connection between the
MMR pathway and cytotoxicity of cisplatin (Fink et al. 1998, Fishel 2001). Similarly
to cytotoxicity of MNNG, the direct signaling and futile processing models have
been suggested. Moreover, due to the variety of DNA repair pathways acting on
cisplatin-induced lesions, other models proposed that MMR shields the lesion and
prevents NER from repairing it, or that MMR interferes with recombination. A
recent study followed the binding of MutS from E. coli to various crosslinks induced
by cisplatin as well as to substrates containing intra-strand crosslinks in which the
involved bases were mispaired with those on the opposite strand. The latter lesions
arise most likely after translesion synthesis in vivo. Whereas lesions directly caused
by cisplatin (i.e. intra-strand crosslink paired with complementary bases) are not
recognized or only with low efficiency, lesions containing intra-strand crosslink and
a mispair are recognized very efficiently. The authors conclude that lesions formed
through misincorporations of bases opposite either adducted bases or intrastrand
crosslinks are the lesions responsible for MMR-mediated cytotoxicity in E. coli
(Fourrier et al. 2003). The MMR-promoted cisplatin sensitivity might therefore stem
from a similar process as the cytotoxicity of alkylating agents; however, due to the
variety of cisplatin induced lesions and repair pathways acting on them, this process
is far from understood.
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The role of MMR in checkpoint activation upon ionizing radiation
Ionizing radiation (IR) induces a spectrum of DNA damage including double
strand breaks (DSBs), single strand breaks, crosslinks, and oxidative base
modifications. DSBs are probably the most toxic lesions induced by IR. Such DNA
damage typically activates a signaling cascade involving ATM, Chk2 and Chk1
protein kinases, leading to G1, S or G2/M cell cycle checkpoints, depending on at
which phase of the cell cycle the damage occurred (Gatei et al. 2003, Jackson 2002).
The role of MMR in these pathways is highly controversial. While several groups
(Frizell et al. 1997, DeWeese et al. 1998) reported that MMR-deficient cells show a
small, but statistically significant increase of radioresistance, other groups (Leadon
and Avrutskaya 1997, Davis et al. 1998) did not find any significant differences.
Yan et al. (2001) reported that the loss of MMR imparts G2/M cell cycle arrest
upon IR, without altering survival. MMR-deficient cells exhibited a reduced and
shorter G2/M arrest compared with matched MMR-proficient cell lines. Importantly,
the differences became apparent 25 hours posttreatment and were most pronounced
between 36 and 72 hours posttreatment. Therefore, MMR seemed to play a role in
sustaining the G2/M arrest upon IR, while it did not have any effect on early
checkpoint activation. It has been observed that IR induces also oxidative base
modifications, most notably the major oxidative product 8-oxoguanine (8-oxoG). This
modified base has been shown to mispair with adenine following DNA replication,
and this mismatch was shown to be recognized (unlike the 8-oxoG /C pair) by MMR
(Mazurek et al. 2001). Therefore, similarly to MNNG- and cisplatin-induced DNA
damage (see above), the MMR-mediated futile cycle of repair and synthesis of
mispairs containing an adducted base in the template strand has been proposed to
ultimately lead to G2/M arrest responses (Yan et al. 2001). It is noteworthy that this
hypothesis is in agreement with the observation that the MMR-mediated effect
became apparent at later timepoints, by which time the 8-oxoG /A mispairs might have
been formed.
Recently, Brown and colleagues (2002) reported that MMR is required for S-
phase checkpoint activation upon IR, and directly activates the ATM protein kinase.
This result was surprising as the effect took place within less than 3 hours
posttreatment. Moreover, this observation was in disagreement with experiments
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performed in multiple laboratories (Jallepalli et al. 2003, Shieh et al. 2000, Falck et
al. 2001, Yu et al. 2002, Wu et al. 2001), which demonstrated the checkpoint is
robustly activated in cells exposed to IR, irrespective of their MMR status. The
inconsistent results are difficult to explain. It might be possible that cell lines,
although nominally identical, acquired in different laboratories additional mutations
in the genetic background. Notably, the p53 signaling cascade has been shown to
significantly affect IR responses (Bunz et al. 1998); hence the presence of such
mutations would inevitably lead to contradictory results. We used the 293T La cells
to look at this phenomenon in an isogenic system and we showed that the checkpoint
was activated identically in MMR-proficient and –deficient cells upon IR. The
results are presented in this thesis.
2.3. Mismatch repair defect and cancer
A mutation or epigenetic inactivation of one of several MMR genes leads to
inactivation of MMR and thus to a drastic reduction in the repair of errors of DNA
replication. The resulting mutations can be divided into two major groups. Simple
misincorporations of nucleotides belong to the first group. They arise, for example,
when DNA polymerase erroneously incorporates thymine opposite to guanine and
the resulting G/T mismatch escapes the 3’Æ 5’ proofreading exonuclease activity.
Such a mismatch is normally efficiently recognized and repaired by MMR. In
contrast, this mismatch goes undetected in MMR-deficient cells and results in a G:C
to T:A transversion mutation in 50% of the progeny DNA. A defect to repair
base/base mismatches therefore leads to highly increased incidence of base
substitutions, generating missense or nonsense mutations. The second group of
mutations are strand misalignments arising during replication. This phenomenon is
particularly frequent in short repetitive sequences (microsatellites). This so called
‘slippage’ of the DNA polymerase complex results in generation of
‘insertion/deletion loops’, which are normally repaired by MMR. However, these
misalignments go undetected in MMR-deficient cells and lead to frameshift
mutations. By looking at the mutation spectra of MMR-deficient cells, it has been
demonstated that the predominant mutation is the loss of one repeat unit, mainly in
mononucleotide and dinucleotide repeats. The microsatellite sequences are thus
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unstable in MMR-deficient cells and this phenomenon is called microsatellite
instability (MSI, Lengauer et al. 1998, Blake et al. 2001).
Hereditary non-polyposis colon cancer (HNPCC)
Germline mutations in MMR genes, predominantly in hMSH2 and hMLH1 and
less frequently in hMSH6, hPMS2 and hPMS1 give rise to hereditary non-polyposis
colon cancer (HNPCC) that accounts for ~5% of colon cancers. The international
diagnostic criteria for HNPCC, known as Amsterdam criteria, were defined in 1990
(Table 1) and summarize the hallmarks of this malignancy: early onset (before the
age of 50) and high penetrance (~80%). These criteria are stringent, exclude
extracolonic cancers typical for HNPCC and are not suitable for small families.
Therefore, Amsterdam revised (Vasen et al. 1999) and Bethesda criteria
(Wullenweber et al.  2001) were later developed.
Amsterdam criteria of HNPCC (Vasen et al. 1991)
There should be at least three relatives with colorectal cancer.
One should be a first degree relative of the other two.
At least two successive generations should be affected.
At least one colorectal cancer should be diagnosed before the age of 50.
Familial adenomatous polyposis should be excluded.
Tumors should be verified by pathological examination.
Table I. Amsterdam criteria for diagnosis of HNPCC.
As mentioned above, HNPCC patients develop not only colon cancer, but also
endometrial cancer and, more rarely, cancer of the brain, biliary tract, ovary,
pancreas, small bowel, stomach and urinary tract. Despite the fact that these tumors
show aggressive histological features, such as poor cell differentiation, the prognosis
is relatively favorable due to significantly reduced metastatic potential (Lawes et al.
2003, Peltomaki 2003, Chung and Rustgi 2003). Several explanations have been
suggested: (1) These tumors contain a high number of cytotoxic T-lymphocytes,
which are activated by the presence of a large number of mutated peptides presented
on the surface of the cancer cells. These T-cells then induce tumor cell apoptosis; (2)
Increased spontaneous mutagenesis of MMR-deficient cells decreases their viability;
(3) MSI tumors are generally diploid or near diploid, which is a good prognostic
sign, however, the molecular basis of this phenomenon has not been explained yet.
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How does the loss of MMR contribute to cancer? Importantly, HNPCC patients
carry a germline mutation in one allele of a MMR gene. This so called first hit does
not cause an increased mutator phenotype or MSI. This commences following the
somatic inactivation of the second allele (second hit). It is not entirely clear whether
the mutation of the second allele occurs more frequently in the tissues associated
with HNPCC cancers (predominantly in the colon), or if the MMR inactivating
mutations are more widespread, but only some tissues tend to develop cancer. Msh2
-/- mice develop HNPCC-like tumors in the gastrointestinal tract (de Wind, 1998).
The authors concluded that the HNPCC tumor spectrum is probably determined by
exposure to exogenous mutagens in the gastrointestinal tract, rather than by tissue-
specific loss of the wild type MMR allele.
Mutator phenotype and accompanying MSI of MMR-deficient cells lead to
subsequent inactivation of important growth regulatory genes, including those
involved in colon tumorigenesis, signal transduction and apoptosis (TGFbRII, BAX
and others; Huang et al. 1996, Konishi 1996). The inactivation of these genes is
believed to play a crucial role in cancer progression.  It is not clear, however,
whether this can be ascribed to increased mutagenesis due to MMR defect per se. It
has been presented above that MMR-deficient cells have reduced apoptotic response
to some kinds of DNA damage. It is possible that while normal MMR-proficient
cells undergo apoptosis, MMR-deficient cells might continue to grow, despite the
presence of DNA damage, and accumulate further mutations. In this context, DNA
damage might provide MMR-deficient cells with an additional growth advantage
(Bellacosa 2001).  This hypothesis would also explain the tissue specificity of
HNPCC cancers, as the epithelium of the colon is constantly exposed to food- and
metabolism-borne mutagens. We found that cells expressing reduced levels of the
MMR protein hMLH1 are still MMR-proficient but show a defect in DNA damage
response. Our data therefore suggested that this process might commence even
before the expression of the MMR gene is completely shut off, such as when only
one allele is affected (as in HNPCC) or in cells where the hMLH1 promoter is only
partially methylated (as in sporadic cancers, see below).
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MMR defect in sporadic cancers
Approximately 10% of sporadic colon cancers display MSI, caused almost
exclusively by the epigenetic inactivation of hMLH1 expression by promoter
hypermethylation. Based on experiments with cell lines, the hypermethylation
inactivates both alleles at the same time (Veigl et al. 1998, Peltomaki 2003).
Moreover, it has been demonstrated that methylation inactivates more targets beside
hMLH1. Therefore, different tumor developmental pathways could be expected in
these tumors as compared with those in HNPCC. Despite this fact, the histological
and biological features of these cancers are very similar, and these cancers are
referred to as ‘sporadic cancers of the HNPCC spectrum’ (Peltomaki 2003).
Table II. Involvement of MMR genes in sporadic tumors of the HNPCC spectrum (adapted
from Peltomaki 2003).
MMR defects in other types of sporadic cancers
MMR defects have been recently described to occur in a significant proportion
(2-50%) of other types of sporadic cancers (breast, lung, bladder, prostate and others;
Peltomaki 2003, Lawes et al. 2003). Unlike in HNPCC or HNPCC-like sporadic
cancers, the inactivation of MMR occurs in most cases during later stages of
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tumorigenesis and it is thus unlikely to be the primary cause of malignancy.
However, MSI might still be a useful genetic marker in prognosis and might help to
decide optimal treatment strategies. For example, MSI has been reported to be a poor
prognosis factor in non-small cell lung cancer (Rosell et al. 1997, Zhou et al. 2000)
and soft tissue sarcoma (Taubert et al. 2003), while it is associated with a favorable
prognosis in gastric cancer (Schneider et al. 2000, Hayden et al. 1997, dos Santos et
al. 1996). However, published results often contradict each other, and more clinical
studies involving a higher number of patients are required to clarify the role of MMR
defects in these cancers.
Table III. Involvement of MMR  genes in sporadic tumors not belonging to the HNPCC
spectrum (adapted from Peltomaki 2003).
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Finally, since MMR deficiency is associated with resistance to certain types of
chemotherapeutics such as the crosslinking agent cisplatin and the alkylating agent
temozolomide, the clinical relevance of this resistance is currently the subject of
intensive studies. Although cisplatin is a highly effective chemotherapeutic drug for
many types of cancer, one concern regarding its use is that its mutagenic effect might
cause somatic mutations in tumor cells that potentially result in resistance to other
drugs or unfavorably alter other characteristics of the malignancy. Indeed, it has been
documented that cisplatin drug-based chemotherapy of ovarian cancer selects for
tumor cells expressing lower levels of hMLH1 and hMSH2 (Samimi 2000), even if
the level of resistance of MMR-deficient cells is only 2-3 fold. In the case the
alkylating agent temozolomide, which is approved for glioma treatment and is now
in the third phase clinical trial for use in the treatment of metastatic melanomas, the
MMR-deficient cells are at least 100-fold more resistant and the selection pressure
for MMR-deficient cells is expected to be much higher. The influence of MMR-
deficient tumor subpopulations on long-term survival after a systemic administration
with these drugs is unknown. Therefore, the development of novel strategies to treat
MMR-deficient tumors is of high interest. Here we present a novel therapeutic
approach that takes advantage of the MSI phenotype of MMR-deficient cells. In
addition to being highly specific to tumor cells, this gene therapy approach should
not encounter acquired resistance to treatment, the common problem associated with
cancer chemotherapy.
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3.  RESULTS
(Short summary of the publications)
“Methylation-induced G(2)/M arrest requires a full complement of the
mismatch repair protein hMLH1” Cejka P., Stojic L., Mojas N., Russell A.M.,
Heinimann K., Cannavo E., di Pietro M., Marra G. and Jiricny J. EMBO J. 2003, 22,
2245-54 (Appendix I).
This publication describes the findings of the first project carried out during my
thesis. We describe the construction of the human 293T La cell line, in which the
expression of the MMR protein hMLH1 can be finely regulated by Doxycycline
(DOX). We provide evidence that while the cells expressing hMLH1 are MMR-
proficient in both in vivo and in vitro MMR assays and sensitive to low doses of the
alkylating agent MNNG, cells in which the expression of the hMLH1 protein was
repressed by DOX are MMR-deficient and MNNG resistant. We further describe the
phenotype of cells expressing reduced amounts of hMLH1. We found that cells
expressing ~10 % of the maximal amount of hMLH1 were still MMR-proficient, but
failed to activate the DNA damage checkpoint and cell cycle arrest upon treatment
with low doses of MNNG. Possible relevance of this phenomenon in the genesis of
cancer is discussed.
“Differential killing of mismatch repair-deficient and –proficient cells:
towards the therapy of tumors with microsatellite instability” Cejka P., Marra
G., Hemmerle C., Cannavo’ E., Storchova Z. and Jiricny J. Cancer Res. In press.
(Appendix II).
This manuscript describes results obtained in the last year of my thesis. We set
out to test the proof of principle of a novel therapy of cancers with MSI. The
principle of the therapy is to introduce into the tumor cells a DNA construct
containing a gene coding for a toxin, frameshifted by a repeat. In MSI cancer cells,
the repeat will be highly unstable and in cases where the frameshifting process
restores the proper reading frame of the toxin, the cell will be killed. Here we present
an assay that allows the comparison of repeat stability between MMR-proficient and
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-deficient cells in a strictly isogenic system. We show that a (C)12 repeat was 20-
times more stable in MMR-proficient background then in a MMR-deficient one. Our
assay will enable us to screen a high number of microsatellites to find those best
suitable for the planned gene therapy approach.
“Mismatch repair-dependent transcriptome changes in human cells treated
with the methylating agent MNNG” di Pietro M., Marra G., Cejka P., Stojic L.,
Menigatti M., Cattaruzza M.S. and Jiricny J. Cancer Res. In press. (Appendix III)
In this paper, di Pietro et al. further characterized signal transduction pathways
leading to cell death, which are activated in MMR-proficient cells after treatment
with the alkylating agent MNNG. Two matched pairs of MMR-proficient and -
deficient cell lines were employed. The first was TK6/MT1, B-cell leukemia cells
with intact p53 and the second 293T La+/ La-, isogenic system described previously,
with inactivated p53. Cells were treated with equimolar MNNG concentrations, so
that ~90% of MMR-proficient cells were killed, while their MMR-deficient
counterparts were left unaffected. As expected, no significant changes in RNA
expression in both MMR-deficient cell lines MT1 and 293T La- were detected. On
the other hand, dramatic changes were observed in TK6 cells, suggesting activation
of both p53 dependent and independent cell death pathways. Surprisingly, the
response was much less pronounced in 293T La+ cells, despite the fact that these
cells activate cell cycle arrest and are killed with the same efficiency as TK6 cells.
Using a variety of apoptotic markers, activation of the classical apoptotic cell death
pathway was confirmed in TK6 cells, while all assays were negative in the case of
293T La+ cells. The authors conclude that functional MMR is fundamentally
responsible for the cytotoxicity of MNNG, and cells are killed even if several of their
signal transduction pathways are inactivated.
“DNA damage signalling induced by low doses of SN1 type methylating
agents is dependent on functional mismatch repair and ATR kinase.” Stojic L.,
Mojas N., Cejka P., Ferrari S., Marra G. and Jiricny J. Manuscript submitted.
(Appendix IV)
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In this paper, Stojic et al. provide detailed characterization of the G2 cell cycle
arrest activated in MMR dependent manner upon treatment with low doses of the
alkylating agent MNNG in 293T La cells. It was shown that MMR proficiency and
cell division are essential for the checkpoint activation. Interestingly, MMR-
proficient cells arrested only in the second G2-phase after treatment with low doses
of MNNG, suggesting that the O6-methylguanine/thymine mispairs generated after
the first S-phase are not directly responsible for the checkpoint activation. Instead,
the processing of these mispairs by MMR in the first cell cycle leads to generation of
lesions, possibly single-strand gaps that are converted to double strand breaks
following the second S-phase posttreatment through aberrant repair/recombination.
This hypothesis is supported by the differential kinetics of activation of the
downstream targets of the checkpoint kinases ATR and ATM. Furthermore, it was
shown that the checkpoint activation after treatment with high doses of MNNG is
substantially different; it is MMR independent and does not require cell division.
“Functional mismatch repair is not required for ionizing radiation-induced
DNA damage signaling.” Cejka P., Stojic L., Marra G. and Jiricny J. Manuscript
submitted. (Appendix V).
Recently, the activation of the S-phase checkpoint upon ionizing radiation (IR)
has been described to be dependent on functional MMR. This work was in
disagreement with observations of others, who reported robust S-phase checkpoint
activation in cells irrespective of their MMR status. It appeared possible that the
discrepancies may have been linked with the heterogeneity of the MMR-proficient
and -deficient cells employed. We thus examined the cellular response to IR using
the isogenic 293T La system. We did not observe any differences in the response to
IR between MMR-deficient and -proficient cells. Moreover, we repeated the analysis
with some of the cell lines used in the previous studies, and verified their MMR
status using in-vitro MMR assays. We conclude that the response to IR-induced
DNA damage is unaffected by their MMR status.
Conclusion and perspectives
35
4. CONCLUSION AND PERSPECTIVES
Postreplicative mismatch repair (MMR) plays a paramount role in maintaining
genomic stability. In recent years, the study of MMR intensified after a discovery
that (i) MMR defects are linked to hereditary non-polyposis colon cancer (HNPCC)
and a significant proportion of sporadic cancers, and that (ii) MMR-deficient cells
are highly resistant to certain types of chemotherapeutics.  However, the MMR
community lacked isogenic MMR-proficient and –deficient cells. The systems
available to date were obtained either by random mutagenesis of the MMR-proficient
cells and subsequent selection of MMR-deficient cells, or by the transfer of a
chromosome carrying the mutated MMR gene or its cDNA into MMR-deficient cells
(which were originally isolated from tumors) to generate a “matched” MMR-
proficient cell line. The shortcoming of these systems was that the MMR-deficient
cells have a mutator phenotype. Thus, even though the matched cell pairs were semi-
isogenic at the beginning of the experiment, the MMR-deficient line acquired
numerous mutations during long-term culturing, which caused it to drift further and
further away from its MMR-proficient counterpart. Therefore, the 293T La cell line
constructed during the course of this thesis, in which the expression of the hMLH1
gene and thus the MMR status can be finely regulated, represents a significant
milestone. It is the first cell line that enables the study of the MMR process in a truly
isogenic genetic background, and in addition, enables to study also the phenotype of
cells expressing varying amounts of hMLH1. 293T La cells are thus becoming an
invaluable tool for a number of different studies. They are currently being used in
several projects ongoing in our laboratory, some of which are described in this thesis,
as well as in five other laboratories in Europe.
At first, these cells were used to study the MMR-dependent cellular responses
upon treatment with alkylating agents. It was shown that cells expressing lower than
wildtype levels of hMLH1 are still MMR-proficient, but show a defect in response to
DNA damage. This observation might have a far-reaching influence on our
understanding of how the MMR defect causes cancer. It is important to note that the
phenotype observed in cell culture experiments in vitro does not prove that the same
effect takes place also in vivo. Thus, the question remains whether a partial
downregulation of expression of a MMR gene gives the cell a growth advantage in
the environment of the colon epithelium or other organs.  Only clinical studies that
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include detailed immunohistochemical and MSI analysis can answer that question.
Moreover, 293T La cells were used to study the checkpoint pathways activated in
MMR-dependent manner upon treatment with MNNG. It was shown that the
checkpoint activation upon treatment with low doses of MNNG is likely ATR-
dependent, requires a functional MMR system and replication. On the other hand,
high dose MNNG induces a very fast checkpoint activation, which is MMR- and
replication-independent. However, the exact biochemical role of MMR in this
process, as well as the nature of the lesions that ultimately trigger the checkpoint
signaling, remain unclear.
Secondly, 293T La cells were used to develop an assay that enables to screen
for the difference in stability of various repeats in MMR-proficient and -deficient
backgrounds. The ultimate goal is to develop a novel tumor therapy that would
exploit the difference in repeat stability to selectively kill MMR-deficient cells. The
study presented in this thesis must be understood as just an initial step towards this
goal. Once the optimal repeat is selected, further experiments must be performed in
vivo, i.e. the stability of the repeat and the efficiency of the therapy must be followed
in a tumor environment. Human tumor xenografts in immunocompromised mice
present an attractive model system for these experiments. We expect that 293T La
cells will form tumors in these mice and that a simple modification of our assay will
enable us to perform experiments using the xenograft system.
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5. APPENDIX I
Methylation-induced G(2)/M arrest requires a full complement of the mismatch
repair protein hMLH1. Cejka P., Stojic L., Mojas N., Russell A.M., Heinimann K.,
Cannavo E., di Pietro M., Marra G. and Jiricny J. EMBO J. 2003, 22, 2245-54.
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The mismatch repair (MMR) gene hMLH1 is mutated
in ~50% of hereditary non-polyposis colon cancers
and transcriptionally silenced in ~25% of sporadic
tumours of the right colon. Cells lacking hMLH1 dis-
play microsatellite instability and resistance to killing
by methylating agents. In an attempt to study the
phenotypic effects of hMLH1 downregulation in
greater detail, we designed an isogenic system, in
which hMLH1 expression is regulated by doxycycline.
We now report that human embryonic kidney 293T
cells expressing high amounts of hMLH1 were MMR-
pro®cient and arrested at the G2/M cell cycle check-
point following treatment with the DNA methylating
agent N-methyl-N¢-nitro-N-nitrosoguanidine (MNNG),
while cells not expressing hMLH1 displayed a MMR
defect and failed to arrest upon MNNG treatment.
Interestingly, MMR pro®ciency was restored even at
low hMLH1 concentrations, while checkpoint activ-
ation required a full complement of hMLH1. In
the MMR-pro®cient cells, activation of the MNNG-
induced G2/M checkpoint was accompanied by phos-
phorylation of p53, but the cell death pathway was
p53 independent, as the latter polypeptide is function-
ally inactivated in these cells by SV40 large T antigen.
Keywords: cell cycle checkpoint/hMLH1/methylating
agent/mismatch repair/TetOff
Introduction
Mutations in mismatch repair (MMR) genes, predomin-
antly hMSH2 and hMLH1, segregate with hereditary non-
polyposis colon cancer (HNPCC). Inheritance of a single
mutated allele of a MMR gene predisposes to precocious
cancers of the colon, endometrium and ovary. Analysis of
HNPCC tumour cells showed that repeated sequence
elements (microsatellites) in their genomic DNA are
frequently mutated (for a review see Peltomaki, 2001). As
microsatellite instability (MSI) is a hallmark of defective
MMR in all organisms tested to date, and has been shown
to be present in all tumour cell lines that have lost both
alleles of hMSH2 or hMLH1 (Boyer et al., 1995), it is
assumed that the wild type alleles of the respective MMR
genes in cells of HNPCC tumours have been lost or
inactivated by mutation. But mutations in MMR genes are
not an absolute prerequisite for MSI. In recent years, a
number of sporadic colon tumours and tumour cell lines
displaying MSI have been described that are MMR-
de®cient due to silencing of the hMLH1 promoter by
hypermethylation (reviewed in Esteller, 2002).
Once both MMR gene alleles have been inactivated, the
cell's propensity towards acquiring mutations increases,
especially in genes carrying microsatellite repeats. Should
the mutated genes be involved in the control of cell
proliferation, the mutator cell in, for example, the colonic
epithelium would be able to divide in an uncontrolled
manner and thus give rise to an adenomatous polyp. As the
cells in this benign growth acquire further mutations with
subsequent cell divisions, the adenoma would rapidly
become transformed into a carcinoma. That such a path to
transformation can be followed in vivo was demonstrated
when numerous HNPCC colon cancers were shown to
carry frameshift mutations in a run of 10 adenines within
the coding sequence of the transforming growth factor b
receptor type II (TGFbRII) gene, as well as in other genes
involved in growth control or apoptosis (reviewed in
Markowitz et al., 2002). Further support for this hypo-
thesis comes from the ®nding that adenomas of HNPCC
kindred transform to carcinomas with a much higher
frequency than those associated with sporadic disease
(Kinzler and Vogelstein, 1998), presumably due to a more
rapid acquisition of transforming mutations.
The above ®ndings help explain how the loss of MMR
might accelerate cellular transformation and tumour
progression. What is unclear to date, however, is whether
the transformation process begins only following the
inactivation of both MMR gene alleles, or whether it
commences already at the stage when only one allele is
affected or when the expression of the given MMR gene is
only attenuated, rather than shut off, such as might be the
case in cells where the hMLH1 promoter is only partially
methylated. The notion that a reduction in MMR protein
levels might promote tumorigenesis originates in studies
with Msh2+/± mice. Although the Msh2+/± embryonic stem
cells were apparently normal in terms of their MMR
capacity as measured by MSI (de Wind et al., 1995), the
heterozygous animals were cancer prone, and presented
with tumours that often still contained the wild-type Msh2
allele (de Wind et al., 1998). The propensity of the MMR
heterozygous cells to transformation would thus appear to
be linked to a process distinct from the correction of
replication errors. What might the nature of these
processes be?
In recent years, MMR defects have been linked to
several other phenomena, such as transcription-coupled
repair and recombinationÐboth mitotic and meiotic
(reviewed in Harfe and Jinks-Robertson, 2000). In
Methylation-induced G2/M arrest requires a full
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addition, the MMR system was implicated in activation
of cell cycle checkpoints and apoptosis, as witnessed by
the increased resistance of MMR-de®cient cells to the
methylating agent N-methyl-N¢-nitro-N-nitrosoguanidine
(MNNG) or cisplatin (reviewed in Bellacosa, 2001).
Thus, while MMR+/± cells, or cells expressing low amounts
of MMR proteins, may not display a mutator phenotype,
they might have at least a partial defect in one of the above
processes, speci®cally in the DNA damage signalling
pathway, which we judged to be of the greatest relevance to
cancer. We wanted to study these processes in detail, but we
lacked isogenic cells expressing varying amounts of MMR
proteins. Cells in which the MMR defect was corrected
either by transfer of a chromosome carrying a single wild-
type copy of the mutated MMR gene (Koi et al., 1994) or its
cDNA (Risinger et al., 1998; Buermeyer et al., 1999;
Lettieri et al., 1999; Claij and Te Riele, 2002) were
unsuitable for our studies, because they express similar or
even higher amounts of the complementing MMR proteins
than MMR-pro®cient controls. Thus, in order to be able to
study the phenotypic consequences associated with reduced
levels of MMR proteins, we had to generate a new line,
preferably of epithelial origin, in which the expression of a
selected MMR gene could be regulated. We now describe
the construction and characterization of a line in which the
expression of hMLH1 can be tightly regulated by
doxycycline with the help of the TetOff system.
Results
Construction of cells with inducible hMLH1
expression
The human embryonic kidney cell line 293T is MMR
de®cient, because the hMLH1 gene in these cells is
epigenetically silenced by promoter hypermethylation
(Trojan et al., 2002). We set out to correct its MMR
defect through the expression of exogenous hMLH1 using
the TetOff expression system, which can be tightly
regulated. We ®rst generated the 293T-TetOff cell line
by stable transfection of the 293T cells with a DNA vector
encoding the tetracycline-controlled transactivator (tTA).
In the second step, we stably transfected the 293T-TetOff
cells with a vector carrying the hMLH1 cDNA under the
control of the tetracycline response element (TRE), thus
creating 293T La cells. In the absence of tetracycline, or
its more stable analogue doxycycline (Dox), the tTA
protein binds to the TRE and activates transcription of
hMLH1; conversely, addition of the drug induces a
conformational change in tTA, which loses its ability to
bind DNA and the transcription of hMLH1 is thus turned
off (Figure 1A). During the initial screening, we used Dox
at a concentration of 2 mg/ml, as recommended by the
manufacturer, but later we found that a concentration of
50 ng/ml was suf®cient to turn off the expression of
hMLH1 below the limit of detection by western blotting
(see below).
In vivo, hMLH1 interacts with hPMS2 to form the
heterodimer hMutLa, which is essential for MMR. Our
previous studies have shown that hPMS2 is unstable in the
absence of its cognate partner (RaÈschle et al., 1999).
Indeed, no hMLH1 could be detected in the extracts of
293T cells, and hPMS2 was hardly detectable (Trojan
et al., 2002). A similar situation also existed in our 293T
La clone grown in the presence of Dox, i.e. under
conditions where the hMLH1 promoter is shut off
(Figure 1B). However, expression of hMLH1 brought
about hPMS2 stabilization through the formation of
hMutLa, such that the levels of the latter protein were
Fig. 1. Inducible hMLH1 expression in 293T La cells. (A) In the Tet-Off system, hMLH1 is expressed in the absence of Dox, because the tTA factor
binds to the promoter of the expression vector and thus activates transcription. Addition of Dox to the culture medium causes a conformational change in
tTA, which leads to its dissociation from the promoter and thus to an inactivation of hMLH1 transcription. (B) Western blot analysis of cytoplasmic (CE)
and nuclear (NE) extracts of cells cultured in the absence (±) or presence (+) of 50 ng/ml Dox. hMLH1 and hPMS2 were visualized using anti-hMLH1 or
anti-hPMS2 antibodies as described in Materials and methods. Total extract (TE) of MMR pro®cient HeLa cells was used as a positive control.
(C) Stability of hMutLa. The cells were cultured without Dox (±) to induce maximal hMLH1 expression. Following the addition of 50 ng/ml Dox (+),
total cell extracts were isolated after 1, 2, 3, 4, 6 and 8 days. Western blot analysis was performed using anti-hMLH1 and anti-hPMS2 antibodies as in (B).
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comparable to those seen in extracts of MMR-pro®cient
cell lines (Figure 1B).
The expression of hMLH1 in the 293T La cells grown
in the absence of Dox was substantially higher than in any
MMR-pro®cient cell line tested by us to date (Figure 1B;
data not shown). Interestingly, this overexpression did not
appear to be toxic to the cells: we detected no increase in
the rates of apoptosis, as described for cells microinjected
with expression vectors encoding hMSH2 and hMLH1
(Zhang et al., 1999). Moreover, cells grown in the absence
or presence of Dox divided roughly once every 24 h (data
not shown), unlike HCT116 and SNU-1 cells, in which the
stable expression of hMLH1 was reported to result in
substantially slower growth rates (Shin et al., 1998). When
the expression of the transgene was turned off by the
addition of Dox, the hMLH1 and hPMS2 proteins were
present in the cell extracts in a 1:1 ratio only 24 h later
(Figure 1C) and decayed with similar kinetics. This
experiment showed that hMutLa is extremely stable, as
it was detectable in the extracts of 293T La cells even
6 days after the expression of hMLH1 was shut off.
In the following text, cells grown in the presence of
50 ng/ml Dox that do not express hMLH1 and thus lack
hMutLa will be referred to as 293T La± cells. Those
grown in the absence of Dox, which express hMLH1 and
thus contain functional hMutLa, will be referred to as
293T La+ cells.
hMLH1 expression in 293T La cells restores MMR
in vitro
Extracts of the 293T La cells were tested for MMR
activity in vitro using two different MMR assays (see
Materials and methods). No MMR activity was detected in
extracts of 293T La± cells, but as the defect could be
complemented by the addition of the recombinant wild-
type hMutLa, we concluded that this heterodimer was the
only factor missing in these extracts (Figure 2). In contrast,
extracts from 293T La+ cells were MMR pro®cient in both
assays (Figure 2). Importantly, these results showed that
the excess partnerless hMLH1 in the 293T La line does
not inhibit MMR, at least not in our in vitro system. This
differs from the situation in Saccharomyces cerevisiae,
where overexpression of MLH1 gave rise to a mutator
phenotype associated most likely with the inhibition of
MMR through the homodimerization of this polypeptide
(Shcherbakova and Kunkel, 1999; Shcherbakova et al.,
2001). The MMR pro®ciency of the 293T La+ cells in our
in vitro assay was similar irrespective of whether the
extracts were prepared from cells grown in the absence of
Dox, or 24 h after the addition of the drug (data not
shown), at which time point the ratio of hMLH1 to hPMS2
was 1:1 (Figure 1C).
Inducible hMLH1 expression restores sensitivity to
alkylating agents
In order to determine the effect of hMLH1 expression on
the sensitivity of 293T La cells to MNNG, we used
clonogenic assays to quantify the surviving fraction of
293T La± and 293T La+ cells following treatment with
5 mM MNNG. [Note that 293T La cells do not express
MGMT, the enzyme responsible for the detoxi®cation of
methylation damage (G.Marra, unpublished data). For this
reason, the experiments described below were carried out
in the absence of the MGMT inhibitor O6-benzylguanine.]
As shown in Figure 3A, 293T La+ cells were very
sensitive to killing by MNNG, and the surviving fraction
was indistinguishable from that obtained after MNNG
treatment of the related MMR-pro®cient 293 cell line. In
contrast, 293T La± cells were resistant to killing by
MNNG, just like the parental, MMR-de®cient 293T cells.
The presence of Dox in the culture medium had no effect
on the survival of any of the control cell lines used in this
study (Figure 3A).
The sensitivity of 293T La cells to MNNG was further
examined using the MTT assay, which is based on the
cleavage of the yellow tetrazolium salt MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
by the action of mitochondrial dehydrogenases to form a
violet formazan dye. As this reaction takes place only in
living cells, these can be distinguished from non-viable
cells in a simple colorimetric assay. As shown in
Figure 3B, 293T La± cells were 125-fold more resistant
Fig. 2. MMR pro®ciency of 293T La cell extracts. (A) Repair ef®-
ciency of a G/T mismatch in the M13mp2 vector carrying a strand
discrimination signal 3¢ from the mispair, using cytoplasmic extracts of
the 293T La+ and 293T La± cells, supplemented or not with recom-
binant hMutLa (see text for details). Error bars show standard errors.
(B) Correction of a G/T mismatch within a BglII restriction site of a
pGEM vector, following incubation with nuclear extracts of 293T La+
or 293T La± cells, supplemented or not with recombinant hMutLa.
The strand discrimination signal in this heteroduplex substrate was 5¢
from the mispair. Ef®cient repair resulted in the restoration of a BglII
site and in the generation of two DNA fragments that co-migrate with
those observed in the reference digest of the homoduplex molecule
carrying a bona ®de BglII site.
Mismatch repair and methylation-induced G2/M arrest
2247
40
40
to killing by MNNG than the same cells in a MMR-
pro®cient mode (i.e. 293T La+ cells).
Expression of hMLH1 in 293T La cells leads to
activation of a methylation damage induced cell
cycle arrest
To determine whether the increased sensitivity of 293T
La+ cells to MNNG resulted from induction of cell cycle
arrest and cell death, the treated 293T La+ and 293T La±
cell populations were analysed by ¯ow cytometry. As
shown in Figure 3C, 2 days after treatment with 0.2 mM
MNNG, the 293T La+ cells were mostly arrested in the
G2/M phase of the cell cycle. One day later, cells
containing sub-G1 amounts of DNA became detectable,
and this population increased with time. In contrast, no
increase in the population of cells either arrested in G2/M
or with a lower than 2n DNA content was detected in
cultures of treated 293T La± cells.
In order to further characterize the response of cells to
MNNG, we analysed the phosphorylation status of Cdc2.
As shown in Figure 4A, Cdc2 phosphorylated on Tyr15
accumulated exclusively in 293T La+ cells treated with
0.2 mM MNNG. This provides molecular evidence for a
G2/M arrest, because so long as this kinase remains
phosphorylated, entry into mitosis should be blocked. No
difference in Cdc2 phosphorylation was observed in the
extracts of MNNG-treated 293T La± cells (Figure 4A).
The above results thus show that induction of hMLH1
expression in the 293T La cells was necessary and
suf®cient to endow them with a MMR-pro®cient status,
which also enabled them to respond to DNA damage
induced by MNNG. What is presently unclear is the role of
the MMR system in this checkpoint activation. DNA
damage signalling is known to be mediated via several
protein phosphorylation cascades, which involve primarily
the DNA-dependent protein kinase (DNA-PK), or the
ataxia telangiectasia-mutated (ATM) and ATM and
Rad3-related (ATR) kinases. The downstream target of
the latter enzymes is the p53 tumour suppressor protein,
the phosphorylation of which on Ser15 is known to lead to
its stabilization and subsequent activation as a transcrip-
tion factor (Tibbetts et al., 1999). Phosphorylation of p53
has indeed been shown to take place upon MNNG
treatment, and was shown to be dependent on functional
hMutSa and hMutLa (Duckett et al., 1999; Hickman and
Samson, 1999; Adamson et al., 2002). However, as the
latter experiments were carried out with drug concentra-
tions 25- to 125-fold higher than those used in our study,
we wanted to test whether Ser15 phosphorylation also took
place in the 293T La cells treated with 0.2 mM MNNG.
These cells overexpress the SV40 large T antigen and thus
contain large amounts of stabilized p53 polypeptide. This
system is ideally suited for the study of post-translational
modi®cation of p53, as the steady-state levels of the latter
protein remain unaltered during the experiment (Tibbetts
et al., 1999). As anticipated, the p53 steady-state levels in
the 293T La cell extracts were high, irrespective of
whether hMLH1 was expressed or not, or whether extracts
of treated or untreated cells were examined (Figure 4A).
However, following MNNG treatment, phosphorylation of
p53 with a Ser15-speci®c antibody could be detected
exclusively in the MMR-pro®cient 293T La+ cells.
Notably, and in contrast to the study by Adamson et al.
(2002), where the phosphorylation of p53 became detect-
able already just minutes after MNNG treatment, the
MMR-dependent post-translational modi®cation of p53
observed in our cells peaked at 48 h, i.e. at a time point
where most cells were arrested at G2/M (Figure 3C). This
difference is probably linked with the high concentration
of MNNG (25 mM) used in the latter study, which would
be expected to introduce numerous single- and double-
strand breaks into DNA that arise through the spontaneous
loss of methylated purines and the subsequent breakage of
the sugar-phosphate DNA backbone by b-elimination at
the resulting abasic sites (Loeb, 1985). DNA strand breaks
rapidly activate the ATM/ATR kinases that subsequently
phosphorylate a number of downstream targets, one of
which is histone H2AX (Redon et al., 2002). This histone
modi®cation is thought to aid the recruitment of DNA
repair factors to the sites of damage (Paull et al., 2000).
H2AX is phosphorylated in the 293T La cells upon
Fig. 3. Sensitivity of 293T La cells to MNNG. (A) Survival of 293T
La+ and 293T La± cells following treatment with 5 mM MNNG. 293
and 293T cells were used as MMR-pro®cient and -de®cient controls,
respectively. The presence of Dox (+Dox) in the culture medium did
not affect the control cells, but had a dramatic effect on the survival of
the 293T La cell populations. (B) IC50 values of 293T La+ and 293T
La± cells. Each value represents the mean 6 SE. (C) Cell cycle pro®les
of 293T La+ and 293T La± cells treated with 0.2 mM MNNG. Shown
are representative cytometrograms of cells expressing (293T La+) and
not expressing (293T La±) hMLH1. G1, cell population in the G1 phase
of the cell cycle with a 2n DNA content; G2, cells in the G2 and M
stages of the cell cycle with a 4n DNA content; S, cells in various
stages of DNA synthesis with a DNA content between 2n and 4n.
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treatment with 0.2 mM MNNG, as witnessed by the
formation of phospho-H2AX foci (Figure 4B). However,
these foci arise in both 293T La+ and 293T La± cells soon
after treatment. Thus, damage caused by direct modi®ca-
tions of DNA at low concentrations of MNNG does not
trigger the G2/M checkpoint. The activation of the
checkpoint machinery must take place after H2AX
phosphorylation, in the second cell cycle post-treatment
(Kaina et al., 1997), and must involve the MMR system,
perhaps in conjunction with another pathway of DNA
metabolism that remains to be identi®ed. Thus, the lesions
that trigger the checkpoint machinery are distinct from
those that bring about phosphorylation of H2AX.
MMR pro®ciency and response to MNNG
treatment require different levels of hMLH1
expression
The principal goal of this study was to investigate the
phenotypic effects of reduced expression of MMR
proteins, such as might be encountered when expression
of the gene is attenuated by cytosine methylation. In order
to achieve this goal, we attempted to modulate hMLH1
expression in the 293T La cells. This could be achieved
by varying the Dox concentration in the culture media.
Thus, cells grown in the presence of 0.1, 0.2, 0.4, 0.8 and
1.5 ng/ml Dox contained steadily decreasing amounts of
hMLH1 and hPMS2, as compared with cells grown in the
absence of the drug (Figure 5A).
When we tested how this variation in the amount of
hMutLa affected MMR ef®ciency, we found that extracts
of cells expressing as little as 10% of the amounts found in
cells grown in the absence of Dox were still pro®cient in
the in vitro MMR assays. Cells cultivated with 0.1 and
0.2 ng/ml Dox showed MMR activities comparable to
those of the MMR-positive 293T La+ cells grown in the
absence of Dox, and even extracts of cells cultivated with
0.4 ng/ml Dox were still able to repair mismatches in vitro,
albeit with lower ef®ciency (Figure 5B). MMR pro®ciency
was lost only in cell extracts in which the hMLH1 and
hPMS2 proteins became dif®cult to detect by western
blotting (Figure 5A). To test whether the results of the
in vitro MMR assays were re¯ected also in the MSI
Fig. 4. Post-translational protein modi®cation and strand break process-
ing in MNNG-treated 293T La cells. (A) Phosphorylation status of p53
and cdc2 in 293T La+ and 293T La± cells 1±4 days after treatment
with 0.2 mM MNNG. P-p53, P-cdc2, phosphorylated p53 and cdc2
proteins, respectively; C, untreated control cells; b-tubulin, internal
standard used to ascertain equal gel loading. (B) g-H2AX foci forma-
tion in MNNG-treated 293T La cells. In the control cell population,
<10% of cells displayed H2AX foci. Following MNNG treatment, all
cells contained foci until 24 h post-treatment. See text for details and
Materials and methods for experimental procedures.
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phenotype of the cells, we analysed the BAT26 micro-
satellite marker, which contains a repeat of 26 deoxy-
adenosines, and which is considered to be a reliable
indicator of MSI. Because the 293T La cells are hypo-
triploid, and because this cell line was MMR de®cient for
many generations prior to our intervention, the BAT26
locus was found to be highly heterogeneous. The product
of PCR ampli®cation had on average eight peaks, and we
therefore applied the HNPCC criteria of MSI (Loukola
et al., 2001), whereby only PCR products that differed by
three or more peaks at this locus were considered to be a
sign of MSI. By these criteria, the BAT26 instability in the
cells propagated for 35 generations in 0 or 0.2 ng/ml
Dox was ~1%, whereas cells grown with 50 ng/ml Dox
displayed MSI that was ~5-fold higher (Table I). How-
ever, closer inspection of the data revealed that cells
propagated in 0 or 0.2 ng/ml Dox displayed no alleles
(0/211) that differed by more than 4 bp from the median. In
contrast, two such alleles (two out of 73; 2.7%) were found
in the cells grown with 50 ng/ml Dox (Table I, numbers in
parentheses). This suggests that MSI at the BAT26 locus
in the 293T La± cells is substantially greater than in cells
expressing hMLH1, and thus that expression of even low
amounts of hMutLa are suf®cient to correct the MMR
defect in these cells, both in vitro (Figure 2) and in vivo
(Table I).
We were interested to determine whether the low
amounts of the hMLH1/hPMS2 heterodimer that were
shown to restore MMR pro®ciency were also able to
activate the DNA damage-induced cell cycle arrest in
293T La cells. To this end, we treated the cells with 5 mM
MNNG and calculated the average doubling time over a
period of 5 days. In accordance with our previous
experiments, only cells expressing the highest amounts
of hMLH1 (i.e. 293T La+ cells grown without Dox) ceased
to grow, as suggested by their increased doubling time.
Cells grown in 0.1 ng/ml Dox were only partially affected,
and cells cultivated with 0.2 ng/ml Dox or more grew
similarly to 293T La± cells (Figure 5C). To test whether
this growth retardation was due to checkpoint activation,
we analysed the DNA content of the cells 3 days after
treatment with 0.2 mM MNNG. As shown in Figure 5D,
FACS analysis showed that only cells expressing the
highest amounts of hMLH1 (i.e. cells cultured without
Dox) displayed a strong G2/M arrest (an average of 63% of
the cells were in G2/M). The response of cells cultivated
with 0.1 ng/ml Dox was substantially weaker (~27% cells
in G2/M), and the cell cycle pro®les of cells grown with
0.2 ng/ml Dox or more were indistinguishable from those
of the untreated controls (~22% cells in G2/M). Notably,
whereas cells grown in the absence of Dox activated the
MNNG-induced G2/M checkpoint, while those grown in
Table I. Instability of the BAT26 chromosomal locus in 293T La
cells expressing varying amounts of hMLH1
Dox (ng/ml) MSI+/total % MSI
0 2 (0)/131 1.5
0.2 1 (0)/80 1.3
50 4 (2)/73 5.5 (2.7)
MSI+ clones were de®ned as those displaying more than three extra
peaks in the sequence of the PCR product. Numbers in parentheses
refer to clones with more than four extra peaks.
Fig. 5. Mismatch correction ef®ciency and MNNG-induced G2/M arrest
in cells expressing different amounts of hMLH1. (A) Dependence of
hMLH1 expression on Dox concentration. hMLH1 and hPMS2 were
visualized as described in Materials and methods. b-tubulin, internal
standard used to ascertain equal loading. (B) MMR ef®ciency of a G/T
mispair in an M13mp2 substrate carrying a strand-discrimination signal
3¢ from the mispair. Error bars show standard errors. (C) Variation in
doubling times of 293T La cells grown in the indicated Dox concentra-
tions following treatment with 5 mM MNNG. (D) FACS analysis of
293T La cell populations grown in the indicated Dox concentrations,
either untreated (Control), or 72 h after treatment with 0.2 mM MNNG
(see also Figure 3C). (E) Phosphorylation of p53 and cdc2 48 h after
treatment of cells (grown in the indicated Dox concentrations) with
0.2 mM MNNG. b-tubulin, internal standard used to ascertain equal
loading.
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0.2 ng/ml Dox failed to do so, phosphorylated forms of
p53 and cdc2 could be detected in both cell populations
(Figure 5E). The extent of cdc2 phosphorylation in
particular would predict that a detectable proportion of
the treated cells should be at the G2/M boundary. This was
clearly not the case, as judged by FACS analysis
(Figure 5D; also see Figure 3C).
Taken together, these experiments show that although
only low amounts of hMutLa are required for MMR
pro®ciency, DNA damage-induced G2/M arrest and cell
death in response to MNNG treatment require a full
complement of this heterodimer. The fact that the 293T
La+ cells arrest and die with kinetics and ef®ciency similar
to other MMR-pro®cient cells con®rms that p53, which is
inactive in these cells, is not required for either of
these processes (Hickman and Samson, 1999). Thus, the
molecular pathways controlling the MNNG-induced G2/M
checkpoint in these cells require further study.
Discussion
We show that expression of hMLH1 in 293T La cells
corrected their MMR defect in vitro and in vivo. The 293T
La+ cells were also found to be >100-fold more sensitive
to killing by MNNG than the isogenic cells lacking
hMLH1. MNNG treatment arrested the MMR-pro®cient
cells in the G2/M phase of the cell cycle, and this arrest
was entirely and solely dependent on the function of
hMLH1. This latter statement is supported by the ®nding
that expression of hMLH1 in 293T La+ cells did not affect
the transcriptional activity of other genes, as demonstrated
by Affymetrix GeneChipÔ analysis (data not shown).
This study also showed that the steady-state levels of the
hMLH1/hPMS2 heterodimer required for MMR pro®-
ciency and DNA damage response were signi®cantly
different. In earlier experiments (Lettieri et al., 1999) we
generated a cell line derived from hMSH6-de®cient
HCT15 cells, which expressed low levels (~20%) of
wild-type hMSH6. This line was MMR pro®cient, but
remained as resistant to killing by methylating agents as
the parental cell line. Similarly, a recent study described a
Msh2±/± mouse embryonic stem cell line in which the
MMR defect was largely corrected by the expression of
low levels (10% of control) of exogenous Msh2, but the
response of these cells to methylating agents was
comparable to that observed with the parental Msh2±/±
cells (Claij and Te Riele, 2002). This damage signalling
defect was suggested by the authors to be linked to poor
recognition of MeG/T mispairs, which arise through the
mispairing of O6-methylguanine (MeG) with thymine
during DNA replication (Karran and Bignami, 1996),
and which are bound less ef®ciently than bona ®de
mispairs by the hMSH2/hMSH6 (hMutSa) heterodimer
(Duckett et al., 1996). Constant loading of hMutSa sliding
clamps at MeG/T mispairs was proposed be responsible for
transmission of the DNA damage signal to the checkpoint
machinery in vivo (Fishel, 1999), and it might be expected
that this process is substantially less ef®cient in cells
expressing only low amounts of the mismatch binding
factor hMutSa. However, the amounts of hMutSa in 293T
La+ and 293T La± cells are equal, and similar to those
found in other MMR-pro®cient cells. Our results thus
extend the above hypothesis by showing that the signal
transduction process also requires the hMLH1/hPMS2
heterodimer, thought to act downstream of damage
recognition. Moreover, our result show that the recogni-
tion of MeG/T mispairs per se is insuf®cient to activate the
checkpoint machinery. The G2/M checkpoint is thought to
be controlled by the phosphoinositide-3 (PI3) kinases
ATM/ATR, which are principally responsible for the
phosphorylation of p53 on Ser15 (Osborn et al., 2002).
The MeG/T mispairs arise already during the ®rst round of
replication, yet no p53 phosphorylation is detectable until
24 h after treatment, at which point the cells are beginning
to enter the second S phase (Figure 3C; data not shown).
Notably, the peak of signalling activity coincides with
that of chromosomal rearrangements (sister chromatid
exchanges and recombinations) induced by MNNG (Kaina
et al., 1997). Thus, MMR-dependent processing of the
MeG/T mispairs that arise during the ®rst S phase
apparently does not activate the checkpoint machinery,
but leads instead to the generation of intermediates that
result in aberrant recombination events during the subse-
quent round of DNA replication, which then signal. What
the exact nature of these intermediates may be is currently
the subject of intensive studies.
The evidence presented here shows that cells with lower
than wild-type levels of MMR proteins are not pheno-
typically normal, despite being MMR pro®cient. The
observed defect in DNA damage signalling may be
relevant to cellular transformation and cancer, particularly
in epithelial cells that are rapidly proliferating and that
may be exposed to stress or carcinogens. In the colon, the
epithelial stem cells that are near the bottom of the crypts
give rise to daughter cells that begin to differentiate during
their migration towards the surface of the colon. Upon
reaching the apex of the crypt, these cells undergo
apoptosis and are shed. When the colonic epithelial cells
become damaged, they should undergo apoptosis and thus
give rise to no mutant progeny. In contrast, cells with a
defect in DNA damage signalling, such as those express-
ing suboptimal amounts of MMR proteins, would not
activate cell cycle checkpoints and apoptosis in response
to DNA damage. Instead, they might acquire mutations
that allow them to continue to proliferate and give rise to
an adenoma.
The relevance of this hypothesis to the situation in vivo
hinges on two points. First, there are currently no
experimental data documenting instances where colono-
cytes or other epithelial cells that are prone to transform-
ation express low MMR protein levels. We obtained some
evidence of lower than normal steady-state levels of
hMSH2 and increased resistance to methylating agents in
the immortalized lymphoblasts of HNPCC patients, which
are heterozygous in the hMSH2 locus, but the hMLH1±/±
cells were normal in all assays (Marra et al., 2001). It is not
known whether hMSH2 and hMLH1 levels in hetero-
zygous colonocytes of HNPCC kindred are lower than in
similar cells of normal individuals, even though some
¯uctuations might be expected. However, the recent
characterization of the hMLH1 promoter as a frequent
target of DNA hypermethylation (Esteller, 2002) implies
that there must be cells with only partially methylated
promoters, because de novo methylation of CpG islands is
a gradual process. These cells, such as the 293T La cells
grown in low concentrations of Dox (Figure 5A), would
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contain decreased levels of hMutLa and would therefore
be likely to also have a defective response to DNA
damage.
The second point concerns the nature of the endogenous
DNA damage that might trigger the transformation
process. It is conceivable that normal colonocytes which
become damaged by endogenous or exogenous DNA
modifying agents would arrest and, in cases where the
extent of the damage is beyond repair, activate cell death
processes, while those expressing reduced levels of
hMutLa would continue to proliferate and thus acquire
mutations. Although human DNA is aberrantly modi®ed
by S-adenosyl methionine and other methyl group donors,
the extent of such modi®cations might be too low to trigger
cell death. However, the deleterious effects of the
checkpoint defect could become evident also in response
to other types of DNA damage; experimental evidence
implicates the MMR system in the processing of DNA
modi®cations ranging from oxidative damage to bulky
moieties such as cisplatin and AAF (reviewed in
Bellacosa, 2001).
We have described a cell line in which the MMR status
can be controlled by the concentration of doxycycline in
the culture medium. Our current results show that the
activation of transcription of exogenous hMLH1 comple-
ments not only the MMR defect of the 293T cells, but also
reactivates their responsiveness to treatment with methyl-
ating agents, providing that the levels of the MMR proteins
are suf®ciently high to activate the DNA damage-induced
checkpoint. This fully isogenic system is clearly open to
further exploitation, and should allow us to study the
involvement of the MMR system in other pathways of
DNA metabolism, such as response to other types of DNA
damaging agents ranging from ionizing radiation to
crosslinking chemotherapeutics, where the involvement
of MMR was found to be only marginal and where it could
not be ruled out that the observed effects (or lack thereof)
were linked to a selection of an atypical clone from the
stably transfected population. The 293T La line could also
be used in the screening for substances that preferentially
kill MMR-de®cient cells. This should prove invaluable in
the treatment of tumours, both hereditary and sporadic,
with defective MMR.
Materials and methods
Cell lines
The 293T cells (a kind gift of K.Ballmer) were grown in Dulbecco's
modi®ed Eagle's medium with Eagle salts (Gibco-BRL, Gaithersburg,
MD), supplemented with 10% Tet System Approved Fetal Bovine Serum
(Clontech, Palo Alto, CA), 2 mM L-glutamine (Gibco-BRL), 100 IU/ml
penicillin and 100 mg/ml streptomycin (Gibco-BRL). For 293T-TetOff or
293T La cells, 100 mg/ml Zeocin (Invitrogen, San Diego, CA) or
100 mg/ml Zeocin and 300 mg/ml Hygromycin B (Roche Molecular
Biochemicals, Mannheim, Germany) were added, respectively.
Plasmid construction
The pTetOff-Zeo plasmid was constructed by ligation of the following
DNA molecules: the ®rst, coding for tTA, was obtained by digestion of
pTetOff (Clontech) with XhoI (New England Biolabs, Beverly, MA)
followed by ®lling-in with dCTP and dTTP using the Klenow fragment of
DNA polymerase I (New England Biolabs). The second, coding for
Zeocin resistance protein, was obtained by digestion of pVgRXR
(Invitrogen) with BamHI (New England Biolabs) followed by ®lling-in
with dGTP and dATP. The pTRE2-hMLH1 plasmid was generated by
subcloning hMLH1 cDNA (a kind gift of R.Michael Liskay) into the
BamHI and NotI sites of pTRE2 (Clontech).
Calcium phosphate transfections
One day before transfection, 250 000 cells were plated in 6-well plates in
3 ml of cell culture medium. The cells reached ~50% con¯uency on the
day of transfection. Three hundred microlitres of solution A (250 mM
CaCl2) was carefully mixed with 15 mg DNA and 300 ml of solution B
(140 mM NaCl, 50 mM HEPES, 1.4 mM Na2HPO4 pH 7) in an Eppendorf
tube. Exactly 1 min after mixing, 300 ml of the precipitation cocktail was
added to the medium. The plates were incubated for 4 h at 37°C. The
medium was then removed, the cells were washed with phosphate-
buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4´7H2O, 1.4 mM KH2PO4) and fresh cell culture medium was
added.
Generation of the 293T La cell line
293T cells were transfected with pTetOff-Zeo using the calcium
phosphate method (see above). The selection of stable cell lines was
initiated 2 days later using 400 mg/ml Zeocin. After 3 weeks, ~50 colonies
were isolated and screened by transient transfection with pTRE2-Luc
(Clontech) for the expression of luciferase in induced and noninduced
cells (with or without 2 mg/ml Dox; Clontech). The clone with the lowest
background and high induction of luciferase (293T-TetOff) was then
transfected with pTRE2-hMLH1 and pTK-Hyg (ratio 15:1). Selection of
stable cell lines was initiated 2 days post-transfection using 400 mg/ml
hygromycin-B. After 3 weeks, ~160 colonies were isolated and their
extracts were screened by western blotting using antibodies against
hMLH1, hPMS2 and b-tubulin. The clone 293T La was selected for
further study, as it displayed the highest induction of hMLH1 in the
absence of Dox, and no background expression with 2 mg/ml Dox.
Regulation of hMLH1 expression
293T La cells were grown in the presence of 50 ng/ml Dox to keep
hMLH1 expression turned off; fresh Dox was added every second day. To
induce hMLH1 expression, the cells were transferred to a Dox-free
medium, and the cells were cultivated for at least 6 more days. To obtain
cells completely free of hMLH1, cells grown in the absence of Dox were
kept for a least 7 days in a medium containing 50 ng/ml Dox. To obtain
intermediate levels of hMLH1, the cells were cultivated with 1.5, 0.8, 0.4,
0.2 or 0.1 ng/ml Dox for at least 7 days.
Preparation of total protein extracts for western blots
Cells were harvested, transferred to a 1.5 ml Eppendorf tube and washed
twice with PBS. Cell lysis was performed on ice in 50 mM Tris±HCl pH 8,
125 mM NaCl, 1% NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl
¯uoride, 13 complete protease inhibitory cocktail (Roche Molecular
Biochemicals) for 25 min. Insoluble material was pelleted by
centrifugation at 18 000 g for 3 min at 2°C. Protein concentration was
determined using the Bradford assay (Bio-Rad, Munich, Germany).
Western blot analyses
The primary antibodies used in this study were: anti-hMLH1
[PharMingen, San Diego, CA), 1:2000 in TBST (20 mM Tris±HCl
pH 7.4, 150 mM NaCl, 0.1% Tween-20 with 2.5% non-fat dry milk],
hPMS2 (Calbiochem; 1:500), b-tubulin, p53 (Santa Cruz Biotechnology;
1:1500 and 1:2000, respectively), cdc2 (Upstate Biotechnology;
1:1000) and phospho-p53-Ser15, phospho-cdc2-Tyr15 (Cell Signalling
Technology; 1:1000 and 1:5000, respectively). The proteins (20±50 mg)
were denatured, reduced, separated by SDS±PAGE (7.5±12.5%) and
transferred to Hybond-P PVDF membrane (Amersham Pharmacia
Biotech) according to standard protocols (Sambrook et al., 1989). The
membranes were blocked with 5% non-fat dry milk in TBST for 60 min,
incubated with primary antibodies for 60 min, washed three times with
TBST for 10 min, incubated with the peroxidase-conjugated secondary
antibody (anti-mouse IgG, 1:5000 in TBST with 2.5% non-fat dry milk)
for 60 min and washed three times with TBST for 10 min.
Immunoreactive proteins were detected using enhanced chemilumines-
cence (ECL; Amersham Pharmacia Biotech).
Indirect immuno¯uorescence experiments
Cells grown on coverslips were treated or mock-treated with MNNG
(0.2 mM end concentration) and incubated for 6, 12 and 24 h (Figure 4B).
Foci of phosphorylated histone H2AX were visualized using an anti-
phospho-H2AX rabbit polyclonal antibody (Upstate Biotechnology) at
+4°C, over night, at a dilution of 1:100. The procedure was as described
previously (Kleczkowska et al., 2001). To allow direct comparisons, all
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the cells were treated and processed simultaneously, and all the images
were obtained using the same magni®cation, brightness and contrast
settings.
MMR assays
The cell extracts were prepared as described previously (Marra et al.,
2001; Nystrom-Lahti et al., 2002). Two different in vitro assays were
used. The ®rst, adapted from Holmes et al. (1990), is based on a circular
3¢ 193 bp DNA molecule containing a G/T mismatch within a unique
BglII recognition site, a single-strand nick 369 nucleotide residues 5¢ from
the mismatch in the G-containing strand, and a unique BsaI site. This
molecule is refractory to cleavage with BglII, unless the mispair is
corrected to an A/T. Thus, the unrepaired heteroduplex digested with both
endonucleases gives rise to only a single fragment of 3¢ 193 bp, whereas
the repaired homoduplex is cleaved into two fragments of 1¢ 833 and
1¢ 360 bp (Nystrom-Lahti et al., 2002).
The second method, originally described by Thomas et al. (1991),
makes use of an M13mp2 DNA heteroduplex containing G/T mismatch
within lacZa complementation gene, obtained by hybridizing single-
stranded viral (+) DNA with the replicative form I (±) strand. The repair is
directed to the (±) strand by the presence of a nick. The method was
described in detail elsewhere (Marra et al., 2001). In the complementation
studies, extracts were supplemented with puri®ed recombinant hMutLa
(0.1 mg).
MTT assays
Two thousand cells/well were plated in 96-well plates, treated the next
day with various concentrations of MNNG (Sigma; diluted in dimethyl
sulfoxide and stored at ±20°C in the dark) and incubated for 5 days. Then,
20 ml of MTT solution (5 mg/ml MTT; Sigma; in PBS, sterile ®ltered) was
added, and the plates were incubated for 4±5 h at 37°C. One volume of
lysis solution was then added (20% SDS, 50% dimethylformamide
pH <4.7), and the plates were incubated overnight at 37°C. The
solubilized formazan was quanti®ed at 570 nm, using the Versamax
microplate reader (Molecular Devices, Sunnyvale, CA). The optical
density values were plotted against logarithm of MNNG concentrations
and IC50 values were calculated from the regression curve.
Colony-forming assays
Cells in log phase (50±80% con¯uent) were treated with 5 mM MNNG,
harvested after 2 h, and 200 or 2000 cells per duplicate were plated in
10 cm plates. Colonies were counted after 15±20 days of incubation.
Survival was calculated as the ratio of the number of colonies from
treated versus untreated samples.
Doubling time assessment
Cells (35 000) were plated in 35 mm plates. The cell number was
determined daily for 4 days. The doubling time was calculated from the
numbers of cells between the ®rst and the fourth day after plating.
Cell cycle analyses
Cells (both attached and ¯oating) were harvested, counted, washed with
PBS, ®xed with 70% ethanol and stored up to 1 week at 4°C. The cells
were then washed once with PBS, incubated in PBS containing RNase A
(100 mg/ml, Sigma) for 1 h at 37°C, stained with propidium iodide
(20 mg/ml, Sigma) and incubated on ice in the dark for 30 min. DNA
content was analysed by Coulter Epics Altra Flow Cytometer (Beckman
Coulter, Inc., Fullerton, CA). DNA cell cycle analysis software
(MultiCycle, Phoenix Flow Systems, Inc., San Diego, CA) was used to
quantify cell cycle distribution.
MSI analysis
293 La cells grown with 50, 0.2 and 0 ng/ml Dox were subcloned, and
grown independently for 35 generations. The chromosomal DNA was
extracted using the TRI Reagent (Molecular Research Center, Lucerne,
Switzerland). MSI was assessed at the mononucleotide repeat locus
BAT26. PCRs were carried out in a total volume of 25 ml containing
~100 ng of genomic DNA, as described by Loukola et al. (2001). The
PCR products were diluted 1:4 and 0.5 ml was added to 10 ml deionized
formamide (including 0.5 ml GS size standard 400 ROX), denatured at
95°C for 5 min, chilled on ice and loaded on a 96-capillary ABI PRISM
3700 DNA Analyzer (PE Applied Biosystems). MSI was de®ned as the
occurrence of novel alleles that differed by 63 nucleotides from the
control (Loukola et al., 2001).
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6. APPENDIX II
Differential killing of mismatch repair-deficient and -proficient cells: towards
the therapy of tumors with microsatellite instability. Cejka P., Marra G., Hemmerle
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Abstract
DNA mismatch repair (MMR) defects bring about a strong mutator
phenotype and microsatellite instability (MSI). In an attempt to exploit MSI in
cancer therapy, we constructed expression vectors carrying a thymidine kinase/
blasticidin deaminase (TKBSD) fusion gene downstream from a (C)12 or an (A)26
microsatellite, and stably transfected these constructs into human cells, in which
the MMR status could be regulated by doxycycline (DOX). We now show that
ganciclovir-resistant clones arising through frameshifts in the (C)12
microsatellite were 20-times more frequent in cells in which MMR was
inactivated. This difference may be exploited in gene therapy of tumors with
MSI, which represent a substantial proportion of cancers of many different
tissues.
Introduction
A substantial proportion of tumors of different organs displays MSI
(microsatellite instability), a phenotypic trait characterized by a large increase in the
frequency of frameshift mutations within repeated sequence elements, the so-called
microsatellites. This anomaly is caused by inactivation of the postreplicative
mismatch repair (MMR) system, which normally corrects strand misalignments
arising in these repeats during DNA replication (1). In hereditary non-polyposis
colon cancer (HNPCC) kindred, who represent ~5% of colon cancer patients, the
MMR defect and MSI are linked to inherited mutations in genes encoding MMR
proteins. In ~10% of sporadic colon cancers, MSI arises as a result of epigenetic
silencing of the MMR gene hMLH1 (2, 3), and an ever-increasing number of reports
describe MSI also in cancers of head and neck, lung, prostate, breast, bladder and
other tissues (reviewed in (4)). Past attempts to identify agents able to selectively kill
MSI+ cells largely failed. Upon treatment with a range of DNA damaging agents,
Appendix II
51
substantial differences in the response of MMR-deficient and –proficient cells were
observed only for cisplatin, which kills MMR-proficient cells around 3-fold more
efficiently that MMR-deficient ones (5), and for SN1-type methylating agents, where
the difference is around 100-fold (6, 7). MMR-deficient cells were reported to be
more sensitive to killing by CCNU than MMR-proficient controls (8), but this
difference appears to be limited to only a subset of MMR-deficient cell lines. Thus,
in an attempt to identify a more general approach towards the therapy of MMR-
deficient tumors, we set out to exploit the MSI phenotype. In cultured human cells
established from these tumors, MSI was reported to be two to three orders of
magnitude higher than in control lines. We plan to introduce into the cells a toxin-
encoding gene, the open reading frame (ORF) of which is preceded by a labile
microsatellite sequence such that the gene is out-of-frame (Fig. 1A). If the
microsatellite undergoes insertion or deletion mutagenesis, the toxin ORF should in a
given number of events be shifted into the correct reading frame; the construct
should thus express the functional toxin polypeptide, and the transduced cell should
be killed. This experimental strategy should result in an efficient elimination of
MMR-deficient cells, while MMR proficient cells, in which the microsatellite
remains stable, should be unaffected. However, prior to deploying the above
strategy, we needed to establish an experimental system that would permit us to
reliably test the relative stability of a variety of microsatellite repeats in MMR-
proficient and -deficient cells. The critical characteristics of the ideal repeat should
be its high stability in the former cells and substantial instability in the latter. The
mutation frequencies of several microsatellites have been studied previously, using a
variety of assays (9-12). However, in these studies, two major problems were
encountered. First, it could not be excluded that the repeats acquired mutations
already during the lengthy selection of the stable transfectants. Second, the studies
did not employ isogenic pairs of MMR-proficient and –deficient cell lines, such that
it was impossible to exclude the effects on the mutation frequency of other genetic
defects present in these cells. Indeed, Hanford et al. (9) described extensive variation
among microsatellite mutation rates of different clones of the same cell line. We now
describe a system that successfully overcomes these drawbacks by making use of a
strictly isogenic cell pair and a reporter system that allows for the elimination of
mutated transfectants prior to the initiation of the experiment.
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Materials and Methods
Cell lines
293T La cells were derived from the hMLH1-deficient human embryonic
kidney 293T cells by stable transfection with a vector carrying the hMLH1 cDNA
under the control of the inducible Tet-Off™ expression system (7).  The cells were
grown in DMEM with Eagle salts (Gibco BRL, Gaithesburg, MD), supplemented
with 10% Tet System Approved Fetal Bovine Serum (Clontech, Palo Alto, CA),
2mM L-glutamine (Gibco BRL, Gaithesburg, MD), 100 IU/ml penicillin, 100 mg/ml
streptomycin (Gibco BRL, Gaithesburg, MD), 100 mg/ml Zeocin (Invitrogen, San
Diego, CA) and 300 mg/ml Hygromycin B (Roche Molecular Biochemicals, Basel,
Switzerland). To obtain cells completely free of the MMR protein hMLH1 (293T
La-), the cells were transferred for at least 7 days to a medium containing 50 ng/ml
doxycycline (DOX, Clontech, Palo Alto, CA). Fresh DOX was added every second
day. To induce hMLH1 expression (293T La+), the cells were transferred to a
medium without DOX, the medium was changed the following day, and the cells
were cultivated for at least 6 more days. Expression of hMLH1 in these cells fully
restored MMR proficiency (7).
Vector construction
The pSBCTKBSD vector (13) containing the fusion gene encoding thymidine
kinase and blasticidin deaminase was used as a template for a PCR reaction in an
assay consisting of 1x Cloned Pfu buffer, 1mM forward primer, 1mM reverse primer,
200ng template DNA, 0.2mM dNTPs and  2.5U/50ml reaction Pfu turbo DNA
polymerase (Stratagene, La Jolla, CA). The primers (Microsynth, Balgach,
Switzerland) were as follows: forward no-repeat:  TGG CCA GGA TCC ACC ATG
ATT GAA GAA TTC ATT GAA CAA GAT GGA TTG CAC GCA GG, forward
(C)12: TGG CCA GGA TCC ACC ATG ATT GAA CCC CCC CCC CCC ATT
GAA CAA GAT GGA TTG CAC GCA GG, forward (A)26:  TGG CCA GGA TCC
ACC ATG ATT GTC AAA AAA AAA AAA AAA AAA AAA AAA ATT GAA
CAA GAT GGA TTG CAC GCA GG, reverse:  TAC TCG CTC GAG TCA ATG
TAT CTT ATC ATG TCT GGA TCG. The PCR cycle was as follows: 98°C for 3
min, (98°C for 1 min, 69°C for 1 min and 72°C for 5 min)30, 72°C for 10 min. The
PCR products were digested with BamHI and XhoI (both New England Biolabs,
Beverly, MA) and cloned into the corresponding sites of pcDNA3 (Invitrogen, San
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Diego, CA), creating pcDNA3-TKBSD, pcDNA3-(C)12TKBSD and pcDNA3-
(A)26TKBSD vectors.
Isolation of stable transfectants
pcDNA3-TKBSD, pcDNA3-(C)12TKBSD and pcDNA3-(A)26TKBSD vectors
were digested with BglII and DraIII (both New England Biolabs, Beverly, MA), and
subjected to preparative gel electrophoresis. The fragments containing the TK-BSD
fusion gene were isolated and used for transfection of 293T La cells using the
FuGENE reagent (Roche, Basel, Switzerland). Selection was initiated 2 days after
transfection with 10 mg/ml blasticidin S (Invitrogen, San Diego, CA). After 2-3
weeks, stable clones were isolated and further propagated with blasticidin (100
mg/ml).
Mutagenesis assays
The selected clone, carrying the microsatellite repeat/TKBSD fusion stably
integrated in the genome, was grown without or with 50 ng/ml DOX in a 6-well plate
in a medium containing 100 mg/ml blasticidin for 7 days. At this time point, the cells
grown in the presence of DOX were completely free of hMLH1 and thus MMR-
deficient, and cells grown without DOX remained MMR-proficient. The high
concentration of blasticidin in the medium ensured elimination of cells with
frameshifted inserts. The blasticidin was then removed and the cells were further
propagated without or with DOX in a 6-well plate. As the doubling time is
approximately 24 hours, the cells were split every 2 days in a ratio 1:4 to maintain a
constant cell number. In the absence of blasticidin, cells in which the TKBSD fusion
gene was inactivated by frameshift mutagenesis (or otherwise) survived.
Immediately upon blasticidin withdrawal, and at the selected time points (4, 8 and 13
days, ~4, 8 and 13 generations), 1x105 or 5x104 cells were plated into 10 cm dishes in
10 ml of medium containing 30mM ganciclovir (GANC, Sigma, St. Louis, MO) to
score for mutant (GANC-resistant) cells. At the same time, 300 cells were plated in a
medium without GANC to assess plating efficiency (control). After 2 weeks of
incubation, the colonies were stained with Giemsa (Fluka, Buchs, Switzerland) and
counted. (See Fig. 1C for a schematic outline of the expriment.)
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MSI analysis
Chromosomal DNA from the GANC-resistant colonies was extracted using the
TRI reagent (Molecular Research Center, Cincinnati, OH). The vector DNA
sequence containing the repeat was amplified by PCR under the following
conditions: 1x Taq buffer, 1mM forward primer, 1mM reverse primer, 300 ng
template DNA, 0.2mM dNTPs and  2U/50ml reaction Taq DNA polymerase (New
England Biolabs, Beverly, MA). The following primers (Microsynth, Balgach,
Switzerland) were used: forward (GCG GTA GGC GTG TAC GGT G), reverse
(CCA GTC CTC CCG CCA CGA CC). The PCR procedure was as follows: 95°C
for 2 min, (95°C for 1 min, 60°C for 1 min and 72°C for 1 min 20 sec)25, 72°C for 10
min. The PCR products were purified and the DNA regions containing the repeats
were sequenced using the primer GTA CGT AGA CGA TAT CGT CG on an ABI
PRISM 310 Genetic Analyser (Applied Biosystems, Foster City, USA).
Results and Discussion
The experimental system intended for use in gene therapy of tumors with MSI is
based on transduction of the tumor cells with a vector carrying a toxin gene that is
out-of-frame due to the insertion of a microsatellite immediately downstream from
its AUG start codon (Fig. 1A). The inherent instability of the microsatellite in MMR-
cells should result in restoration of the correct reading frame in a given percentage of
the transduced cells and thus in expression of the toxin, and cell death. However, for
the purposes of the present study, we decided to invert this strategy by making use of
an in-frame reporter/toxin combination that allows for a more accurate estimation of
mutation frequencies and is free of artifacts (Fig. 1BC). The reporter gene construct
was a fusion of blasticidin deaminase from Aspergillus terreus (BSD) and thymidine
kinase (TK) from Herpes simplex virus (13). This fusion gene was preceded by a
microsatellite repeat, which was inserted immediately downstream from the start
codon, but which maintained the correct reading frame of the fusion gene. For the
initial experiments, we chose the  (A)26 and (C)12 repeats, together with a control
construct that carried no repeat (Fig. 1B). The BSD protein confers resistance against
blasticidin, which permits the selection of clones carrying the non-mutated construct
stably integrated in the genome. Inducing MMR deficiency in one half of the cells by
adding DOX to the culture medium, and propagating the cells independently in a
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MMR-deficient or -proficient mode for several generations without selection, allows
for mutations within the repeat to occur. Addition of ganciclovir (GANC) to the
medium then eliminates cells in which no frameshifting occurred (Fig. 1C). Thus, by
counting the surviving TK- (GANC resistant) colonies, we can calculate the mutation
frequency in a cell population that consisted initially exclusively of TK+ cells (i.e.
without preexisting mutants), all carrying the vector integrated in the same genomic
sequence context, and in a strictly isogenic genetic background.
Prior to initiating this study, we had to check the integrity of the stable clones
carrying the reporter constructs, more specifically, the integrity of the Tet-Off system
that controls the inducible expression of hMLH1. As shown in Fig. 2A, the 293T La+
cells and the clone stably-transfected with the pcDNA3-(C)12TKBSD vector
(denoted 293T La+(C)12TKBSD) expressed both hPMS2 and hMLH1 in similar
amounts. In the presence of DOX, the transcription of hMLH1 was shut off, which
resulted in the depletion of the hMLH1/hPMS2 heterodimer (7); these cells are
denoted 293T La-(C)12TKBSD. The selected clones carrying the pcDNA3-
(A)26TKBSD and pcDNA3-TKBSD vectors, 293T La(A)26TKBSD and 293T
LaTKBSD, respectively, behaved similarly (data not shown).
Results of the mutagenesis assays (Materials and Methods) indicated that the
(C)12 repeat remained stable in the MMR-proficient 293T La+ cells (Table I, Fig.
2BC). The TK gene remained in-frame, and, upon addition of GANC, most of the
cells were killed. In contrast, frequent frameshift mutations within this repeat in a
MMR-deficient background gave rise to an approximately 20-fold higher number of
GANC-resistant clones in which the TKBSD gene was shifted out-of-frame (Fig.
2BC). The number of GANC-resistant colonies increased with time in both MMR-
proficient and –deficient backgrounds, but the fold-difference remained relatively
stable (Fig. 2C). In contrast to (C)12, the (A)26 repeat was labile in both MMR-
proficient and -deficient  backgrounds, displaying only ~2 fold difference in stability
(Fig 2BC and Table I).
In order to confirm that the GANC-resistant phenotype resulted from a mutation
in the reporter construct, we sequenced the DNA regions containing the repeat and
its close proximity. Microsatellite frameshifts were detected in all the 293T La-
samples sequenced (30/30). Only -1 frameshifts were observed in the (C)12 repeat,
and -1 or, less frequently, -2 frameshifts in the (A)26 repeat (Fig. 2D). Although most
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of the DNA samples isolated from the GANC-resistant MMR-proficient cells also
contained -1 or -2 microsatellite frameshifts, other types of mutations (3/30) were
also detected (not shown), in agreement with previous studies (9). In control clones
not containing a repeat within the reporter gene, the construct remained relatively
stable and we did not detect significant differences in stability between MMR-
proficient and -deficient backgrounds (Fig. 2C and Table I). The above information
is invaluable for the design of the therapeutic “out-of-frame” vector (Fig. 1A). In
theory, only a fraction of frameshift mutations should lead to the restoration of the
correct reading frame, due to the possibility of both insertions and deletions. Our
data demonstrate that deletions of a single repeat unit of a given microsatellite repeat
predominate. Taking this evidence into account, it should be possible to design
vectors with a high propensity towards shifting into the correct reading frame, i.e. by
having the toxin gene insert in the vector in a +1 reading frame in cases where it is
preceded by a mononucleotide repeat.
Microsatellite mutation frequencies measured in our MMR-deficient cells (Fig.
2C, Table II) roughly corresponded to those described by others (9, 14, 15).
However, the relative differences between MMR-proficient and -deficient cells were
somewhat smaller: ~20-fold in our system as compared to 16 to 340-fold as
described by Hanford et al. (9) or 25 to 100-fold as described by Kahn et al. (12).
However, the latter studies compared mutation frequencies of MMR-deficient colon
carcinoma cells either with those of unrelated MMR-proficient colon carcinoma
cells, or even with those of MMR-proficient cancer or normal cells of different type.
It has been well documented that cells acquire a plethora of mutations during
transformation. Some of these mutations might inactivate cell cycle checkpoint
pathways, which might allow DNA replication in the presence of DNA damage, and
thus permit the accumulation of further mutations even in a MMR-proficient
background. Indeed, Boyer and Farber (16) found a 75-fold difference in the
mutation frequency of the same microsatellite in MMR-proficient normal human
fibroblasts and fibrosarcoma cells. Clearly, genetic differences between cells of
different origin make a direct comparison of mutation frequencies very difficult.
A recent study (10) employed the human MMR-deficient colon cancer cells
HCT116 and their MMR-proficient counterparts (HCT116+Chr3), where the MMR
defect was corrected by chromosome 3 transfer. These two cell lines, although not
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isogenic, are more closely related than those used in the studies cited above.
Interestingly, the observed 30-fold difference in the stability of a (CA)13
microsatellite is quite close to that of the (C)12 repeat examined in our study.
The 20-fold difference in the stability of the (C)12 microsatellite between MMR-
proficient and –deficient cells is lower than might have been anticipated from the
results of earlier studies, however, given the extremely low mutation frequency in the
MMR-proficient cells, it is likely to be therapeutically exploitable. Moreover, it is
highly likely that analysis of a larger number of mono- and dinucleotide repeats will
identify a sequence with a substantially higher therapeutic index. Thus, exploitation
of the MSI phenotype, which is currently estimated to segregate with ~15% of colon
cancers, may represent a valid approach towards combating these tumors and, more
importantly, their metastases.
One of the major challenges of tumor therapy is acquired resistance to
treatment. Because the MSI phenotype is linked with defective MMR, the only
chance the transduced cell has to escape death is either to stop replicating, which
would in itself lead to tumor regression, or to silence the transcription of the
transgene. The latter scenario is unlikely, as gene silencing requires as a rule many
cell divisions, and as the microsatellite repeat tested in our study was unstable after
only four replication cycles. Even if this problem should arise, it could be overcome
by repeated transductions. It is therefore likely that the problem of resistance will not
pose a substantial threat to this approach.
The study described above represents but an initial step towards this goal. As the
environment of cells in tumors differs dramatically from that in cell culture, it will be
necessary to carry out in vivo experiments using, in the first instance, human tumor
xenografts in nude mice. Should these experiments meet with success, the
transducing vector will be remodeled to carry the suicide gene out-of-frame, which
would be moved into the correct reading frame through selective frameshift
mutagenesis in MSI cells, as shown in Fig. 1A. In a gene therapy setting, most cells
in solid tumors are not transduced and it is likely that not each cell will mutate the
microsatellite. But as tumor cells are in close contact, it is anticipated that the suicide
gene will exert a “bystander effect”, which should bring about the death not only of
the transduced cell that acquired the frameshift mutation, but also of a number of
surrounding cells (17). A complete eradication of a tumor expressing TK has been
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reported, even though only 10% of the tumor cells expressed the enzyme (17).
Cytosine deaminase, another suicide gene frequently used in gene therapy trials, has
been reported to be effective even if only 2% of the tumor cells were transduced (18)
and strategies causing even more effective bystander effects are being developed
(19). The system described in this study should permit the identification of the most
effective microsatellite/ enzyme/pro-drug combination that could then be further
developed for therapeutic use.
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FIGURE LEGENDS
Figure 1. A, Scheme of a gene therapy approach designed to target MSI+ cells.
The microsatellite repeat puts the toxin out of the correct reading frame, and thus the
vector produces no functional polypeptide. In a MMR- cell, the toxin gene may be
reverted into its correct reading frame through MSI, and the cell will be killed. In
contrast, the repeat should remain stable in cells with functional MMR. B, The
constructs used in this study. The (C)12 and (A)26 microsatellites, or a control DNA
sequence without a repeat, were inserted downstream from the start codon of the
TKBSD fusion protein, while keeping the ORF in its correct reading frame. C,
Scheme of the test assay (see also Materials and Methods). 293T La cells were
transfected with constructs shown in panel B, and stable clones were isolated using
blasticidin selection. The selected clones were then grown in two separate
subcultures: in the MMR-proficient (La+, without DOX) and -deficient (La-, with
DOX). After 4, 8 and 13 days (which corresponds to approximately 4, 8 and 13 cell
generations, respectively), the cells were treated with GANC and plated to select for
TK- mutants.
Figure 2. Differences in repeat stability in isogenic 293T La cells. A, Western
blot analysis of total cell extracts of 293T La (C)12TKBSD cells cultured in the
absence (La+, expressing hMLH1/hPMS2) or presence (La-, not expressing
hMLH1/hPMS2) of 50 ng/ml DOX. The extracts of 293T La+ cells are shown as the
positive control. (See ref. (7) for experimental details). b-tubulin was used to
ascertain equal gel loading. B and C. Comparison of repeat stabilities in isogenic
MMR-proficient (La+) and -deficient (La-) cells. B, Example of a typical result of an
assay described in Fig. 1C. Cells were grown for 8 days without blasticidin, treated
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with GANC, plated, and the GANC-resistant colonies (GANCr) were stained and
counted after two weeks. Control, cells plated without GANC to estimate plating
efficiency (see Materials and Methods). C, Numbers of GANC-resistant colonies
were adjusted, using plating efficiency, for 5x104 plated colony-forming cells, and
plotted for each time point. Each data point represents the mean of 5 independent
experiments, error bars show standard deviation. D, MSI analysis. Left panel,
original sequence without mutations; right panel, loss of one repeat unit.
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Table 1. Average fold-differences in the number of GANC-resistant colonies in
MMR-deficient versus -proficient background
293T LaDays without
selection (C)12TKBSD (A)26TKBSD TKBSD
4 29.5 (± 17) 1.6 (± 0.1) 1.4 (± 0.1)
8 17.1 (± 3.9)     2.1 (± 0.3) 1.2 (± 0.1)
13 19.2 (± 2.8) 2.6 (± 0.2) 1.6 (± 0.1)
The values shown in the table were calculated by dividing the number of GANC-
resistant colonies in the MMR-deficient background by the number of GANC-
resistant colonies in the MMR-proficient background at each time point (4, 8, 13
days) for each individual experiment. Shown are average values for each time point
from 5 independent experiments. See also Materials and Methods. Numbers in
parentheses show standard errors.
Table 2. Average mutation frequencies (fractions of mutated cells/generation)
293T La MMR+ MMR-
(C)12TKBSD 8.0 (±1.0) x10-5 1.6 (±0.1) x10-3
(A)26TKBSD 8.2 (±0.6) x10-4 2.6 (±0.3) x10-3
TKBSD 1.7 (±0.1) x10-4 2.4 (±0.2) x10-4
The values were obtained by plotting the number of GANC-resistant colonies against
time for each individual experiment. The increment of GANC-resistant colonies per
doubling time (22 hours) was calculated from the regression curve, and was divided
by the number of cells plated (corrected for plating efficiency). The results are based
on 5 independent experiments. See also Materials and Methods. Numbers in
parentheses show standard errors.
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Figure 1.
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7. APPENDIX III
Mismatch repair-dependent transcriptome changes in human cells treated with
the methylating agent MNNG. di Pietro M., Marra G., Cejka P., Stojic L., Menigatti
M., Cattaruzza M.S. and Jiricny J. Cancer Res. In press.
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Abstract
DNA mismatch repair (MMR) plays a key role in the cytotoxic response of
human cells to methylating agents, however, the cascade of events leading to cell
cycle arrest and cell death has yet to be characterized. We studied the role of MMR
in the transcriptional response to DNA methylation damage in two human cellular
models: i) the lymphoblastoid cell line TK6 and its derivative MT1, which is mutated
in the MMR gene hMSH6, and ii) the epithelial cell line 293T La, in which the
expression of the MMR gene hMLH1 can be tightly regulated and p53 is inactivated.
Upon MNNG treatment, only cells with functional MMR were killed, but the type of
cytotoxic response differed. In TK6 cells, S phase arrest and apoptosis were
accompanied by a dramatic change in gene expression, notably, an up-regulation of
several genes encoding growth inhibitors and pro-apoptotic factors both p53-
dependent and independent. In contrast, the MMR-dependent transcriptional
response in 293T La cells was substantially less pronounced than in TK6 cells, in
spite of an efficient induction of a G2/M checkpoint and non-apoptotic cell death.
Thus, we demonstrate that in human cells of different origin, MMR-mediated killing
by methylating agents occurs through different pathways and regardless of the p53
status. Moreover, once DNA methylation damage has been processed by the MMR
system, tumor cells might be committed to die even though one or more of their
signalling pathways are impaired.
Introduction
Alkylating agents were introduced into clinical practice more than 50 years
ago, when their anti-tumor properties, linked to their ability to covalently modify
nucleophilic centres in DNA, were demonstrated. A subgroup of these agents, mainly
hydrazine and triazine derivatives, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG),
N-methyl-N-nitrosourea (MNU) and temozolomide, have one reactive group and
react with only one strand of DNA. The reaction primarily associated with the
mutagenicity of these agents is the methylation of the O6 position of guanines in
DNA. When the methyl group is not removed by the detoxifying enzyme
methylguanine methyl transferase (MGMT), O6-methylguanine can mispair with
thymine during DNA replication, which results in G/C to A/T transitions.
Paradoxically, the cytotoxicity of methylating agents has been attributed to the anti-
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mutagenic attempts of the MMR system to process these O6-meG/T mismatches, the
hypothesis being that mismatch correction directed to the newly synthesized strand
(carrying the thymine) would be ineffectual as long as the methylated base in the
template strand persists. Reiterated cycles of MMR-driven exonucleolytic
degradation of the newly synthesized strand, followed by DNA synthesis and
reintroduction of T opposite to O6-meG, are presumed to result in cell cycle arrest
and lethality (1). Whether or not this hypothesis is correct, a characteristic phenotype
of the MMR-deficient human cells, i.e. tolerance to monofunctional methylating
agents, corroborates a relationship between methylation-induced killing and repair
attempts. This phenotype was first described in 1993 in two seminal works, in which
MNU-tolerant human and rodent cell lines were found to be defective in DNA
mismatch binding (2), and the MMR-deficient human lymphoblastoid MT1 cell line
showed G/C to A/T transitions in the HPRT gene upon MNNG treatment (3).
Consistent with these findings, the sensitivity to MNNG in the MMR-deficient
human colon cancer cell line HCT116 (mutated in both alleles of the MMR gene
hMLH1) was restored by expression of a functional hMLH1 gene in a chromosome
transfer experiment (4, 5). A series of studies followed, in which the methylation-
tolerance phenotype was confirmed in all human and rodent cells with impaired
MMR, regardless of the MMR gene mutated (hMSH2, hMSH6, hMLH1 or hPMS2)
(6). The relationship between MMR deficiency and tolerance to methylating agents
could recently be verified in a truly isogenic cellular model, the 293T La cell line
established in our laboratory, in which the expression of hMLH1 can be tightly
regulated (7).
The clinical implications of these studies are that tumors with non-functional
MMR (about 15% of colon cancers) should not be responsive to deployment of
methylating agents, and MMR-deficient cells in a tumor might be selected for during
such treatment (6). The other known causes of reduced cellular sensitivity to
methylating agents are typical resistance mechanisms acting upstream of O6-meG/T
mispairing, one being the over-expression of MGMT. This enzyme plays an
important role in DNA detoxification, by removing methyl- and other, small alkyl
groups from the O6 position of guanine. Thus, tumors with functional MMR and low
levels of MGMT should respond favorably to methylating agents. This situation
arises rather frequently, as the levels of MGMT vary widely among individuals.
Appendix III
69
Moreover, the MGMT gene was shown to be silenced by promoter methylation in
many tumor types, for example in ~40% of MMR-proficient colorectal cancers (8).
However, as the sensitivity to methylating agents ultimately depends on the
processing of the damage by MMR, it is crucial to identify the cascade of events that
is triggered by this repair process and that ultimately leads to cell death. To date it
has been demonstrated that p53 is stabilized and apoptosis is induced in the MMR-
proficient lymphoblastoid cell line TK6 (9), that MNNG-induced apoptosis depends
on the function of the hMSH2/hMSH6 mismatch recognition heterodimer and occurs
also in TK6 cells in the absence of p53 (10) and that p53 phosphorylation on serine
residues 15 and 392 is dependent on the presence of functional hMSH2/hMSH6 and
hMLH1/hPMS2 complexes (11). In order to gain more insight into the MMR-
mediated cytotoxicity of methylating agents, we investigated the global
transcriptional response to MNNG in cell lines harbouring diverse combinations of
MMR- and p53-status, all devoid of MGMT.
Methods
Cell lines
The human B lymphoblastoid cell lines TK6 and MT1 were a gift of WG.
Thilly (Massachusetts Institute of Technology, Cambridge, MA) and WTK1 was
kindly provided by P. Morgenthaler (University of Lausanne, Switzerland). These
cells were cultured at 37°C in a 5% CO2 humidified atmosphere and maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum and 2 mM L-glutamine
(Life Technologies). The cell line 293T La+ / La- was recently developed in our
laboratory (7) from HEK293T human embryonic kidney cells, immortalized with
adenovirus 5 DNA and further transfected with large T antigen from Simian Virus 40
(12). The hMLH1  gene in this line is epigenetically silenced by promoter
hypermethylation (13). hMLH1 cDNA was stably introduced into this line under the
control of the tetracycline response promoter, using the Tet-Off system (Clontech).
In the absence of doxycycline, this cell line expresses the wild type hMLH1 protein
and is MMR proficient (293T La+), whereas the addition of doxycycline specifically
turns off hMLH1 expression (293T La-) and brings about MMR deficiency. These
cells were cultured at 37°C in a 5% CO2 humidified atmosphere and maintained in
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DMEM medium (Life Technologies) supplemented with 10% tetracycline-free fetal
calf serum (Clontech), 2 mM L-glutamine, 300 µg/ml Hygromycin B (Roche), 100
µg/ml Zeocin (Invitrogen) and 50 ng/ml Doxycycline when necessary (Clontech).
Cell cycle analysis
1.2 x 106 cells were washed with PBS and fixed in ice-cold 70% ethanol. They
were treated with 200 U/ml RNase A and stained with 20 µg/ml propidium iodide.
Cell cycle analysis was performed using a Becton Dickinson FACscan flow
cytometer and Cell Quest software.
Pulse Field Gel Electrophoresis
Cells were washed and mixed with low melting agarose at 43°C. Agarose
plugs were incubated overnight at 50°C with gentle agitation in lysis buffer (100mM
EDTA pH8, 10mM TrisHCl, pH8.0, 1% sarcosyl, 100 µg/ml proteinase K) followed
by a second overnight incubation at 37°C with fresh lysis buffer. After equilibration
in Tris-borate/EDTA (TBE) buffer, the agarose plugs were loaded in the wells of 1%
pulse field certified agarose (BIO-RAD) in TBE buffer. Electrophoresis was carried
out in the CHEF-DR III Pulse Field Electrophoresis System (BIO-RAD) as follows:
14°C, switch time 50-90 seconds, run time 22 hours, angle 120° and voltage gradient
6 V/cm. Finally, the DNA was stained with ethidium bromide in TBE buffer.
Microscopy
Cells were plated on coverslips in 6-well culture plates and exposed to MNNG
at 37°C in a 5% CO2 humidified atmosphere. After fixation with 3.7 %
formaldehyde/PBS for 15 min at 4°C and washing with PBS, 4', 6'-diamidino-2-
phenylindole hydrochloride (DAPI, Sigma) was added (0.1 µg/ml) for 30 min at
37°C. Finally, the coverslips were mounted in 50% glycerol and DNA morphology
was examined by fluorescence microscopy (Leica DC 200).
Microarray experiments
Total RNA was isolated from 5 x106 TK6, MT1 or WTK1 cells, untreated or
30h after treatment with 0.4 µM MNNG, or from 7 x 106 293T La+ or La- cells,
untreated or 12h, 30h and 72h after 0.2 µM MNNG treatment, using an affinity resin
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column (RNeasy, Qiagen). Total RNA was converted to cDNA using a cDNA
synthesis kit (Invitrogen). Double-stranded cDNA was then converted to biotin-
labeled cRNA by a T7 RNA polymerase-catalyzed reaction (MEGA Script,
Ambion,) with biotin-containing ribonucleotides (LOXO). Labeled cRNAs were then
purified (RNeasy, Qiagen) and fragmented. 15 µg of cRNA were used to hybridize
with Affymetrix U95Av2 chips (Affymetrix) carrying in situ synthesized
oligonucleotides representing more than 12,000 functionally characterized
sequences.
Data analysis
Expression profiles were analyzed in three independent experiments using the
Data Mining Tool software (Affymetrix). For each comparison, 3 experimental lines
(EL), e.g. treated cells, were compared to 3 base lines (BL), e.g. untreated cells. Data
were evaluated with both the absolute analysis and the comparative analysis
algorithms. The former algorithm measures, for each array, the abundance of
transcripts (signal) and the specificity of hybridization (P = Present, M = Marginally
present, A = Absent). The latter algorithm compares two arrays (one EL vs one BL,
e.g., 9 comparisons for 3 arrays per group) and indicates, for each gene, the direction
of the change (I = Increased, MI = Moderately Increased, NC = Not Changed, MD =
Moderately Decreased, D = Decreased).
In order to eliminate genes with low abundance and specificity of hybridization
and to identify significant changes, we employed a two-step selection procedure. For
TK6 and MT1 cells, in which only one time point after treatment was evaluated, in
the first step we compared three EL vs three BL and selected genes matching all of
the following four criteria: i) at least one P or M out of the 6 arrays; ii) signal > 50 in
at least one of these arrays; iii) fold change >1.8 or <-1.8 (average signal of three EL
vs three BL); iv) Mann Whitney p-value < 0.05. In the second step, the selected
genes were filtered using an arbitrary score system based on: i) signal: average EL
for up-regulated genes (or average BL for down-regulated) >1000, 1000<100 or
<100 (points 2, 1 or 0, respectively); ii) number of “P + M”: 3, 2 or 1 (points 2, 1 or
0, respectively) in the three EL for up-regulated genes (or in the three BL for down-
regulated); iii) number of  “I + MI” in 9 comparisons (for up-regulation) or “D +
MD” (for down-regulation): points 3 (from 7 to 9 times), 2 (from 4 to 6), 1 (from 1 to
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3), and 0 (all NC). With a maximum of 7 points, a score ≥ 4 was considered
significant. The same procedure was applied in the comparison between untreated
MT1 and TK6, where MT1 were considered the EL.
For 293T La cells, in which four time points were analyzed (time point 0,
untreated; time points 12, 30 and 72 hours after treatment), the two-step selection
procedure was applied to the following comparisons: 293T La+ vs La- at 0, 12, 30
and 72 hours, and untreated vs treated (time point 0 vs each time point after treatment
for both La+ and La-). Genes with score ≥ 4 were then analyzed with multiple linear
regression to estimate the independent role of each of the explanatory variables
(presence of MLH1 and time after treatment) on the change of the signal.
Quantitative RT-PCR
One-step RT-Real Time PCR was performed with the Roche LightCycler
System using the Light Cycle-RNA Master SYBR Green I Kit (Roche) according to
the manufacturer’s instructions, 0.3 µM of each oligonucleotide primer (Microsynth)
and 300 ng of total RNA in 20 µL reaction volume. Primer sequences and RT-PCR
reaction conditions are available on request. The cycle corresponding to the
beginning of the log phase amplification was denominated “threshold amplification
cycle” (TAC). One cycle-difference in TAC corresponds theoretically to a two-fold
change in RNA concentration. Fold changes were obtained by normalizing  to
GAPDH used as internal reference. All the experiments were performed in duplicate
and the specificity of each amplification product was verified by agarose gel
electrophoresis.
Western blotting
Western blotting was performed as previously described (7) by using the
following primary antibodies: TFIIHp89, Santa Cruz sc-293; b-tubulin, Santa Cruz
sc-5274; p53 Santa Cruz sc-98; PIG3, Oncogene Research OP148; p21, 05-345
Upstate; c-myc, Santa Cruz sc-40; bcl-2 Transduction Laboratories 610538; XPC,
kindly provided by Jan Hoeijmakers; PARP, Calbiochem AM30; hPMS2
PharMingen 556415; hMLH1 PharMingen 554072.
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Results
The lymphoblastoid cell line MT1 was derived from TK6 cells by treatment
with the Acridine ICR191 and selection for resistant clones with MNNG (14). MT1
cells are MMR-deficient, because both alleles of hMSH6 carry different missense
mutations (15). We exposed both cell lines to 0.4 µM MNNG (IC90 for TK6) and
evaluated the cell cycle distribution by flow cytometry. TK6 cells accumulated in S
phase as early as 24 hours after treatment (Figure 1A). The sub-G1 peak observed at
later time points, along with the presence of DNA fragmentation (Figure 1D) and
PARP cleavage (Figure 1E), was indicative of apoptosis induction. In contrast, the
cell cycle distribution was completely unaffected in MT1 cells (Figure 1A).
RNA was isolated from TK6 and MT1 cells 30 hours after treatment, as at this
time point the significant changes observed in cell cycle perturbation were expected
to be accompanied by alterations in the transcriptome. In Figure 2, the scatter graphs
show an overview of the gene expression changes in TK6 (panel A) and MT1 (panel
B) upon treatment. A dramatic change in the transcriptome of TK6 cells contrasted
with the stability of RNA levels in MT1 cells. Applying the two-step selection
procedure described in Methods, we did not find statistically significant changes in
MT1 cells, whereas 340 genes were up- or down-regulated more than 1.8-fold in
TK6 cells (Table A, supplementary material). A selection of these genes is listed in
Table 1, categorized according to their putative function. In accordance with the
cellular response observed, among up-regulated transcripts were the products of
several pro-apoptotic genes (PIG3, PUMA, BAX, Fas/APO1 and TNFSF10), cell
cycle regulators (p21/WAF1, GADD45, 14-3-3s, SMAD5, SMAD3, and CDC6) and
growth inhibitors (MIC-1, CEACAM1, BTG2, BTG1 and TIEG). The DNA repair
genes XP-C, DDB2, RAD51 L3, Ligase-I and BRCA2 were also up-regulated, along
with several genes involved in metabolism, cytoskeleton oganisation and
transcription. As shown in Figure 2C, we could verify the reliability of the
microarray data by quantitative RT-PCR for all the genes tested. Furthermore, most
of the genes found differentially regulated in a previous study using subtractive
hybridization and Northern blot (our unpublished results) were identified in this
study.
In accordance with the increase of p53 protein in TK6 cells (Figure 2D), we
detected up-regulation of the transcripts of many p53-target genes (Table 1) and for
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some, such as PIG3 and XP-C for which antibodies were available, an increase in
protein levels was also observed (Figure 2D and 2F, respectively). Conversely, the
protein level of the p53-target p21/WAF1 (Figure 2D) was unchanged until 72 hours
post treatment, despite the early rise in RNA level. In order to investigate the role of
p53 in the transcriptional response of lymphoblastoid cells to MNNG, we examined
the MMR-proficient WTK1 cells, which were derived from the same progenitor as
TK6, but harbour a homozygous missense mutation in the p53 gene that leads to
overexpression of an inactive form of the protein (16). Treatment of WTK1 cells
arrested them in S phase and precipitated apoptosis, but the appearance of apoptotic
cells was delayed by 24 hours as compared to TK6 (Figure 1, panels B and D), as
reported earlier (10). Microarray analysis (Table 1, genes in bold, and Table C,
supplementary material) showed a p53-independent up-regulation of several cell
cycle regulators and pro-apoptotic factors in WTK1 cells (see Discussion).
In TK6 cells, the most down-regulated gene was c-myc, a promoter of cell
cycle progression (17), the protein level of which dramatically decreased (Figure
2E), presumably via repression mediated by the TGFb effectors SMADs (18).
Among the other down-regulated genes were growth stimulators (IRF4, INSIG1 and
INSR) and cell cycle modulators (DIM1 and cyclin B1), as well as transcripts of four
heat shock proteins, which play a role in preventing apoptosis (19).
Since MT1 was derived from TK6, it was important to know to what extent the
two cell lines could be considered isogenic. Comparison of their basal gene
expression profiles (Figure 2I) showed noticeable differences and, after the two-step
selection procedure, we identified several significant changes (Table B,
supplementary material) that might contribute to the absence of any detectable effect
of MNNG on MT1. Amongst the over-expressed genes, we found the anti-apoptotic
factors CD44 (different isoforms increased between 10- and 44-fold) and Bcl-2
(confirmed at protein level in Fig. 2G), whereas some pro-apoptotic molecules
(BNIP3L, CD20, DAPK1, caspase-6 and TNFRSF9) and growth inhibitors
(GADD45 A and B, GAS-7) were under-expressed. In an attempt to test the integrity
of the p53-dependent signalling, we treated MT1 cells with 23µM MNNG (IC90 for
this cell line). This dose efficiently induced p53 stabilization and transcription of its
targets p21/WAF1, PIG3 and XP-C (Figure 2H and 2F).
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These results prompted us to use the isogenic system consisting of the hMLH1-
negative 293T cell line, in which the expression of the stably transfected hMLH1
gene can be induced by doxycycline withdrawal. In this cell line, p53 is inactivated
and the apoptotic response is likely to be impaired, as witnessed also by its extreme
resistance to Fas ligand treatment (our unpublished results). In order to rule out
secondary changes in the transcriptome induced by the overexpression of hMLH1,
we compared the RNA population of 293T La+ with that of La - cells. The
isogenicity of this cellular system was demonstrated by the very narrow distribution
of the transcripts along the central diagonal line (Figure 2J) and further confirmed by
the absence of significant gene expression differences (i.e. score ≥ 4) showed by the
two-step-selection procedure, with the notable exception of hMLH1. Also, the
exposure to doxycycline in the absence of the vector carrying hMLH1 did not induce
any changes in transcript levels (Figure 1, supplementary material).
The treatment of 293T La cells with 0.2 µM MNNG (IC90 for La+) caused a
perturbation in the cell cycle (Figure 1C) and finally cell death, albeit only in the
presence of functional MMR, i.e. in 293T La+ cells. Accumulation of cells with a
DNA content of 4n was observed as early as 30h and a sub-G1 peak was evident
after 48h. As expected, nuclei of G2/M arrested 293T La + cells appeared
considerably larger than in untreated cells (Figure 1F), but no apoptotic bodies were
detectable at later time points. In addition, we failed to detect DNA fragmentation
(Figure 1D) and PARP cleavage (Figure 1E).
In spite of the dramatic impact of the presence of hMLH1 on the cellular fate in
response to MNNG, we detected relatively few genes differentially transcribed in
293T La+ cells compared to La- 30 hours after treatment (Figure 3A), as well as at
other time points. In addition, MNNG treatment affected the transcriptome of 293T
La cells regardless of the MMR status. By multiple regression analysis, we could
distinguish gene regulations induced by the genotoxic treatment per se from changes
following MMR-dependent DNA damage processing. As shown in Table 2, the
genes belonging to the latter category (panel A) were not as numerous as those
regulated upon MNNG treatment independently of the MMR status (panel B;
complete list in Table D, supplementary material). Most of the significant changes
between MMR-proficient and MMR-deficient cells were recorded at the latest time
point (72 hours). Indeed, at this time we observed in 293T La+ cells an augmented
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expression of genes encoding proteins involved in signalling, such as the kinases
SNK, FAK and CLK1 and the growth inhibitors PTGER2 (20) and IGFBP7/Mac25
(21) (Table 2A). The increased level of IGFBP7/Mac25 mRNA was confirmed by
RT-PCR (Figure 3B).
The majority of changes induced by MNNG independently of the MMR status
were present already 12 hours after treatment. A paradigm is the transcription factor
ATF3 that has been reported to be transcriptionally induced upon DNA damage (22).
ATF3 was upregulated in 293T La cells to the same extent as in TK6 and MT1 (the
latter treated with an equitoxic concentration of MNNG) (Figure 3C). Thus, 293T
cells are likely to sense the MNNG treatment also in the absence of MMR, as further
witnessed by the up-regulation of the two stress response factors STK39 and
GADD34. As p53 is stabilized and inactivated in 293T cells (Figure 3D), we did not
observe any induction of its transcriptional targets upon treatment. On the contrary,
some p53-inducible genes, such as p21/WAF1, BAX and BTG2 were down-
regulated. For p21/WAF1, this type of regulation was associated with a decrease of
the corresponding polypeptide, as confirmed by immunoblot analysis showed in
Figure 3E. Finally, in contrast to the lymphoblastoid cells, the cell cycle arrest was
not associated with changes in c-myc RNA and protein levels (Figure 3E).
Discussion
In this work, we investigated the MMR-dependent changes in gene expression
occurring upon treatment with the DNA-methylating agent MNNG, using two
different human cellular models. Our aim was to mimic what happens in normal and
tumor cells exposed to agents that methylate the O6-position of deoxyguanosine,
because it is the processing of this lesion by the MMR system that governs the
cytotoxicity of these drugs (see Introduction). This is the first study in which the
global gene expression in human cells treated with methylating agents has been
investigated. Similar studies were performed in yeast, but using methyl
methanesulfonate which does not methylate on O6-deoxyguanosine (23, 24). In
addition, there is no evidence that the toxicity of methylating agents in yeast is
affected by the MMR status (6).
MNNG efficiently killed the MMR-proficient lymphoblastoid TK6 cells, in
which a cell cycle delay in S phase was followed by apoptosis. This phenomenon
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could be ascribed to the attempts of the MMR system to process O 6-meG/T
mismatches during DNA replication (see Introduction). The same repair process is
probably responsible for the dramatic transcriptional response leading to cell death.
In contrast, MNNG failed to cause even mild perturbation of the cell cycle in the
hMSH6-deficient MT1 cells. Microarray experiments showed that the transcriptome
of MT1 cells was globally unmodified, whereas in TK6 cells the treatment had a
large impact on gene expression. The presence of many p53-inducible genes and
TGFb effectors amongst the most up-regulated transcripts in TK6 cells indicates that
these two pathways are both activated in order to arrest cell proliferation. Our data
are consistent with a previous microarray experiment, in which p53-regulated genes
were identified employing a human lung cancer cell line expressing temperature
sensitive p53 (25). We detected up-regulation of five DNA repair genes upon
MNNG treatment, at least two, XP-C and DDB2, known to carry p53-responsive
elements in their promoters (26, 27). Our microarray data revealed that the activation
of apoptosis was only partially accomplished through p53-inducible effectors (PIG3,
BAX and PUMA) (28-31). The up-regulation of IFNg and its downstream effectors
STAT1 and IRF1, as well as the induction of Fas/APO1 and some members of the
TNF super-family, suggest also an activation of a pro-apoptotic cross-talk among
cells through the death receptor system (32-34). Surprisingly, the negative modulator
of cell cycle, p21/WAF1, although transcriptionally activated at 30 hours, was not
up-regulated at the protein level at this time, when cells were delayed in S phase.
That p21/WAF1 is dispensable for cell cycle arrest in this cell cycle phase has
already been suggested by the observation that a transient intra-S phase checkpoint
can be p21/WAF1-independent (35). Thus, the fact that the protein level of
p21/WAF1 was not changed 30 hours post treatment in spite of an increase in its
RNA suggests that a post-transcriptional mechanism may control this function at this
time point in order to promote DNA repair (36) and eventually allow apoptosis (37,
38).
Interesting findings regarding the role of p53 in lymphoblastoid cells treated
with low doses of MNNG were gathered when we examined the p53-mutated WTK1
cell line. Microarray analysis (Table 1, genes in bold and Table C, supplementary
material) revealed up-regulation of death receptors (Fas/APO1, and TNFRSF 9 and
17) and activation of the TGFb-dependent signalling through up-regulation of
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SMAD5 and TIEG (18). Surprisingly, the transcripts of some cell-cycle inhibitors
such as p21/WAF1, GADD45, CGR19 and BTG2, generally thought to be p53-
dependent, were up-regulated to the same extent as in TK6, pointing to a
transcriptional activation independent of p53. In contrast, the pro-apoptotic p53-
targets BAX, PUMA and PIG3 were unchanged. These findings suggest that MMR-
proficient lymphoblastoid cells can employ alternative pathways to trigger cell death
independently of the transcriptional activity of p53.
The absence of any transcriptional response in MT1 cells exposed to equimolar
(0.4 µM) doses of MNNG could be ascribed to mechanisms other than MMR-
deficiency. We could exclude resistance mediated by detoxifying enzymes, because
MGMT and GSH-S-transferases have the same pattern of expression as in TK6. In
addition, the integrity of the p53-dependent pathway in MT1 was ascertained upon
exposure to equitoxic doses (23µM) of MNNG. However, from the basal gene
expression pattern (Table B, supplementary material) it would appear that MT1 cells
have acquired a more transformed phenotype than TK6. Seven tumor antigens
(GAGE isoforms and BAGE) were among the most up-regulated transcripts in MT1
compared to TK6, as well as the tumorigenic factor PRKACb (catalytic subunit of
PKA). Different isoforms of the tumor marker CD44, found associated with
inhibition of apoptosis and growth advantage (39), were overexpressed, whereas the
transcript for the structural protein SNL/fascin1, reported to play an important role in
cell adhesion and migration of peripheral blood cells (40), was more than 40 times
less abundant. Finally, the balance between pro- and anti-apoptotic factors was
strongly biased in favour of the latter (see Results). Because these findings
demonstrated that TK6 and MT1 cells cannot be considered isogenic as previously
invoked, we extended our study to the truly isogenic model 293T La+/La-.
As shown for the lymphoblastoid cell lines, only 293T cells with a functional
MMR system were sensitive to MNNG, although the features of the cellular response
of 293T La+ differed from TK6, in that a G2/M checkpoint was activated after a
transient S phase slowdown and cell death was delayed. The absence of any sign of
apoptosis (upon MNNG and Fas ligand treatments) might be explained by the
general tolerance of this cell line to apoptotic stimuli. This phenotype results, at least
in part, from the expression of adenovirus E1A and E1B proteins and of SV40 large
T antigen (12) that brings about inactivation of p53- (41, 42) and of TGFb-dependent
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pathways (43). Indeed, none of the effectors of p53 and TGFb pathways were
transcriptionally induced upon MNNG treatment and some, such as the growth
inhibitors p21/WAF1, BTG2 and SMAD4, as well as the pro-apoptotic BAX, were
down-regulated. Interestingly, this type of regulation was detected also in the
absence of MMR, presumably as a global response of the 293T La cells aimed at
surviving the treatment. This is also supported by the enhanced transcription, in both
293T La+ and La-, of the oncogenes c-fos and c-jun. Among the cellular processes
regulated by c-Fos and c-Jun, a stimulation of cell cycle progression via repression of
p21/WAF1 transcription has been reported (44). A synergistic effect might be
accomplished by the up-regulation of the MAPK phosphatases DUSP1 and DUSP 8
(Table 2), which have been shown to be involved in the dephosphorylation and
inactivation of the stress-inducible and antiproliferative MAP kinases JNK and p38
(45, 46). This type of gene regulation may suggest that 293T La cells sensed the
treatment also in the absence of functional MMR. This is further witnessed by the
up-regulation, independently of the MMR-status, of the transcription factor ATF3,
previously correlated with the response to genotoxic agents in a p53-dependent and -
independent fashion (22).
These findings suggest that MNNG induces a general response in 293T
La cells characterized by an increase of survival signals. Notwithstanding this, 293T
La+ cells, where the O6-meG/T mismatches can be addressed by the MMR, stopped
cycling and eventually died. Indeed, in these cells we detected post-translational
modifications that accompanied the G2/M arrest (i.e: CHK1 and CHK2
phosphorylation, CDC25A degradation and CDC2 Tyr-15 phosphorylation; Stojic
L., et al., manuscript in preparation), but, in contrast to lymphoblastoid cells,
activation of the G2/M checkpoint was reflected in only a moderate transcriptional
response. This might be ascribed to the inactivation of pRb by the transfected E1A
that brings about deregulation of E2F activity, a pivotal transcription factor acting in
response to cell cycle modulators (47). Microarray data failed to help us identify the
pathways responsible of cell death in these cells, yet some signalling molecules,
differentially transcribed in MMR-proficient 293T La cells upon treatment, might be
biologically relevant in determining their cellular fate. One example is the up-
regulation of the tumor suppressor IGFBP7/Mac25 that was reported to be down-
regulated in some breast cancer cells (21) and increased in cells committed to death
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by senescence or apoptosis (48, 49). Taken together, these data showed that, even
though MNNG can induce a general stress response in 293T La cells, its cytotoxicity
depends exclusively on the recognition and processing of DNA damage by the MMR
system. The absence of MGMT in these cells, as well as in TK6 cells, enabled us to
employ doses of MNNG that were so low as to prevent any MMR-independent
cytotoxicity.
In conclusion, we demonstrated that in the presence of DNA-methylation
damage, the MMR system swings the balance between survival and death in favour
of the latter. The type of response strongly depends on the cellular background and
relies on the signalling pathways available to the cells. Even though p53 may be one
of the main effectors of cell death induced by MNNG, its inactivation does not
prevent cell death. The experiments with 293T cells showed that even in the presence
of strong survival signals, a situation that might mimic tumor environment, MMR is
sufficient to activate pathways leading to proliferation arrest and eventually cell
death. Thus, MMR most likely plays a crucial role in the efficacy of methylating
agents in cancer therapy. Unfortunately, by playing a similar role also in rapidly-
proliferating normal tissues such as bone marrow and gastrointestinal mucosa, MMR
is responsible for the toxicity of this treatment. In order to prevent side effects, lower
doses of methylating agents would have to be deployed, which requires that the level
of MGMT in the tumor be reduced. Targeted down-regulation of this enzyme in
MMR- and MGMT-positive tumors is subject to investigation.
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FIGURE LEGENDS
Figure 1. Flow-cytometric analysis of cell-cycle progression of TK6, MT1 (A),
WTK1 (B) and 293T La+/La- (C) cells after treatment with MNNG. TK6 and WTK1
underwent an S phase arrest, whereas 293T La+ cells arrested in G2/M. No alteration
in cell cycle progression was observed in MT1 and 293T La - cells. D) DNA
fragmentation analysis by Pulse Field Gel Electrophoresis. Only TK6 and WTK1
cells showed DNA fragmentation (~50 kb) 72 hours after MNNG treatment. E)
Western blot showing cleavage of PARP to the characteristic 89-kDa fragment in
TK6 cells 72 hours post treatment. F) DAPI staining of 293T La+ cells 48 hours post
treatment, showing a substantial increase in nuclear size that is indicative of G2/M
arrest.
Figure 2. Microarray data and quantitative evaluation of RNA and proteins in
TK6 and MT1 cells. The scatter graphs show the overall changes of TK6 (A) and
MT1 (B) transcriptomes upon MNNG treatment (x and y axes: signal values). Each
dot represents a gene and the four diagonal lines correspond to different fold changes
of expression (i.e. dots outside the 2 inner lines represent transcripts the levels of
which deviated more than 2-fold from the central line). Hundreds of dots spreading
over the 2-fold change lines (A) indicate dramatic changes in gene modulation in the
TK6 cells upon MNNG treatment. The transcriptome of MT1 cells (B) remained
globally unmodified upon similar treatment. N.B.: the bottom left parts of the graphs
carry limited significance, as transcripts of low abundance are difficult to quantitate
reproducibly. C) Quantitative analysis of transcripts by RT-PCR. The height of the
bars corresponds to TAC (see Methods) and inversely correlates with the abundance
of the transcript (some error bars are very small and not visible in this picture).
GAPDH was used as control. D - H) Western blot analyses (see Results). TFIIHp89
and b-tubulin: loading controls. I and J) Scatter graphs obtained by comparing the
basal level of transcripts in the MMR-proficient cells with the respective MMR-
deficient counterparts. A substantial number of genes were differentially expressed
in MT1 cells as compared to TK6 (I). No differences were detectable in 293T La+
versus La- cells (J), except for the two hMLH1probes (arrowed).
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Figure 3. Microarray data and quantitative evaluation of transcripts and proteins
in 293T La+/La- cells. A) Several genes were differentially expressed in La+ cells
compared to La- 30 hours after MNNG treatment (see Table 2 for details). The
arrows show the two probes for hMLH1. B) Quantitative RT-PCR analysis of
IGFBP7, the 2.6-fold up-regulation of which in La+ compared to La- was confirmed
by the difference in TAC (1.5 cycles earlier in La+). GAPDH was used as control. C)
Quantitative RT-PCR analysis of ATF3. Significant increase of this transcript was
recorded in all the cell lines treated with equitoxic amounts of MNNG. D and E)
Western blot analyses showing p53 stabilization (panel D), unchanged c-myc levels
and down-regulation of p21 protein levels (panel E). TFIIHp89 and b-tubulin:
loading controls. Dox: addition of doxycycline turns off hMLH1 expression.
Table 1. A selection of the 340 transcripts that significantly changed in TK6
cells upon MNNG treatment. Genes in bold were found up-regulated also in treated
WTK1 cells (complete lists in Tables A and C of supplementary material).
1 Derived from LocusLink and SwissProt databases or recent publications in
case of incomplete annotations
2 Average signal of MNNG-treated TK6 cells vs average signal of untreated
TK6 cells
3 See Methods
Table 2. A) Genes whose expression significantly varied upon MNNG
treatment in 293T La+ cells compared to La- at the time point indicated. B) A
selection of genes that were up- or down-regulated in 293T La cells upon MNNG
treatment independently of the hMLH1 expression (for a complete list, see Table D
of supplementary material).
1 Derived from LocusLink and SwissProt databases or recent publications in
case of incomplete annotations
2 Time point at which the multiple regression analysis showed a statistically
significant (p<0.05) interaction between the presence of hMLH1 and the time
after treatment
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3 Time point at which the multiple regression analysis showed a significant
(p<0.05) up- or down-regulation of the gene upon MNNG treatment regardless of
the presence of hMLH1 (in both 293T La+ and La- cells)
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Table 1.
Category1 GeneBank Title Function1 Fold2 SCORE3
 Access. No   change  
UP-REGULATED GENES     
Metabolism M29877 L-fucosidase a Glycan metabolism 30.8 7
J03826 Ferrodoxin reductase Electron transport 3.5 7
M30474 gGT2 Amino acid metabolism 3.0 7
Cytoskeleton AF001691 Periplakin Cell shape control 20.2 6
X13839 Vascular smooth a actin Cell shape control 4.6 7
AI888563 Smoothelin Cell shape control 2.1 7
U03057 SNL/fascin1 Cell shape control 2.1 7
Signaling AL022310 TNF SF 4/OX40L Cell growth control 16.5 6
U78305 WIP-1 Cell growth control (p53 inducible) 4.8 7
U07358 MAP 3K 12 MAP kinase signaling 2.1 6
Immune response U02388 CYP4F2 Leukotriene metabolism 12.0 6
J00219 INFg Growth suppression 8.0 5
Transcription W47047 P8 protein Candidate for metastasis 11.0 5
AA635153 ZNF 79 Transcription factor 5.4 5
U59913 SMAD5 Growth suppression (TGFb pathway) 3.6 6
L19871 ATF3 Stress response 3.5 6
U68019 SMAD3 Growth suppression (TGFb pathway) 2.4 6
L29277 STAT 3 Growth control (INFg pathway) 2.3 7
M97936 STAT1 Pro-apoptotic (INFg pathway) 2.2 6
Cell growth AB00584 MIC-1 Growth suppression (p53 inducible) 10.9 7
X16354 CEACAM1 Growth suppression 9.3 6
M14083 PAI-1 Induction of senescence 5.6 6
AF059611 NRP/B (Pig10) Neurogenesis (p53 inducible) 4.8 7
AF038844 DUSP14/MPK6 MAPK inactivation 4.7 7
U72649 BTG 2 Growth suppression (p53 inducible) 4.0 7
AF050110 TIEG Growth suppression (TGFb pathway, p53 ind) 3.9 7
U91512 ninjurin1 Neurogenesis 3.8 7
X61123 BTG1 Growth suppression 2.9 7
U66469 CGR19 Growth suppression (p53 inducible) 2.1 6
U51127 IRF5 Growth control (INFg pathway) 1.9 7
Cell cycle U33203 mdm2 (isoforms D,E,A) P53 nuclear export (p53 inducible) 5.6 6
U57317 P/CAF Acetylation (p53 activation) 4.7 4
M60974 GADD45 Cell cycle arrest (p53 inducible) 3.9 7
U03106 p21/Waf1 Cell cycle arrest (p53 inducible) 3.9 7
X57348 14-3-3s Cell cycle arrest (p53 inducible) 2.8 7
U83981 GADD34 Cell cycle arrest 2.7 6
U77949 CDC6 Cell cycle control 2.1 7
M92287 Cyclin D3 G1/S cyclin 1.8 7
Apoptosis AF010309 Pig3 Apoptosis induction (p53 inducible) 10.5 7
U82987 PUMA Apoptosis induction (p53 inducible) 2.8 7
U19599 BAX d Apoptosis induction (p53 inducible) 2.2 7
X63717/Z70519 FAS/APO1 Apoptosis induction (death receptor) 2.2 7
L05072 IRF1 Apoptosis induction (INFg pathway) 2.1 7
U60519 CASP 10 B Apoptosis induction 2.1 5
L22473 BAX a Apoptosis induction (p53 inducible) 2.1 7
U37518 TNFSF10 Apoptosis induction 2.0 6
U77845 hTRIP Apoptosis induction 2.0 6
U16811 Bak Apoptosis induction (p53 inducible) 1.9 6
DNA repair D21089 XP-C Nucleotide excision repair (p53 inducible) 4.3 7
U18300 XP-E/DDB2 Nucleotide excision repair (p53 inducible) 4.3 7
AF034956 RAD 51 L3 Recombination 2.1 5
M36067 Ligase I DNA ligation 2.0 7
X95152 BRCA2 exon2 Recombination 2.0 6
 
DOWN-REGULATED GENES     
Cell growth V00568 c-myc Growth stimulation -3.1 7
U52682 IRF 4 Growth stimulation -2.7 7
U96876 Insulin induced gene 1 Growth stimulation -1.9 7
X02160 Insulin receptor Growth stimulation -1.9 5
Cell cycle AF023612 DIM1 Essential for mitosis -2.4 4
M25753 Cyclin B1 related G2/M transition -1.9 7
U11791 Cyclin H CDC2 activation -1.8 7
Protein folding AI912041 HSP E1 Heat shock protein -2.3 7
M59830 HSP70-2 Heat shock protein -2.3 6
Y00371 HSC 70 Heat shock protein -2.1 7
M11717 HSP 70 Heat shock protein -2.0 7
Metabolism S68805 AGAT Energetic metabolism -2.4 6
X66435 HMGCS1 Lipid metabolism -2.2 6
D78130 Squalene Epoxidase Lipid metabolism -2.1 7
X60221 ATP5F1 Energetic metabolism -2.0 5
Translation M15353 EIF 4E Protein synthesis -2.1 6
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Table 2.
A GeneBank Title Category1 Function1 Timent(s)2
Access no
La+ > La- L19182 IGFBP7 Signal transduction Growth suppression 72
AF059617 SNK Signal transduction Mitogenic response 72
HG3075-HT3236 FAK Signal transduction Integrin signaling 72
HG3484-HT3678 CLK1 Signal transduction Dual specificity kinase 72
L06797 CXCR4 Signal transduction Chemokine receptor (Immune response) 72
HG2167-HT2237 PK HT31 Signal transduction Scaffolding for PKA 72
U19487 PTGER2 Signal transduction Prostaglandin E2 receptor EP2 72
U97669 Notch homolog 3 Signal transduction Cell differentiation 72
AB022718 DEPP ? Decidual protein induced by progesterone 72
U59632 PNUTL1 Cytoskeleton Cell shape 72
AB002323 DNCH1 Cytoskeleton Spindle formation 72
U66689 ABCC6 Membrane fraction Small molecule transport 72
X54871 RAB5B Membrane fraction Vesicle transport 72
M86917 OSBP Lipid metabolism Oxysterol binding protein 12
La+ < La- Y00067 NEF 3 Cytoskeleton Intermediate filament 72
W28588 NEFL Cytoskeleton Neurofilament 12
AB007892 CDC5-like Cell cycle Spliceosome, G2/M transition 72
M27396 ASNS Metabolism Asparagine synthetase 72
AB002345 PER2 Metabolism Not known 30
U31875 DHRS2 Energetic metabolism Alcohol dehydrogenase 30, 72
X03473 H1F0 Nucleosome Histone 72
AL049223 SCAMP1 Membrane trafficking Endocytosis 72
AB011141 SMADIP1 Transcription SMAD interacting protein 12
U79273 clone23933 ? Homology to Alu sequence and EIF4A 72
B GeneBank Title Category1 Function1
Time
nt(s)3
UP-REGULATED V01512 c-fos Signal transduction Growth and apoptosis control 12,30,72
J04111 c-jun Signal transduction Growth and apoptosis control 72
U27193 DUSP8 Signal transduction JNK-p38 inactivation 12,30,72
X68277 DUSP1 Signal transduction JNK inactivation 12,30,72
AJ131693 AKAP9 Signal transduction Scaffolding for PKA 72
J03358 FER Signal transduction Kinase 72
AA224832 STK39 (SPAK) Signal transduction Stress response 12
U83981 GADD34 Cell cycle Cell growth and apoptosis 30, 72
L19871 ATF3 Transcription Stress response 12,30,72
U66619 SMARCD3 Transcription Chromatin modeling 12,30,72
AB007931 Rb-assoc factor 600 Transcription Zinc finger protein 12,30,72
S78296 INA Cytoskeleton Intermediate filament 12,30,72
M13452 lamin A Cytoskeleton Cell shape 12,30,72
AA669799 ASMTL Metabolism Acetylserotonin methyltransferase-like 12,30,72
D13642 SF3b RNA binding prot Splicing factor 12,30,72
D64108 DMC1 DNA repair Recombination 30, 72
DOWN-REGULATED U59305 PK428 Signal transduction Ser/Thr kinase 12,30,72
U50062 RIPK1 Signal transduction Ser/Thr kinase 12,30,72
M34181 PKA catalytic sub b Signal transduction Kinase activity 12, 30
D88532 PI3K reg sub 3PIK 3R3 Signal transduction Insulin pathway 12,30,72
AF007567 IRS4 Signal transduction Insulin pathway 12,30,72
L27560 IGFBP5 Signal transduction Growth stimulation 12
Z71929 FGFRec 2 Signal transduction Growth stimulation 12,30,72
X76061 Rb-like 2 (p130) Signal transduction Growth control 12, 30
Z11695 MAPK1 Signal transduction Stress response 12,30,72
L33881 PKC iota Signal transduction Kinase 12, 30
U24153 PAK2 Signal transduction Apoptotic signaling 12,30,72
U03106 p21 Cell cycle Growth suppression 12,30,72
AF023158 CDC14B Cell cycle M-phase regulator 12,30,72
L07648 MXI1 Cell cycle c-myc  inhibitor 12, 30
U72649 BTG2 Cell growth Growth suppression 12, 30
L22475 BAX g Apoptotic signaling Apoptosis 12,30,72
U19599 BAX d Apoptotic signaling Apoptosis 12,30,72
U65092 MSG1 Transcription Cbp/p300-interacting factor 30, 72
AF040963 SMAD4 Transcription Growth suppression 12,30,72
M27691 CREB1 Transcription G-protein signaling 12,30,72
M88163 SMARCA1 Transcription Chromatin modeling 12
X13839 Vascular smooth a actin Cytoskeleton Cell shape 12,30,72
X07834 SOD2 Metabolism Oxidative stress response 12,30,72
AA877795 ATP6V1D Metabolism ATP synthesis 12,30,72
NM001098 Aconitase Metabolism Energy metabolism 12, 30
M10905 Fibronectin 1 Extracellular matrix Cell adhesion 12, 30
L13210 Mac-2 bind protein Extracellular matrix Scavenger receptor 12, 30
M61916 Laminin b 1 Extracellular matrix Basement membrane protein 12, 30
M82809 AnnexinIV Membrane fraction Phospholipase A2 inhibitor 12, 30
U50410 Glypican3 Membrane fraction Growth control ? 12, 30
X59841 PBX3 Development Transcription factor 12,30,72
Appendix III
90
Figure 1.
Appendix III
91
Figure 2.
Appendix III
92
Figure 3.
Appendix IV
93
8. APPENDIX IV
DNA damage signalling induced by low doses of SN1 type methylating agents is
dependent on functional mismatch repair and ATR kinase. Stojic L., Mojas N., Cejka
P., Ferrari S., Marra G. and Jiricny J. Manuscript submitted.
Appendix IV
94
DNA damage signalling induced by low doses of SN1 type methylating agents is
dependent on functional mismatch repair and ATR kinase.
Lovorka Stojic, Nina Mojas, Petr Cejka, Massimiliano di Pietro, Stefano Ferrari,
Giancarlo Marra and Josef Jiricny*
Institute of Molecular Cancer Research
University of Zurich
August Forel-Strasse 7
CH-8008 Zurich
*Corresponding author
Tel.: +41-1-634 8910
Fax.: +41-1-634 8904
E-mail: jiricny@imr.unizh.ch
Appendix IV
95
Abstract
SN1 type alkylating agents represent an important class of chemotherapeutics,
but their molecular mode of action remains to be elucidated. The prototypic
methylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) modifies
predominantly purine nitrogen atoms, but its toxicity is believed to result from
the futile processing of O6-methylguanine (6MeG)/thymine mispairs by the
mismatch repair (MMR) system. Thus, MNNG-induced cell cycle arrest is
dependent on functional MMR, and cells with defective MMR are highly
resistant to killing by this agent. In an attempt to understand the molecular
transactions underlying these phenomena, we studied the MNNG response of
human 293T La  cells, the MMR status of which can be controlled by
doxycycline. We now show that low MNNG doses triggered a MMR-dependent
DNA damage signalling cascade that lead to a cell cycle arrest, but only in the
second G2 phase after treatment. Both ATM (Ataxia telangiectasia mutated)
and ATR (ATM and Rad3-related) kinases were activated during this process,
but only the latter enzyme was indispensable. We propose that this signalling
cascade is activated by tracts of single-stranded DNA generated during MMR-
dependent processing of 6MeG/T mispairs. In contrast, high dose MNNG
treatment resulted in the activation of a signalling cascade that was much more
rapid and MMR-independent.
Introduction
Treatment of cells with clastogenic DNA damaging agents such as ionizing radiation
(IR) generally results in the rapid activation of damage signalling pathways, cell
cycle arrest and, depending on the extent of damage, either recovery, or cell death.
Although IR causes many different types of DNA modifications, ranging from base
oxidations to single- and double-strand breaks (DSBs), the DNA damage signalling
events are thought to be associated exclusively with the detection and/or processing
of strand breaks and involve the rapid activation of ATM and its downstream targets
(Bakkenist and Kastan 2003), followed by ATR. DNA damage signalling cascades
can be activated also by DNA replication forks stalled by DNA damage (e.g. UV-
induced photodimers or cross-links), nucleotide depletion (e.g. by hydroxyurea, HU)
or polymerase arrest (e.g. by aphidicolin). In this scenario, the signalling events are
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triggered in the first S-phase after treatment and involve primarily ATR and its
downstream targets (Abraham 2001; Hammond et al. 2002; Osborn et al. 2002;
Shiloh 2003).
DNA damage signalling induced by SN1 type methylating agents has to date
not been studied in detail, possibly due to the lack of suitable experimental systems,
or to the pleiotropic mode of action of these agents. Treatment of cells with agents
such as N-methyl-N-nitrosourea (MNU) and N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) gives rise predominantly to N7-methylguanine (7MeG), N3-methyladenine
(3MeA ) ,  O4-methylthymine (4MeT), O 6-methylguanine (6MeG) and methyl-
phosphotriesters in their DNA. The major adducts, 7MeG and 3MeA, which represent
around 70% of the damage, are efficiently removed from DNA by alkyladenine
DNA-glycosylase (AAG) (Scharer and Jiricny 2001) and the resulting abasic sites
are repaired by the base excision repair (BER) pathway (Seeberg et al. 1995). The
mutagenic bases 4MeT and 6MeG are not substrates for BER. Instead, 6MeG is detoxified
by methylguanine methyl transferase (MGMT), which reverts it back to guanine
(Sedgwick and Lindahl 2002). 3MeA is a polymerase-blocking lesion and might
therefore seem reasonable to expect this lesion to be responsible for cell killing.
Interestingly, the cytotoxicity of the above methylating agents was ascribed to 6MeG,
as cells expressing high levels of MGMT were shown to be highly resistant to killing
by MNU (Karran 2001). But how do persistent 6MeG residues in DNA, which are
mutagenic due to preferential base-pairing with thymines during replication, lead to
cell death?
More than three decades ago, Plant and Roberts observed that treatment of
mammalian cells with MNU inhibited DNA synthesis in the second S-phase post
treatment (Plant and Roberts 1971). Based on this evidence and on findings
implicating 6MeG in the cytotoxicity of MNU and MNNG, they proposed a model
accounting for the delayed cytotoxicity caused by these agents. It suggested that
DNA replication past 6MeG residues in the template strand leaves a gap in the newly-
synthesised strand opposite this modified nucleotide, which is converted to a
cytotoxic DNA double-strand break (DSB) during the following round of replication.
This model has so far not been experimentally substantiated, but support for it comes
from more recent work, which demonstrated that MNNG- or MNU-induced
chromosomal aberrations also arise after the second S-phase post-treatment (Rasouli
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et al. 1994; Kaina et al. 1997). Importantly, Karran and co-workers showed that,
unlike in the case of UV radiation or other replication-blocking treatments, DNA
synthesis in cells treated with methylating agents was apparently not directly blocked
by the DNA damage, as MNU treatment of cells carrying episomal, autonomously-
replicating vectors arrested the replication of both genomic and episomal DNA, even
though the dose of the methylating agent was too low to damage the latter
(Zhukovskaya et al. 1994). They therefore proposed that methylation damage
generates a trans-acting signal, which stalls all replication forks. In the intervening
years, the cytotoxicity of SN1 methylating agents MNU, MNNG, procarbazine and
temozolomide was linked with postreplicative mismatch repair (MMR), inasmuch as
the tolerance of MMR-deficient MGMT-deficient cells to killing by methylating
agents was ascribed to their failure to convert MeG-containing mispairs into pro-toxic
lesions (Goldmacher et al. 1986; Branch et al. 1993; Kat et al. 1993; Hawn et al.
1995) (see also (Bellacosa 2001; Karran 2001) for recent reviews). The finding that
MNNG treatment induced a G2/M arrest in MMR-proficient, but not –deficient cells
(Hawn et al. 1995) lead to the hypothesis that MMR proteins may be involved in
DNA damage signalling (Fishel 1998). Mechanistic insights into this phenomenon
have not been forthcoming, however, partly due to the lack of suitable model
systems, which have hitherto been based on matched, rather than isogenic MMR-
deficient and MMR-proficient cell pairs. Having developed a cell line in which the
MMR status can be controlled (Cejka et al. 2003), we deployed it to study the
cellular response to treatment with different doses of MNNG.
Results
MNNG-induced MMR-dependent G2 arrest in 293T La cells occurs in the second
cell cycle.
The human embryonic kidney cell line 293T is MMR-deficient and does not convert
MeG in its DNA back to G, as the promoters of the hMLH1 (Trojan et al. 2002) and
MGMT (Cejka et al. 2003) genes are epigenetically silenced. We used these cells to
generate the 293T La cell line, which carries a stably-integrated hMLH1 cDNA
mini-gene controlled by the TetOffTM expression system. In the absence of
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doxycycline (Dox), these cells, referred to as 293T La+, express hMLH1, are MMR-
proficient and sensitive to killing by MNNG. In contrast, when the same cells are
grown in the presence of 50 ng/ml Dox (293T La- cells), they shut off hMLH1
expression, display a MMR defect and are 125-fold more resistant to MNNG than
293T La+ cells. Flow cytometric analysis showed that upon treatment with 0.2 µM
MNNG, the 293T La+ cells arrested with a DNA content of 4n (Cejka et al. 2003),
like other MMR-proficient cells (Hawn et al. 1995). However, our cells express the
SV40 large T antigen, as well as the adenoviral E1A and E1B proteins that inhibit
the functions of the retinoblastoma (Rb) and p53 tumour suppressor proteins, which
are required for induction of DNA damage checkpoints (Bartek and Lukas 2001;
Naderi et al. 2002). The proper functioning of DNA damage response in these cells
might therefore be affected. We thus first had to confirm that the cells indeed
arrested in the G2-phase of the cell cycle, rather than stopping due to a mitotic
catastrophe. To this end, we added nocodazole, an inhibitor of mitotic spindle
formation, to the cultures 24 and 48 h after MNNG-treatment. Because cells arrested
in G2 cannot traverse to mitosis, nocodazole should block only cells that fail to arrest
and continue to cycle. As shown in Fig. 1A, the MMR-deficient 293T La- cells
treated with MNNG in the presence of nocodazole were generally arrested in mitosis.
In contrast, when nocodazole was added to the MMR-proficient 293T La+ cells after
MNNG treatment, only very few cells reached mitosis. Flow cytometric analysis
(Fig. 1B) also showed that synchronised 293T La cells treated with MNNG at the
G1/S-transition progressed through the first mitosis and G2/M boundary irrespective
of their MMR status. The arrest was activated after the second S-phase, and only in
the MMR-proficient 293T La+ cells. This finding was further confirmed by BrdU
labelling experiments, in which synchronized, MNNG-treated 293T La cells were
shown to enter the second S-phase between T14 and T24 irrespective of their MMR
status (Fig. 1C). As shown in the graph, the number of cells in the second S-phase
appeared lower than in the first. This could be due to some cells dying between the
two cycles and thus being lost from the FACS analysis, or due to the loss of
synchronization. We therefore followed the proliferation of the unsynchronised
treated cell populations. As shown in Fig. 1D, no cell loss occurred; the MNNG-
treated MMR-proficient cells doubled in number during the first 24h and then
arrested, whereas the treated MMR-deficient cells continued to proliferate. In
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addition, we noted no increase in the dead cell population during this time, as shown
by trypan blue staining (data not shown) and FACS analysis (Cejka et al. 2003). This
showed that the decrease in the cell number in the second S-phase (Fig. 1C) was only
apparent, and was due to the loss of synchronization. In summary, the MNNG-
induced G2 checkpoint in 293T La cells is activated after the second S-phase, and is
absolutely dependent on a functional MMR system.
G2 arrest in the MMR-proficient 293T La+ cells is caffeine-sensitive.
We wanted to check whether the MNNG-induced cell cycle arrest observed in the
293T La+ cells was brought about by physical blocks to DNA synthesis (e.g.
collapsed replication forks, aberrant recombination intermediates), or whether it was
brought about by the activation of a DNA damage checkpoint. As the latter process
involves the major DNA damage signalling protein kinases ATM and ATR, which
are sensitive to caffeine (Sarkaria et al. 1999; Zhou et al. 2000), we decided to test
whether the MNNG-induced G2 arrest was sensitive to this drug. As shown in Fig. 2,
this was indeed the case. FACS analysis of cell populations doubly-stained with
propidium iodide (PI) and an antibody against phosphorylated form of histone H3
(Xu et al. 2001) allowed us to distinguish between G2-arrested and mitotic cells, as
H3 is phosphorylated on Ser-10 only during mitosis (Crosio et al. 2002). In the initial
set of experiments, we pre-treated cells with caffeine 30 min before adding MNNG,
and then incubated them for 24 or 48 hr. Using this protocol, we failed to observe
any difference between caffeine-treated and untreated cells, as measured by western
blotting with the phospho-H3 antibody, possibly due to the short half-life of caffeine.
We therefore adopted a different approach and added the kinase inhibitor only some
hours after the MNNG treatment. As shown in Fig. 2A, MNNG-treated cells
accumulated in G2 as observed previously 9Fig. 1B), but the addition of caffeine to
the treated cells 16 h prior to harvesting reduced the number of G2 cells by a
substantial amount at both 24 and 48 h time points, as well as causing some cell
death. This latter effect was most likely due to an increased fraction of cells arriving
in mitosis with unrepaired DNA. Indeed, analysis of phospho-H3-positive cells (Fig.
2B) showed that the fraction of mitotic cells in the MNNG- and caffeine-treated
sample increased with time, until it doubled at 48 h. These results agree with earlier
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observations (Zhukovskaya et al. 1994) and indicate that the MNNG-induced cell
cycle arrest was indeed induced by a DNA damage signalling cascade.
To test whether the prolonged G2 arrest in MMR-proficient cells was
beneficial for cell survival, we studied the treated cells from the same experiment in
clonogenic assays. As shown in Fig. 2C, when the G2 checkpoint was abrogated with
caffeine, the survival of MNNG-treated MMR-proficient cells was reduced by 50%
at the 48 h time point. This shows that activation of the checkpoint does indeed allow
for DNA repair and thus reduces the killing effect of the methylating agent.
Low dose MNNG treatment brings about MMR-dependent phosphorylation of both
ATM and ATR downstream targets.
ATM and ATR are both activated by DNA damage. However, whereas ATM
responds rapidly to clastogenic damage such as that induced by IR (Bakkenist and
Kastan 2003), ATR responds slower and co-operates with ATM in the later phases of
the response (Brown and Baltimore 2003). ATR is also known to be preferentially
activated upon replication fork arrest induced by UV light, hypoxia, hydroxyurea
(HU) or DNA polymerase inhibitors such as aphidicolin (Abraham 2001; Hammond
et al. 2002; Osborn et al. 2002; Shiloh 2003). As MNNG treatment is thought to
exert its cytotoxicity through the processing of 6MeG residues during DNA synthesis
(Karran and Bignami 1992), it might be anticipated that the damage-induced
signalling cascade might initiate in S-phase and involve ATR rather than ATM.
Indeed, when the 293T La+ cells were treated with 0.2 µM MNNG, phosphorylation
of the ATR-activated checkpoint kinase CHK1 on Ser-345 became detectable after
12h and peaked at 48h, while phosphorylation of Thr-68 of CHK2, a preferred target
for ATM, lagged by 12 h and increased steadily until 96 h, when most cells were
dying (Cejka et al. 2003). We also examined the post-translational modification
of the single-stranded DNA binding protein RPA, reported to redirect its function
from replication to repair (Wang et al. 2001) through recruitment of the ATR/ATRIP
(ATR-interacting protein) complex onto sites of DNA damage, which leads to an
ATR-mediated activation of CHK1 (Zou and Elledge 2003). The p34 subunit of RPA
was indeed phosphorylated after MNNG treatment, and the peak of this post-
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translational modification coincided with the highest levels of phospho-CHK1 (Fig.
3A).
The steady-state levels of CDC25A, a cell cycle phosphatase that is degraded
upon phosphorylation by CHK1 or CHK2 (Falck et al. 2001; Zhao et al. 2002),
CDC25A controls the activation of CDK1 and CDK2 kinases and is known to
regulate the G1 (Hoffmann et al. 1994), intra-S (Falck et al. 2001) and G2/M
(Mailand et al. 2002) checkpoints. Its phosphorylation by CHK1/CHK2 leads to its
destruction by the proteasome and thus also to cell cycle arrest. Indeed, 24h after
treatment, CDC25A levels were substantially lower than at the earlier time points.
Taken together, this evidence suggests that ATR downstream targets are activated
already during the first cell cycle, and that ATM becomes activated later, after the
second S–phase. Importantly, none of these phenomena were apparent in the MMR-
deficient 293T La- cells (Fig. 3A), which failed to arrest following this treatment
(Fig. 1B,D). Moreover, they were dependent on DNA replication, as the signalling
cascade was not activated in confluent cultures treated with MNNG (data not
shown).
In a control experiment, we treated the 293T La cells with hydroxyurea
(HU), which is known to bring about a MMR-independent cell cycle arrest in the
first S phase. As shown in Fig. 3B, CHK1, CHK2 and RPA-p34 phosphorylation was
detectable at the 24h time point, and, as anticipated, no differences were observed
between the MMR-proficient and -deficient cells. CDC25A was undetectable in the
treated cells at this time point, again irrespective of their MMR status. We failed to
observe MMR-dependent differences in phosphorylation patterns and CDC25A
degradation also after 6 and 48 h (data not shown). These results confirm that
checkpoint activation by HU and MNNG is distinct. Moreover, it shows that the
293T La- cells do not have defective checkpoint activating pathways.
MNNG treatment induces ATM/ATR activation in vivo.
As shown above (Fig. 2), the MNNG-induced G2 checkpoint in 293T La+ cells was
sensitive to caffeine. This substance is known to inhibit both ATM and ATR protein
kinases and we therefore set out to seek evidence of activation of these damage
sensors also in living cells. To this end, we employed the phospho-(Ser/Thr)
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ATM/ATR substrate (S*/T*Q) antibody that was raised against peptides carrying SQ
or TQ amino acid motifs known to be post-translationally modified by these enzymes
in several different substrates and that is an accepted marker of ATM/ATR-
dependent phosphorylation events (DiTullio et al. 2002). As shown in Fig. 3C, foci
of phosphorylated polypeptides began to appear after 24h, but were most numerous
48h post-treatment. A similar phenomenon was observed also for RPA and ATR.
Again, these changes were observed exclusively in the MMR-proficient 293T La+
cells. For technical reasons, it was not possible to carry out co-localization
experiments in these cells, however, in MNNG-treated MMR-proficient HeLa cells,
the ATR and RPA foci co-localised (Fig. 3D) (Zou and Elledge 2003).  Notably, the
initial signs of checkpoint activation in the form of phosphorylation of CHK1 and
degradation of CDC25A in 293T La+ cells (Fig. 3A) preceded the appearance of the
foci in both cell types by ~40 h. This implied that the ATM/ATR kinases were
activated much before the ATR, RPA and S*/T*Q proteins translocated to the foci.
As the appearance of the foci coincides with the formation of chromosomal
aberrations (N.M., L.S. and J.J., manuscript in preparation), it is possible that the
nuclear foci represent structures such as resected DSBs or recombination
intermediates arising during the second S-phase, as predicted by the model of Pant
and Roberts (Plant and Roberts 1971).
ATM is dispensable for cell cycle arrest induced by low dose MNNG treatment.
As discussed above, both ATM and ATR kinases could have been responsible for the
activation of the G2 checkpoint and for the post-translational modification of the
targets examined in Fig. 3. Non-productive processing of 6MeG/T mispairs by the
MMR system should signal during the S-phase, however, and this type of event
would have been expected to involve the activation of ATR rather than ATM
(Abraham 2001; Osborn et al. 2002). We therefore postulated that ATM might be
dispensable for of the MNNG-induced G2 arrest and set out to gather evidence in
support of this hypothesis. Under normal conditions, ATM is present in the nucleus
in an inactive, dimeric form, but can be rapidly activated by stress stimuli. This
activation involves disruption of the dimer and is accompanied by
autophoshorylation of Ser-1981 (Bakkenist and Kastan 2003). Using a monoclonal
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antibody against this phosphorylated isoform of ATM, we were able to follow
activation of this kinase in the 293T La cells following treatment with 0.2 µM
MNNG. As shown in Fig. 4A, in a control experiment, ATM was efficiently
activated by IR treatment in these cells, irrespective of their MMR status. HU
treatment was significantly less effective in activating ATM, as anticipated.
Treatment with MNNG triggered ATM activation, although only at the 48 and 72 h
time points, which coincided with the peak phosphorylation of CHK2, a known
downstream target of ATM, and only in the MMR-proficient 293T La+ cells (Fig.
3A).
Although the above experiment demonstrated that ATM was activated in a
MMR-dependent manner by MNNG treatment in 293T La+ cells, it failed to show
whether this kinase was indispensable for activation of the cell cycle arrest. This
question was answered with the help of a matched pair of fibroblasts lines, one
mutated in ATM and the other derived from the former, but stably expressing ATM
cDNA (Ziv et al. 1997). As shown in Fig. 4B, these cells displayed no major
differences in G2 arrest efficiency upon MNNG treatment, as assessed by FACS
analysis. As in the case of HeLa cells, MGMT activity in the AT and AT+ATM cells
was inhibited by O6-benzylguanine, such that no repair of 6MeG could take place
throughout the experiment.
Consistent with the above evidence, the number and kinetics of appearance of
S*/T*Q foci upon treatment with 0.2 µM MNNG was similar in the AT and
AT+ATM cells (Fig. 4C). As no S*/T*Q foci were detected in the AT cells upon IR
treatment (DiTullio et al. 2002), this strongly suggested that the lesions generated by
the MMR system during processing of MNNG-induced damage are distinct from IR-
induced strand breaks and that the signalling involves primarily ATR (see below).
Analysis of protein phosphorylation cascades by western blotting revealed
that CHK1 and CHK2 were post-translationally modified in both cell lines, albeit
with somewhat different kinetics (Fig. 4D). In a recent report, Wang and colleagues
showed that in IR-treated AT-deficient cells, the ATR kinase compensates for the
lack of ATM through over-activation of CHK1 (Wang et al. 2003). We now extend
these findings also to MNNG treatment, as the phosphorylation of CHK1 at the 48 h
time point was substantially stronger in the AT cells than in the corrected AT+ATM
line. Taken together, the results presented in Fig. 4 demonstrate that although
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MNNG treatment leads to activation of ATM, this kinase is dispensable for
triggering the protein phosphorylation cascade and the G2 cell cycle arrest.
The MNNG-induced G2 arrest and DNA damage dependent signalling requires ATR.
As ATM was shown not to be required for the MNNG-induced G2 checkpoint
activation (Fig. 4), we set out to confirm the involvement of ATR. Unlike in the case
of ATM, there are no stable ATR-defective cell lines, as the loss of this kinase is
lethal. Thus, to be able to study the role of ATR in the MNNG-induced G2
checkpoint, we resorted to using U2OS cells, which overexpressed a kinase-dead
variant of ATR (ATR-kd) under the control the doxycycline-regulated TetON
promoter system (Nghiem et al. 2002). These cells were substantially more resistant
to MNNG than the 293T La+ line (even though the MGMT activity was inhibited
with O6-benzylguanine) and we therefore had to use a 1.5 µM concentration of the
drug to obtain cytotoxicity comparable to that exerted on the latter cells with 0.2 µM
MNNG. Under these experimental conditions, the uninduced U2OS cells were
largely arrested in the G2 phase of the cell cycle 48 h after treatment (Fig. 5A, left
panel), which was analogous to that observed in the 293T La+ cells (Fig. 1B).
However, this arrest was substantially attenuated when the cells were induced to
overexpress ATR-kd (Fig. 5A, right panel). Phosphorylation of CHK1 in the
uninduced cells was somewhat delayed as compared to the 293T La+ cells, but
overexpression of ATR-kd totally abrogated it, while CHK2 phosphorylation
remained largely unchanged (Fig. 5B). Moreover, overexpression of ATR-kd had a
dramatic effect on the formation of S*/T*Q foci. The uninduced cells displayed no
defect in focus formation; both RPA and S*/T*Q foci were abundant 48 h after
MNNG treatment, and the fact that they largely co-localised substantiated recent
reports, which demonstrated the requirement for RPA-bound stretches of single-
stranded DNA for the recruitment of ATR and for focus formation (Barr et al. 2003;
Zou and Elledge 2003). In ATR-kd overexpressing cells, RPA foci formed normally,
but we failed to observe ATR foci. This demonstrated that the kinase activity of ATR
is required for ATR focus formation and that neither the wild type, not the kinase-
dead variant assemble into foci in the MNNG-treated U2OS cells overexpressing
ATR-kd. This experimental evidence also demonstrated that the formation of RPA
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foci is ATR-independent, i.e. that RPA is recruited to sites of damage before ATR, as
discussed by others (Barr et al. 2003; Zou and Elledge 2003).
Response to high dose MNNG treatment is MMR-independent.
In a recent publication (Adamson et al. 2002), ATM was reported to be activated by
MNNG treatment in both MMR-proficient and –deficient cells. In contrast to the
results presented above, however, the activation described by Adamson and
colleagues was rapid and resembled that observed upon treatment with IR. As the
dose of the chemical used in the latter study was 125-fold higher than that employed
by us, we postulated that DNA damage signalling at such high concentrations
(25µM) of MNNG might have been triggered by DSBs arising through the
simultaneous, BER-mediated processing of methylated bases such as 7MeG and 3MeA
situated in close proximity on opposite strands (Loeb 1985), rather than by MMR-
dependent processing of 6MeG. In order to try and substantiate this hypothesis, we
treated the AT+ ATM and AT cell line pair with IR and with 25 µM MNNG. As
shown in Fig. 6A, IR treatment induced ATM-dependent phosphorylation of both
CHK1 and CHK2. This represents the first experimental evidence that IR-induced
phosphorylation of CHK1 on Ser–345 is ATM-dependent and confirms that CHK1 is
not an exclusive target of ATR (Gatei et al. 2003). High dose MNNG treatment also
induced a rapid phosphorylation of CHK1, but, importantly, this process was ATM-
independent. CHK2 phosphorylation was ATM-dependent, at least at the 3 h time
point. These results implied that if both IR and high dose MNNG treatments generate
DSBs, the processing of these lesions activates different signalling pathways (see
below).
In order to examine the possible role of the MMR system in response to such
high damage levels, we treated the 293T La cells with increasing concentrations of
MNNG. Fig. 6B shows that at 30 µM MNNG, both MMR-proficient and –deficient
cells were killed with similar efficiency. We therefore decided to study the response
of the 293T La+ and 293T La- cells to the latter concentration of the methylating
agent. As shown in Fig. 6C, phosphorylation of CHK1 and CHK2 kinases, as well as
of p53, was apparent already a few hours after high dose MNNG treatment, and was
similar in both cell types, independent of their MMR status.
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MNNG treatment induces formation of g-H2AX foci that are not associated with
double-strand breaks.
The above evidence showed that DNA damage produced by high concentrations of
MNNG signals differently from that induced by IR and thus put into question the
hypothesis that both treatments signal through the production of DSBs. It should be
noted that, similarly to the SN2-type methylating agent methyl methanesulphonate
(MMS), high MNNG concentrations may have brought about a depletion of
glutathione levels, which has been reported to cause oxidative stress and result in
hyperactivation of the JNK/SAPK and p38 kinases (Wilhelm et al. 1997). This might
help explain the rapid, MMR-independent phosphorylation of CHK1, CH2 and p53.
However, this treatment causes also extensive DNA damage and it is likely that this
is also an important contributing factor in activation of the signalling cascade. In
order to gain information about the type of damage generated by MNNG treatment,
we set out to visualise the formation of strand breaks in the treated cells. In pulse
field gel electrophoresis (PFGE), TUNEL and neutral pH comet assays, we failed to
detect the formation of DSBs (data not shown). In contrast, at alkaline pH, where
apurinic sites generated by removal of methylated bases are cleaved and the double-
stranded DNA is denatured, we found evidence of extensive DNA degradation only
4 h post-treatment. Importantly, these single-stranded breaks disappeared with time
in the MMR-deficient cells. Their number appeared to decrease also in the MMR-
proficient cells, but a substantial number of them persisted even 48 h after treatment
(Fig. 7AB). This observation was confirmed also by studying the appearance of
nuclear foci of the phosphorylated form of histone H2AX (g-H2AX), which was
reported to associate with DSBs (Rogakou et al. 1999) and to recruit repair factors to
these sites (Paull et al. 2000). As shown in Fig. 7C, numerous g-H2AX foci appeared
soon after MNNG treatment in a MMR-independent manner, and their number
diminished with time. The lesions associated with these early foci were apparently
not responsible for triggering the signalling cascade, as they appeared in similar
numbers and with similar kinetics in both MMR-proficient and –deficient cells and
as no signalling cascade was triggered in the latter cells at low MNNG dose. It is
therefore unlikely that these foci represent sites of DSB formation. A more likely
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scenario is that the early g-H2AX foci represent regions where chromatin structure is
disrupted due to the processing of modified purines by the base excision repair
(BER) system.
At later time points, the g-H2AX foci gradually disappeared from the nuclei
of MMR-deficient cells, while, in the MMR-proficient cells, they appeared to change
form and increase in number (Fig. 7C). As this change coincided temporally with the
phosphorylation of CHK2 (Fig. 3A), which is modified by ATM activated by
clastogenic DNA damage, it is possible that these late foci represent sites of DSBs or
recombination intermediates.
As anticipated, g-H2AX foci could be observed also in the 293T La cells
treated with 30 µM MNNG. They were more numerous than those generated by 0.2
µM concentration of the agent and their appearance was independent of the MMR
status of the cells (Fig. 7C). Moreover, they persisted over long time periods and no
difference in their number or form could be observed between the MMR-proficient
and –deficient cells at the 24 and 48 h time points (data not shown).
Discussion
A functional MMR system has been postulated to be required for the activation of a
G2/M cell cycle arrest (Hawn et al. 1995; Claij and Te Riele 2002; Cejka et al. 2003)
and apoptosis (D'Atri et al. 1998) induced in mammalian cells by SN1 type
methylating agents. Using an isogenic system developed in our laboratory (Cejka et
al. 2003), in which the MMR status of the human embryonic kidney 293T La cells
can be controlled by doxycycxline, we now show that the MMR-proficient cells
treated with low dose of MNNG arrested in the G2 phase of the cell cycle, rather
than undergoing a mitotic catastrophe (Fig. 1A). We were further able to confirm
that the arrest occurred in the second G2 phase after treatment (Fig. 1B), as reported
almost 30 years ago (Plant and Roberts 1971). We set out to identify the molecular
mechanisms underlying this phenomenon. In the first series of experiments, we
showed that the accumulation of MNNG-treated cells in G2 was attenuated by
caffeine, a competitive inhibitor of the ATM/ATR kinases (Fig. 2). This evidence
further confirmed that the increase in the number of cells with a 4n DNA content, as
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observed by FACS, was due to activation of a G2 checkpoint rather than through an
arrest of cell cycle progression caused by physical barriers such as DSBs or
recombination intermediates in the genomic DNA of these cells, which would cause
a mitotic catastrophe. These results also confirm previous findings, in which MNU
treatment of cells was shown to arrest DNA synthesis by a trans-acting mechanism
(Zhukovskaya et al. 1994). Correspondingly, we could show that MNNG treatment
of the MMR-proficient cells activated a protein phosphorylation cascade that
modified a number of downstream targets of the ATM/ATR kinases, many of which
are known to be involved in cell cycle checkpoint control (Abraham 2001; Bartek et
al. 2001). It appeared most likely that these phosphorylation events actually triggered
the arrest, as the post-translational modification of these targets temporally coincided
with its activation. We were able to rule out the requirement for ATM in the
activation of the MNNG-induced checkpoint; although the kinase appeared to be
activated at late time points in the MNNG-treated 293T La+ cells (Fig. 4A), the AT
fibroblasts lacking this kinase arrested similarly to ATM-proficient ones (Fig. 4B).
This hypothesis is further supported by earlier findings, which showed that HCT15
cells that lack CHK2, one of the downstream targets of ATM, arrested normally
upon treatment with methylating agents when their MMR defect was corrected
(Umar et al. 1997; Lettieri et al. 1999). In contrast, ATR kinase was shown to
required for the efficient activation of the MNNG-induced G2 checkpoint, as the
number of cells with a 4n DNA content was dramatically decreased in MNNG-
treated cells overexpressing the kinase-dead ATR variant (Fig. 5), which showed that
these cells failed to arrest. The involvement of other damage-specific kinases has not
been ruled out, however, it is unlikely that DNA-dependent protein kinase (DNA-
PK) is involved, as it generally does not appear to be required for DNA damage
signalling (Durocher and Jackson 2001). Moreover, cells mutated in its Ku80 subunit
are hypersensitive to IR, but appear to respond normally to MNNG (Jeggo and Kemp
1983). Furthermore, DNA-PK is activated by DSBs and we found no evidence of
such breaks in the neutral comet assay (data not shown). JNK/SAPK kinases have
been reported to be activated by methylating agents. However, this process appears
to be linked with alteration of glutathione levels (Wilhelm et al. 1997; Hirose et al.
2003) and should therefore be MMR-independent. It was therefore surprising that, in
a very recent report, Hirose and colleagues (Hirose et al. 2003) described the MMR-
Appendix IV
109
dependent activation of the mitogen-activated protein kinase p38a  by 100 µM
temozolomide, another member of the SN1 family of methylating agents. This effect
could be linked with the high concentration of the reagent and does not appear to be
general, as in the 293T La cells, p38, ERK(p44/42) and JNK/SAPK were indeed
activated 48 and 72 h after treatment with low MNNG concentrations, but this
activation was independent of the MMR status of the cells (data not shown).
If ATR is the most upstream DNA damage signalling kinase, what is the
nature of the MNNG-induced lesions that trigger its activation? Our results show that
the kinase cascade is not activated directly by 6MeG/T mispairs, for example through
interaction with the mismatch binding heterodimer hMSH2/hMSH6 (Duckett et al.
1996; Fishel 1999). First, these mispairs arise already during the first S-phase and
even if they were to activate the signalling cascade, there is no reason why cells
should be arrested in the second cell cycle, when the number of these mispairs is
reduced by 50% due to the semi-conservative nature of DNA replication. (The half-
life of MNNG in culture medium is ~1hr; it has thus been inactivated long before the
onset of the second cell division.) Second, cells lacking hMLH1/hPMS2 (e.g.
HCT116, 293T, 293T La -) express normal levels of the hMSH2/hMSH6
heterodimer, yet are highly-resistant to killing by MNNG and don’t arrest in G2.
This implies that the damage has to be processed, not simply bound by the
hMSH2/hMSH6 sliding clamp. But what is the nature of the processing?
Plant and Roberts suggested that the processing of 6MeG-containing DNA during the
first S-phase may give rise to single-stranded gaps, which are converted into DSBs
during the second replication cycle (Plant and Roberts 1971). It is conceivable that
such gaps do indeed arise in DNA methylated by SN1-type agents. The replicating
polymerase will try to incorporate either T or C into the newly-synthesised strand
opposite 6MeG residues in the template strand, and it had been suggested that the
MMR system will detect these non-Watson-Crick structures (Duckett et al. 1996)
and attempt to repair them. The repair process would exonucleolytically degrade a
short stretch of the newly-replicated DNA, i.e. the strand containing the T or the C.
However, as the 6MeG residue persists in the template strand, resynthesis of this
region would again generate the 6MeG/T or 6MeG/C mispair. The repeated processing
of these mispairs by the MMR system (Karran and Bignami 1996) may eventually
result in stalling of the replication fork. One might pose the question why these
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structures would fail to activate the S-phase checkpoint, when other polymerase
arresting agents such as HU or aphidicolin do so extremely efficiently (Abraham
2001; Hammond et al. 2002; Osborn et al. 2002; Shiloh 2003). The difference here is
that unlike HU, which brings about a depletion of purine nucleotides, or aphidicolin,
which directly inhibits the polymerases, 6MeG residues in the template strand do not
prevent a replication restart downstream from the modified base. In such cases, a
single-stranded gap would appear in the newly-synthesised strand. The existence of
single-stranded regions or breaks in the DNA of MNNG-treated MMR-proficient
cells after the first S-phase is supported by our observation of DNA tails in alkaline
comet assays (Fig. 7A), as well as by recent experimental evidence showing that
treatment of cells with 6-thioguanine, which is believed to exert its cytotoxicity via a
mechanism analogous to MNNG (Swann et al. 1996), also results in the
accumulation of MMR-dependent single-strand DNA breaks (Yan et al. 2003). The
reason why such gaps may not activate a checkpoint is because the replisome is no
longer stalled there. This could be the reason why the CHK1 kinase, which has been
identified in complexes that associate with strand breaks and with single-stranded
DNA (Goudelock et al. 2003), could be seen to be activated so weakly in our cells
during the first cell cycle after MNNG treatment (Fig. 3A).
Assuming that the single-stranded gaps do indeed form, how could they
persist until the subsequent S-phase as suggested (Plant and Roberts 1971; Kaina et
al. 1997)? This could also be linked to the fact that the early signalling is only weak.
Thus, although the degradation of CDC25A has commenced, this phosphatase was
still detectable at the 24h time point (Fig. 3A) and it is therefore conceivable that its
residual activity might have allowed the cells to transit through the first G2, M and
the next G1/S checkpoint (Mailand et al. 2002; Zhao et al. 2002), and enter the
second S-phase. In this case, they would give rise to DSBs during replication and
thus also to aberrant repair/recombination intermediates. This hypothesis is
substantiated by the post-translational modification of BRCA1 (data not shown) and
RPA (Fig. 3A), events implicated in the activation of the G2 checkpoint, as well as
by the appearance of nuclear foci of RPA, ATR (Fig. 3C,D) and g-H2AX (Fig. 7A).
Importantly, these events coincided temporally with an increase in the frequency of
aberrant sister chromatid exchanges in the MNNG-treated 293T La+ cells (data not
shown; N.M., L.S. and J.J., manuscript in preparation), which might help explain
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why we failed to detect DSBs in the neutral comet assays (data not shown):
recombination between sister chromatids occurs via a concerted crossover
mechanism, in which no free DSBs are involved. The caveat of this model lies in the
fact that although we have experimental evidence that the single-stranded gaps or
breaks indeed form (Fig. 7A), we cannot explain how (and if) they persist through
mitosis. The answer to this problem must await the results of experiments aimed at
visualising these structures in replicating DNA.
The response of cells to high MNNG concentrations was substantially
different. This treatment triggered a phosphorylation cascade that involved
essentially the same checkpoint proteins, and resulted in the formation of g-H2AX
foci (Fig. 7C), but these events were much more rapid, being detectable within hours
rather than days. Moreover, they were independent of MMR, but were affected by
ATM status (Fig. 6).  In this case, the signalling was apparently activated by the
processing (or saturation thereof) of bases such as 7MeG or 3MeA, which are introduced
into the DNA by the methylating agent in considerably greater amounts than 6MeG
(Lindahl 2000) and which are rapidly lost through hydrolysis or excised by the base
excision repair system in a DNA replication-independent manner. It should be
pointed out that these latter phenomena bear little relevance to cancer chemotherapy,
as they are triggered by methylating agent concentrations that are clinically
unachievable.
In conclusion, treatment of mammalian cells with SN1 type
methylating agents has been shown to bring about a G2/M cell cycle arrest that was
dependent on a functional MMR system. We now show that these agents activate the
ATR/ATM-dependent DNA damage-dependent signalling pathways and that the
cellular response is dose-dependent. Thus, at high concentrations, MNNG acts
similarly to IR or UV by activating the checkpoint response shortly after treatment,
and in a manner independent of MMR. In contrast, clinically-relevant levels of DNA
methylation are well tolerated and do not activate damage signalling pathways until
the unsuccessful processing of O6-metyhylguanine residues by the MMR system
during DNA replication generates intermediates that do so. These then activate a G2
checkpoint that requires the ATR kinase that is unique, inasmuch as it comes into
effect only in the second cell cycle after treatment. Our present findings thus provide
an important insight into the molecular mode of action of SN1 type methylating
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agents such as the chemotherapeutics procarbazine and temozolomide, which act
similarly to MNNG. They furthermore show that the resistance of MMR-deficient
cells to these agents can be explained by their failure to address methylation damage
and thus to trigger the ATR-dependent DNA damage-induced checkpoint.
Methods
Cell lines
The 293T La cell line was established in our laboratory(Cejka et al. 2003) and
grown as described. HeLa cells were maintained in DMEM (OmniLab)
supplemented with 10% fetal calf serum (FCS, Life Technologies), penicillin
(100U/ml) and streptomycin (100µg/ml). The ATM-deficient (AT) fibroblasts
AT22IJE-T, and the matched line complemented with ATM mini-gene (AT + ATM)
were kindly provided by Yosef Shiloh (Tel Aviv University) and were maintained as
described (Ziv et al. 1997). The U2OS cell line conditionally expressing ATR-wild
type and ATR-kinase dead poteins ( a kind gift of Paul Nghiem, Harvard University)
were maintained in DMEM supplemented with 10% FCS, 200 µg/ml G418 and 200
µg/ml Hygromycin B. Induction of ATR-wt or ATR-kd  was accomplished by
supplementing the growth medium with Doxycycline (1 µg/ml) for 48 hours as
described (Nghiem et al. 2002). Expression of all mismatch repair proteins was
confirmed in both AT fibroblasts and ATR inducible cells by immunobloting (data
not shown). To inhibit MGMT activity, HeLa cells, AT fibroblasts and ATR
inducible cells were pre-treated with 10µM O6-benzylguanine two hours prior to
MNNG treatment. All cell lines were cultured at 37°C in a 5% CO2 humidified
atmosphere.
Chemicals and irradiations
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, Sigma) was dissolved in DMSO and
stored at -20°C in the dark. O6-benzylguanine (Sigma) was dissolved in ethanol and
stored at -80 °C. Hydroxyurea (HU, Sigma) and Doxycycline (Dox, Clontech) were
dissolved in water and stored at –20˚C. Caffeine (Calbiochem) was dissolved in
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water; the solutions were always prepared fresh. Irradiations were carried out at the
doses indicated using Philips PW2184/00-Monitor SN4.
Mitotic index assays
The 293T La cells were treated with 0.2µM MNNG and incubated for 24 or 48
hours. Nocodazole (0.3 µg/ml, Sigma) was then added and the cells were incubated
for a further 24 hours. The floating and attached cells were then harvested and
centrifuged at 400 x g. The pellet was suspended in 3 ml of 75 mM KCl for 10 min,
pelleted and resuspended in Carnoy’s fixative (1:3 v/v acetic acid:methanol). This
latter step was repeated three times. 20 µl of the cell suspension were spotted onto a
microscope slide and allowed to air-dry. Once dry, the cells were stained with 0.1
µg/ml DAPI (Sigma) for 10 min, washed with water and mounted in SlowFade
Antifade (Molecular Probes). Using a fluorescence microscope, cells with broken
nuclei and condensed chromatin were counted as mitotic. Five hundred cells were
counted per sample.
Cell synchronizations
The 293T La  cells were grown to 50% confluency in a serum-rich medium.
Thymidine (2mM, SynGen Inc.) was added and the cells were incubated for 18
hours, washed three times with PBS and released into thymidine-free medium for 9
hours. Thymidine (2 mM) was then added for a second period (15h). The cells were
then washed three times with PBS. At this point, designated G1/S (Fig. 1b), the cells
were treated with 0.2 µM MNNG in a serum-rich medium without thymidine and
time points were collected four (T 4), eight (T 8), fourteen (T 14), twenty (T 20),
twenty four (T 24) and thirty (T 30) hours after MNNG treatment. Cells collected at
these time points were analyzed by propidium iodide-flow cytometry analysis as
described previously (Cejka et al. 2003).
Cell cycle analyses
For bromodeoxyuridine (BrdU) labelling, cells were pulse-labelled with 10µM BrdU
(Sigma) for 30 min before harvesting and fixation in 70% ethanol at 4°C. After
centrifugation, the cells were resuspended in ice-cold 0.1M HCl/0.5% Triton X-100
and incubated on ice for 10 min. Then 5 ml of water were added in order to dilute the
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acid, the cells were centrifuged again, resuspended in 1ml of water and placed in a
boiling water bath. After 10 min of incubation, the cells were immediately put on ice
for an additional 5 min, washed two times with cold PBS containing 0.5%Triton  X-
100 and incubated with anti-BrdU-FITC-conjugated antibody solution (Roche) at a
final concentration of 5µg/ml. After a 30 min incubation at room temperature in the
dark, the cells were washed twice with PBS and incubated with 100 µg/ml of RNase
A for 30 min at 37°C. Finally, a propidium iodide (PI) solution (20 µg/ml, Sigma)
was added and the suspension was incubated on ice prior to FACS analysis. BrdU
incorporation studies and cell cycle distribution was analyzed by Becton Dickinson
CELLQuest software.
For immunofluorescence-based detection of phosphorylated histone H3, the cells
were treated with 0.2µM MNNG and 16 hours before harvesting 2 mM caffeine was
added or not to the growth medium. The subsequent steps were carried out as
described (Xu et al. 2001).
Cell doubling and MTT assays
These were carried out as described previously (Cejka et al. 2003).
Alkaline comet assays
These were carried out using Trevigen CometSlidesTM according to the
manufacturer’s recommendations. DNA was stained with Ethidium Bromide
(10µg/ml) and visualized using a fluorescence microscope. Fifty comets were
analyzed per slide using NIH image with Comet macro (Helma and Uhl 2000).
Antibodies and Immunobloting
Anti-MLH1 (554072) and anti-PMS2 (556415) monoclonal antibodies were from
BD Pharmingen, anti-CHK1 (611152) from BD Transduction Laboratories, anti-b-
tubulin (D-10), anti-TFIIH p89 (S-19), anti-CDC25A (F-6), anti-p53 (Pab 1801) and
anti–ATR (FRP1, N-19) from Santa Cruz Biotechnology. Anti- RPA p34 (Ab-3) was
from Oncogene. Anti-phospho-CHK1 (Ser345), anti-phospho-CHK2 (Thr68), anti-
phospho-p53 (Ser15) and anti-phospho-Ser/Thr (S*/T*Q) ATM/ATR substrate
antibodies were from Cell Signaling. Anti-CHK2 (07-126) and anti-g-H2AX
(Ser139) antibodies were from Upstate Biotechnology and anti-NBS1 (ab398) from
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Novus. The anti-ATM protein kinase phospho-Ser1981 antibody was obtained from
Rockland. The anti-ATM antibody was kindly provided by Stephen P. Jackson
(Cambridge, UK). Immunoblotting and total protein extractions were performed as
described previously (Cejka et al. 2003).
Immunofluorescence studies
Cells grown on glass cover slips were treated or mock-treated with MNNG and
incubated for the indicated time periods. Fixation was done in 3.7%
formaldehyde/PBS (15 min, 4˚C) followed by permeabilization in 0.2% Triton X-
100/PBS (5 min, 4˚C). In the case of anti-g-H2AX, the cells were fixed in ice-cold
methanol (20 min, -20˚C). The coverslips were blocked with 3% Low Fat Milk/PBS
and incubated with the primary antibodies overnight at 4˚C. The cells were labelled
with anti-phospho-(Ser/Thr) ATM/ATR substrate, anti-g-H2AX (Ser139), anti-ATR
and anti-RPA p34, all at 1:100 dilution. After washing, the cells were incubated with
fluorescein isothiocyanate (FITC)–conjugated antibodies (Sigma) for 1 hour at 37˚C
and the nuclei were counter-stained with DAPI (0.1µg/ml, Sigma). Images were
captured on a Leica DC 200 fluorescence microscope.
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FIGURE LEGENDS
Figure1. Kinetics of G2/M arrest in 293T La cells treated with 0.2 µM MNNG. A,
Mitotic index of 293T La cells 24 and 48 h after MNNG treatment. The treated cells
were incubated with nocodazole, inhibitor of mitotic spindle formation, as described
in Methods. When nocodazole was added to the treated cultures 48 h after treatment,
the MMR-deficient 293T La- cells were more frequently arrested in mitosis. This
indicates that MNNG-treated MMR-proficient cells were arrested in G2 and thus
failed to arrive to mitosis. B, FACS analysis of synchronized cultures of MNNG-
treated 293T La cells. The cells synchronized in G1/S with double-thymidine block
were treated with 0.2 µM MNNG and analyzed at the indicated time points. Initially,
both MMR-proficient 293T La+ cells and MMR-deficient 293T La- cells proceeded
through the cell cycle with similar kinetics and failed to accumulate in the first G2/M
(T8 to T14). The cells went through the second S-phase between T14 and T20 and
the MNNG-treated 293T La+ cells then accumulated in the second G2/M phase
(Cejka et al. 2003), whereas the 293T La- cells continued to cycle and lost their
synchronisation after the T20 time point. C, Synchronized 293T La cells (Figure 1B)
were labelled with BrdU and the number of cells in S- phase was estimated by
CELLQuest software. Both 293T La+ (l ) and 293T La- (s) cells entered the
second S-phase between T14 and T24. D, Doubling time analysis of unsynchronised
MNNG-treated 293T La cells. While the treated 293T La+ cells (l) doubled their
number 24 h after treatment and then ceased to proliferate, the 293T La- cells (s)
continued to grow.
Figure 2. The G2 arrest in MMR-proficient 293T La+ cells is caffeine-sensitive. A,
293T La+ cells were treated with MNNG (0.2 µM) for the indicated times and
caffeine (2 mM) was added 16 hours before harvesting. The cells were stained with
PI and phospho-histone H3 antibody to distinguish mitotic cells from those in G2.
The results show that caffeine attenuated the G2 arrest in MNNG-treated cells. B,
Quantification of phospho-H3-positive cells from panel A. The number of cells
entering mitosis in the caffeine- and MNNG-treated cells was higher than in the
controls, which shows that the ATR/ATM kinase inhibitor abrogated the G2 arrest
and allowed more cells to enter mitosis. C, Caffeine treatment reduces cell survival
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after MNNG treatment. In this clonogenic assay, the cells were treated with MNNG
for 48 hr and caffeine was added for the last 16 hours. The cells were then re-plated
in duplicates and incubated for 14 days and the surviving colonies were counted. As
shown, caffeine-treated cells were more sensitive to killing by MNNG, apparently
due to abrogation of the G2 arrest, which permitted them to enter mitosis with
damaged genomic DNA.
Figure 3. MMR-dependent DNA damage signalling in 293T La cells. A, The 293T
La+ cells express hMLH1 and hPMS2 and are MMR-proficient (Cejka et al. 2003).
Treatment with 0.2 µM MNNG brings about the phosphorylation of the checkpoint
kinases CHK1, CHK2, as well as the single-strand DNA binding protein RPA (p34
subunit), while phosphorylation of CDC25A by CHK1 and/or CHK2 brings about its
degradation. None of these modifications were observed in the MMR-deficient 293T
La- cells. The proteins and their post-translational modifications were visualized by
immunoblotting as described in Methods. N.B. The phosphorylation status of RPA is
indicated by the slower migration of the modified polypeptides through
polyacrylamide gels. TFIIH was used as loading control. B, Treatment of 293T La
cells with 1mM HU brings about the phosphorylation of CHK1, CHK2 and RPA
(p34 subunit), and the degradation of CDC25A within 24h and independently of
MMR. b-tubulin was used as loading control. C, Indirect immunofluorescence
imaging of nuclear foci formed by RPA (p34), ATR and protein targets of the
ATM/ATR kinases phosphorylated on serine and threonine residues in the SQ and/or
TQ motifs. As shown, the foci formed only in the MMR-proficient 293T La+ cells
and peaked 48h after treatment. D, Indirect immunofluorescence imaging of nuclear
foci formed by RPA (p34) and ATR in HeLa cells treated with 0.2 µM MNNG (see
Methods). The cells were pre-treated with O6-benzylguanine, to inhibit their MGMT
activity. We can therefore exclude the possibility that the MNNG-induced 6MeG
residues were repaired in these cells prior to processing by the MMR system.
The images were superimposed using Adobe Photoshop software. C, control,
untreated cells.
Figure 4. ATM is activated but dispensable for the MNNG-induced G2 arrest in
MMR-proficient cells. A, ATM was activated in both 293T La+ and 293T La- cells
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upon IR (10 Gy,1h) and to a lesser degree after HU treatment (1 mM, 6h). In
contrast, upon treatment with MNNG, ATM was activated only in MMR-proficient
(293T La+) cells. ATM activation was assessed using an antibody against
phosphorylated Ser-1981. B, FACS analysis of unsynchronized cultures of AT and
AT+ATM fibroblasts following treatment with MNNG. The cells were treated with
0.2 µM MNNG and analyzed at the indicated time points. Both ATM-proficient
(AT+ATM) and ATM-deficient (AT) cells proceeded through the cell cycle with
similar kinetics, and began to accumulate in G2/M after two days. C , Indirect
immunofluorescence imaging of nuclear foci formed by protein targets of the
ATM/ATR kinases phosphorylated on serine and threonine residues in the SQ and/or
TQ motifs. As shown, the foci began to form in both ATM-proficient (AT+ATM)
and ATM-deficient (AT) cells after the 24h time point. At 48h, both cell types
contained foci, even though those in the AT cells were less numerous. However, at
72h, no differences in focus number or intensity were observed in the two cell types.
As no foci were observed in these cells upon IR treatment (DiTullio et al. 2002), we
propose that MNNG damage activated the ATR kinase. (The cells were pre-treated
with 10 µM O6-benzylguanine two hours prior to the addition of MNNG in order to
inhibit MGMT – see Materials.) D, MNNG treatment leads to ATM-independent
CHK1 and CHK2 activation, albeit with different kinetics.
Figure 5. The G2 checkpoint induced by low MNNG doses is ATR-dependent. A,
FACS analysis of U2OS cells that overexpress the kinase-dead ATR variant under
doxycycline control. The figure shows that the G2 arrest activated by MNNG
treatment in these cells was attenuated by induction of the ATR-kd protein. B, CHK2
phosphorylation was largely unaffected by expression of ATR-kd in the treated
U2OS cells. In contrats, activation of CHK1 was dependent on the presence of
functional ATR. C. Indirect immunofluorescence of ATR-kd inducible U2OS cells
showing that formation of S*/T*Q foci and their co-localization with RPA (p34)
after MNNG treatment is ATR dependent. (The cells were pre-treated with 10 µM
O6-benzylguanine two hours prior to the addition of MNNG in order to inhibit
MGMT – see Materials.)
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Figure  6. DNA damage signalling induced by high-dose MNNG treatment. A,
Response of ATM-proficient and -deficient cells to IR and high-dose MNNG
treatments. ATM-deficient fibroblasts (AT) and an isogenic line (AT+ATM) stably-
transfected with ATM cDNA were treated with IR (10 Gy, 1h) or MNNG (25 µM)
for 3 and 24 hours. The blots revealed only a weak phosphorylation of CHK2 kinase
in AT cells upon both treatments, but efficient phosphorylation was restored in the
AT+ATM line. The modification of CHK1 upon treatment with MNNG was
independent of ATM status. Phosphorylation of the CHK1 (Ser-345) kinase upon IR
treatment was ATM-dependent, but MNNG treatment yielded comparable levels of
phospho-CHK1 in both cell lines, which suggests that the mechanism(s) activating
this pathway is ATM-independent. This implies that the lesions triggering the
response to IR or high dose MNNG treatments are distinct. TFIIH was used as a
loading control. C, control, untreated cells. B, Sensitivity and response of 293T La
cells to MNNG treatment in relation to dose and MMR status. In these cell viability
assays, the 293T La+ (l) and 293T La - (s) cells were treated with increasing
concentrations of MNNG and their viability was assessed using the MTT test  after 5
days. C, Kinetics of phosphorylation of CHK1, CHK2 and p53 in 293T La cells
treated with 30 µM MNNG. This immunoblot shows that DNA damage signalling in
the 293T La cells followed a similar course, irrespective of the MMR status of the
cells. b-tubulin and TFIIH were used as loading controls. C, control, untreated cells.
Figure  7 MMR-dependent processing of methylation damage. A, Alkaline comet
assay showing the appearance/repair of DNA single strand breaks in 293T La cells
upon MNNG treatment. (See panel C.)  B. Quantification of the tail moment of the
cells in panel A. C. Differential response of 293T La cells to MNNG treatment. At
low (0.2 µM) concentrations of the drug, the foci of phosphorylated histone H2AX
appeared soon after treatment, independently of the MMR status of the cells. They
then diminished in number, until they disappeared in the MMR-deficient cells. In the
MMR-proficient cells, the number of foci increased after 24 h and peaked at 48 h.
This time point coincided with the highest levels of CHK1 phosphorylation. High
(30 µM) drug concentrations brought about an equal response in both MMR-
proficient and –deficient cells, which was detectable already a few hours post-
treatment and persisted until the cells died.
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9. APPENDIX V
Functional mismatch repair is not required for ionizing radiation-induced DNA
damage signaling. Cejka P., Stojic L., Marra G. and Jiricny J. Manuscript submitted.
(Appendix V).
Appendix V
132
Functional mismatch repair is not required for ionizing radiation-
induced DNA damage signaling.
Petr Cejka, Lovorka Stojic, Giancarlo Marra & Josef Jiricny*
Institute of Molecular Cancer Research
University of Zurich
August Forel-Strasse 7
CH-8008 Zurich
*Corresponding author
Tel.: +41-1-634 8910
Fax.: +41-1-634 8904
E-mail:jiricny@imr.unizh.ch
Appendix V
133
Mismatch repair (MMR) status of mammalian cells is known to modulate their
response to methylating agents and cisplatin. Recently, activation of the S-phase
checkpoint and phosphorylation of the checkpoint kinase CHK2 in cells treated
with ionizing radiation (IR) were also reported to be MMR-dependent. Having
subjected several human cell lines to IR treatment, we now report that their
response to IR-induced DNA damage is unaffected by their MMR status.
The MMR system has evolved to remove mispaired nucleotides incorporated into the
newly-synthesized strand during DNA replication1. However, evidence from studies
carried out with E. coli and mammalian cells showed that cells with a defective
MMR system were also more resistant (around 100-fold) to killing by methylating
agents such as N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-
nitrosourea (MNU)2,3. This phenotype was ascribed to the attempts of the MMR
system to process mispairs formed between O6-methylguanine residues in the
template strand and thymines or cytosines in the newly-synthesized one. As the
methylated guanine has no perfect match, the MMR system is thought to carry out
iterative repair/resynthesis steps, which eventually lead to cell cycle arrest4 and
apoptosis5. In support of this hypothesis, the presence of O6-methylguanine in DNA
was shown to elicit DNA repair synthesis6 and the heterodimeric mismatch
recognition factor consisting of hMSH2 and hMSH6 was shown to bind
oligonucleotides containing O 6-methylguanine/thymine mispairs in vitro7.
Importantly, the cell cycle arrest induced in MMR-proficient cells by low dose
MNNG treatment is strictly linked to cell division and DNA synthesis (L.S. et al.,
submitted), as would be expected of a signaling process that is triggered by lesions
arising during DNA replication.
Since the above discovery, a number of reports described the differential
sensitivity of MMR-proficient and –deficient cells also to several other DNA
damaging agents, but the differences were substantially less marked. MMR-deficient
cells are generally 2-3-fold more resistant to cisplatin than MMR-proficient ones,
and this difference was also explained by the involvement of the MMR system in
cisplatin damage recognition and processing7. The link between the MMR system
and response to other types of DNA damage is more ambiguous. MMR-deficient
cells were reported to be more resistant to ionizing radiation8,9, but the survival
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differences were very small and were even questioned, inasmuch as the MMR status
was reported to affect the length of the G2/M checkpoint rather than cell viability10.
A recent report by Brown et al.11 has reopened the discussion by describing the
requirement of a functional MMR system in activation of the S-phase checkpoint and
signaling of IR-induced damage.
It appeared possible that some of the discrepancies between the above studies
may have been linked with the heterogeneity of the MMR-proficient/MMR-deficient
cell pairs deployed. In order to eliminate this possibility, we set out to examine the
response of human cells to IR in a 293T La cell system, in which the MMR status is
defined by expression of the MMR protein hMLH1 from a TetOFF system that is
controlled by doxycycline3, such that the MMR-proficient 293T La+ cells differ from
the MMR-deficient 293T La- cells solely by the presence of a single gene product,
the MMR protein hMLH1, which is not expressed in the latter cells.
The MMR-proficient and -deficient 293T La cells were exposed to IR and
their progress through the cell cycle and viability were followed over the period of
72h. IR treatment (2Gy) arrested both cell types after 21h (data not shown) and no
differences in clonogenic survival were observed (data not shown). We also failed to
detect MMR-dependent differences in phosphorylation of the checkpoint kinases
CHK1 and CHK2, the activation of which is required for triggering the arrest (Fig.
1a). The extent of phosphorylation of the Nijmegen Breakage Syndrome protein
NBS1 (not shown) and breast cancer protein BRCA1 (Fig. 1a), implicated in the
processing of IR-induced strand breaks, also did not differ between the MMR-
proficient and –deficient 293T La cells. Thus, the MMR status of these cells did not
appear to affect DNA damage signaling upon IR treatment.
As the above results contrasted with those of Brown and colleagues11, we had
to eliminate the possibility that the observed discrepancies were associated with
differences in the genetic background of the cell systems deployed. We thus repeated
the analysis with syngenic MMR-proficient and -deficient cell line pairs, some of
which were also used in the latter study. We also used the same dose of IR (5Gy). As
shown in Fig. 1b, we failed to observe the described MMR-dependent differences in
early post-translational modification of CHK2, one of the primary downstream
targets of the Ataxia telangiectasia mutated (ATM) kinase. Although we cannot
exclude the possibility that the cell clones used in our laboratory were not identical
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with those used by Brown and colleagues11, the steady-state levels of the relevant
MMR proteins in our cell lines corresponded to expectations as shown by
immunoblotting analysis of their extracts (Fig. 1). Moreover, we tested the MMR
capacity of all the lines used in this study by in vitro MMR assays12,13 (data not
shown) and confirmed that our HCT116, HEC59 and MT1 clones were indeed
MMR-deficient, whereas the HCT116+chr3, HEC59+chr2 and TK6 cells were
MMR-proficient.
IR introduces different types of damage into DNA. The most common type by far (~
75%) is oxidation and fragmentation of DNA bases, followed by damage to the
sugar-phosphate backbone. Single- and double-strand breaks appear to be the most
deleterious kind of DNA damage, but experimental evidence implicating MMR in
the processing of these lesions is not available at this time. In contrast, the MMR
system is known to be involved in the processing of 8-oxoguanosine monophosphate
residues incorporated into the newly-synthesized strand during DNA replication14.
The source of these aberrant nucleotides, which can erroneously base-pair with
adenosines in the template strand, is the oxidised nucleotide pool.  However, as the
repair of the resulting 8-oxoguanine/adenine mispairs would be directed to the
newly-synthesized strand, i.e. that containing the oxidized nucleotides, intervention
of the MMR system would result in their efficient removal from DNA and these
events would thus not be expected to signal, as they would not delay the progress of
replication fork in the same way as do O6-methylguanines in the template strand, due
to the fact that they cannot be removed by the MMR system and thus trigger repeated
cycles of excision and repair synthesis. Moreover, even if these events were to
signal, this process would not be triggered until the first S-phase. This is clearly
inconsistent with the experimental findings, which show that the post-translational
modification of the examined polypeptides was detectable already within minutes of
the IR treatment, at which time point most of the cells were still in G1. In contrast,
MNNG-induced posttranslational modifications were apparent only 24h after
treatment (ref. 3 and L.S. et al., submitted).
Thus, based on our current knowledge, we would not expect the MMR
system to be involved in the signalling of IR-induced damage, a hypothesis that is
substantiated by the findings presented above.
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FIGURE LEGENDS
Figure 1. DNA damage signalling response of cells to IR is independent of their
MMR status. a, Response of MMR-proficient (293T La+) and –deficient (293T La-)
cells to treatment with ionizing radiation (IR). The cells were treated with IR (4Gy)
and the extracts were analyzed after 1h. b-tubulin was used as loading control. b,
Response of MMR-proficient and –deficient lines to IR (5Gy) 1h post treatment. The
cells used were the lymphoblastoid lines TK6 (MMR+) and MT1 (MMR-, derived
from TK6, carries mutations in both alleles of hMSH6), the epithelial colon cancer
lines HCT116 (MMR-, mutated in both alleles of hMLH1) and HCT116+ch3
(MMR+, derived from HCT116 by transfer of chromosome 3, which carries the wild
type hMLH1 gene) and the MMR-deficient HEC59 cells (derived from a human
endometrial tumor, carry mutations in both alleles of the hMSH2 gene). b-tubulin
was used as loading control.
The extracts were immunoblotted with antibodies against the MMR proteins
hMSH2, hMSH6, hMLH1 and hPMS2 (upper panels) to help ascertain the MMR
status of the cells, or against BRCA1, CHK1, phospho-CHK1, CHK2 and phospho-
CHK2 (lower panels) to examine the extent of IR-induced DNA damage signaling.
No differences in the post-translational modification of the latter polypeptides were
observed. IR -/+ indicates lanes containing extracts from untreated or treated cells,
respectively. MMR -/+ indicates extracts of MMR-proficient or –deficient cells,
respectively.
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Figure 1.
Acknowledgements
139
10. ACKNOWLEDGEMENTS
I would like to thank Prof. Josef Jiricny, who gave me the opportunity to make
my thesis at his institute, and for the excellent supervision of the projects.
I would like to thank the UBS Stiftung, which financially supported my studies.
The help of Lovorka Stojic, Giancarlo Marra, Christine Hemmerle, Katja
Bärenfaller, Elda Cannavò, Zuzana Storchova, Natalie Jiricny, Nina Mojas,
Massimiliano di Pietro, Franziska Fischer, Helga Pletscher and other institute
members is also gratefully acknowledged.
I thank my parents and Elda, I would never get so far without them.
Lebenslauf
140
11.  LEBENSLAUF
Name Cejka
Vorname Petr
Geboren am 25.07.1977
Heimatort Horovice, Tschechische Republik
Ausbildung
- Gymnasium: Gymnazium Na Vitezne plani, Prag (1991-1995)
Abschlussprüfung (Matura) in 1995
- Universität: Univerzita Karlova, Prag,
Naturwissenschaftliche Fakultät
Biologiestudium (1995-2000, 10 Semester)
- Diplomfach: Molekularbiologie
- Titel der Diplomarbeit: The influence of the RAD6 gene product and other
members of the RAD6 epistaic group on the starvation-
associated mutagenesis in S. cerevisie
- Abschluss Staatsprüfung in Molekularbiologie mit Abschluss
"summa cum laude" in 2000
Dissertation Seit 01.11.2000: Promotiosstudium am Institut für
Molekulare Krebsforschung der Universität Zürich
- Titel der Dissertation: Therapy of cancers with microsatellite instability
- Leiter der Dissertation: prof. Dr. Josef Jiricny, Institut für Molekulare
Krebsforschung
List of publications
141
12. LIST OF PUBLICATIONS
Cejka P., Vondrejs V. and Storchova Z. Dissection of the functions of the
Saccharomyces cerevisiae RAD6 postreplicative repair group in mutagenesis and
UV sensitivity. Genetics. 2001, 159, 953-63.
Cejka P., Stojic L., Mojas N., Russell A.M., Heinimann K., Cannavo E., di Pietro
M., Marra G. and Jiricny J. Methylation-induced G(2)/M arrest requires a full
complement of the mismatch repair protein hMLH1. EMBO J. 2003, 22, 2245-54.
Stojic L., Mojas N., Cejka P., Ferrari S., Marra G. and Jiricny J. MMR-dependent
and -independent signaling induced by SN1 type methylating agents requires
functional mismatch repair. Manuscript submitted.
di Pietro M., Marra G., Cejka P., Stojic L., Menigatti M., Cattaruzza M.S. and Jiricny
J. Mismatch repair-dependent transcriptome changes in human cells treated with the
methylating agent MNNG. Cancer Res. In press.
Cejka P., Marra G., Hemmerle C., Cannavo’ E., Storchova Z. and Jiricny J.
Differential killing of mismatch repair-deficient and -proficient cells: towards the
therapy of tumors with microsatellite instability. Cancer Res. In press.
Cejka P., Stojic L., Marra G. and Jiricny J. DNA damage signalling induced by low
doses of SN1 type methylating agents is dependent on functional mismatch repair and
ATR kinase. Manuscript submitted.
